



US 20030167511A1

(19) **United States**

(12) **Patent Application Publication**
Narbad et al.

(10) **Pub. No.: US 2003/0167511 A1**

(43) **Pub. Date: Sep. 4, 2003**

(54) **PRODUCTION OF P-HYDROXYBENZOIC ACID**

09/155,185, filed on Sep. 22, 1998, now abandoned, filed as 371 of international application No. PCT/GB97/00809, filed on Mar. 24, 1997.

(76) Inventors: **Arjan Narbad**, Norfolk (GB); **Michael John Charles Rhodes**, Norfolk (GB); **Michael John Gasson**, Norfolk (GB); **Nicholas John Walton**, Norfolk (GB)

(30) **Foreign Application Priority Data**

Mar. 23, 1996 (GB) GB96/06187

Correspondence Address:
Michael L. Goldman
NIXON PEABODY LLP
Clinton Square
P.O. Box 31051
Rochester, NY 14603-1051 (US)

Publication Classification

(51) **Int. Cl.⁷** **A01H 5/00**; C07H 21/04;
C12P 7/40

(52) **U.S. Cl.** **800/278**; 435/136; 536/23.2

(21) Appl. No.: **10/199,405**

(22) Filed: **Jul. 18, 2002**

Related U.S. Application Data

(62) Division of application No. 09/733,383, filed on Dec. 7, 2000, which is a division of application No.

(57) **ABSTRACT**

One aspect of the present invention relates to a transgenic plant which, by presence of a transgene, is able to produce p-hydroxybenzoic acid or a β -D-glycoside or β -D-glucose ester thereof. A method is also disclosed for producing p-hydroxybenzoic acid or a β -D-glycoside or β -D-glucose ester thereof using a transgenic plant of the present invention.

Vanillin Pathway in *Pseudomonas fluorescens*, biovar V, strain AN103




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7

Fig 8.



97.4 kDa	Phosphorylase b
66.2 kDa	Bovine serum albumin
45.5. kDa	Hen egg white ovalbumin
31.0 kDa	Bovine carbonic anhydrase
21.5 kDa	Soybean trypsin inhibitor
14.4. kDa	Hen egg white lysozyme

EcoRI/PstI digests of cosmid clones




Figure 9

Redundant primers designed from 20 N-terminal amino acid sequence

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Ser	Thr	Tyr	Glu	Gly	Arg	Trp	Lys	Thr	Val	Lys	Val	Glu	Ile	Gln	Asp	Gly	Ile	Ala	Phe
Primer P66					Primer P67														
TCC	ACG	TAC	GAG	GGC	CGC	TGG	AAG	ACG	GTC	AAG	GTC	GAG	ATC	CAG	GAC	GGC	ATC	GCG	TTT
GG	C	T	A	T	G	G	A	C	G	A	A	A	T	A	T	T	T	C	C

Figure 10




Figure 11

Nucleotide and amino acid sequence of the cleavage enzyme and vanillin dehydrogenase.
Sequence determined from sub-cloned fragments pFI989 and pFI1056 and from the cosmid
clone pFI794

1	GAATTCTCTCGCGCTTTGCCAGTCTTACCCGCTGGTGCAGATCGAGGTG	50
51	CATTGCGAGTCGTCCAAGCAACTTCTCTTGCGCCAGGACCTCGACCTGTC	100
101	CATCGTGACCCGCGAACCCGGCAACGAAATCGGCCAGCTGTTGCGCAAGG	150
151	AGCGTTTTGTCTGGGCCCAGGCCAGTGCTACAACCCTGTCGAGCAATCA	200
201	CCCTTGCCGCTGGCGATGTTCAACAGTGACTGCTTCTGCCGTCTTTGGGC	250
251	CTGTAATGCGCTGGATGCCGCCGACGTGAATACCGCATCGCCTACAACA	300
301	GTTCGAGCCTGTGCGCGCTGATGGCAGTGGTCAGCGCCGGGCTGGCGGTG	350
351	ACCGCTCAATTGGAAAGCCTGATCCCGCAGGACATGCGCATCCTCGGCGA	400
401	GGCCGAAGGCCTGCCCCAACTGCCCGAGGCGAGCATCATGCTGCTGCGCA	450
451	ATCTGCATAATCCGTCGCCGATTACCGAATGTCTGGCGGAGCACATCGTC	500
501	GAAGGCTTCAAACCTTAAAGGCGAGCATCACCGCGCAGAGCACCAGAAAA	550
551	CCGCAGAACAAACCGCGTAGTAGCCGCTCCGGCAGGGCGTGGGCAATCTT	600
601	CACGCCCCAACTGATACTGAGCAGACCGCCCACCGCCATGGGCAACGCGA	650
651	TGTGCCAGTCGACTTGCTGGTGCAGGGCGTAGGTCGCCAGGGTTACACCG	700
701	GTGCTGGGTAAAGCCAGTGCCAACGACAGGCCCTGGGCCACCACCTGGGT	750
751	GGTGCCAAACAAGCTGGTCAATACCGGCGTTGCGACCACAGCGCCGCCCA	800
801	CCCCGAACAAGCCACCCATGACGCCGGACGCCGCGCCCAGCACCCCGAGC	850
851	CAGGGCCACGAATAGCGCATCTGCGCAGTCGGTGCCGCCGCGAGTCATGAA	900
901	CATGCGCATCAGGTTGTAGACCGACAAGGCCACCAGAAACACCACGAACC	950
951	CGATGCGCATCACCTGAGCGTCGATCCCCACCGCCCAGATCGAACCGAGC	1000
1001	CAGGCAAAGCAGAACCCCATGGAGGCCAACGGCAGCGCGTGGCGCAACTC	1050
1051	GATGCGATTACGTTGGTGATAACGCCATAACGCCAGCATCACGTTCCGGCA	1100
1101	CCACCATGACCAGAGCTGTGCCCTGGGCAAGCTGCTGATCCAGGCCAAAT	1150
1151	AACACGCCCAGAGCGGGAATGGCGATCAAGCCACCGCCGATTCCAAACAA	1200
1201	ACCACCTACGGTCCCCAAGGCTGCACCGAGCAGCAGGTACATCGTCAACT	1250
1251	CAATCACAGGTCAAATTCCTCACGTCAATGGGTGCATCCTACGCAGTCG	1300

Figure 12A

1301	GGGCTAGCGGGGAAACGCACAGCAACGCACAATGGCTATGCCAAATTCGC	1350
1351	ACAAGCAATCCTCCATGAACCCACACGCTCACCGATCAATTGGGTCTA	1400
1401	TTCCTTGATGTCGTGGAAACCGGCAGTTTTTCCGCTGCGTCCCGACGCCA	1450
1451	TCCGCTGACACCCTCCGCCGTCGCCAGGCGTATCGATAGTCTGGAACAGG	1500
1501	CGCTCGACAGCCAATTGTTTCGTGCGCACCACCTCATGCTGTGCGTCCTACG	1550
1551	CCAGCGGGATTGGCGTTTGCCGAGCGAGCCCGACGCATTGTTCGGCGAGTT	1600
1601	GCGCCTGGCGCGGGCCGAGGTCGCCTCCCTGAGCAGCGCGCCTGAAGGAC	1650
1651	TGATTCGGGTCGACGCCCCCGCAGCCTTCGGCCGCAGGCACCTGGCGCCG	1700
1701	GTGATCTATGACTACGACTTCGCCGCCTCCGGCGTGCCCGGGCTGCGGGG	1750
1751	CCGGTTGCGCTACCTGCGCGGCGACAACATCGAGTTGAAAGCCTTCAACG	1800
1801	CCGAAGACCGCAAGGAGCGCGAGTTCCAGATGGAGCTGGGCTACGTGGTG	1850
1851	CAAAGCGGTCCGCTGAAAAACGTGGCCTGGTGGCGCGCAAGGCAATCTA	1900
1901	CCGCAATGACTTCCCCACTGGCGCCGCCTTCGCGGATGAAAACCAGACGC	1950
1951	GGTTTCTGGTGACCTATACCTTGCCGATCTGGTGAGTGCGCGTGTTGCGG	2000
2001	TGGGGCTGATGGCCCCATCGCGAGCGGGCTCGCTCCTACAGTGGGTTTGG	2050
2051	TGTTAATCACAGAGGCTGTGGAGCTTGCAGCCCCGTAGGCGCTGGCTTG	2100
2101	CCAGCGAGGCGTAGGCACTGCTGGCGCAAGGCTCAAGGCCCCACAGGCCC	2150
2151	GCTCCCACCCTTCAGATTTTCTATTCCCTGATAAATCTTCTTCAGCAGCCG	2200
2201	CAGCAGCTCGTCGCGTTCCTGGTCGTCCAGTGCCGAGGTGGCGTCGAGGT	2250
2251	CGCTTTGGGCGGCGATCTGGTTCAGTTCCTTGAGCAGGGTCTCGCCGGTC	2300
2301	TTGCTGAGGAATATCCCGTACGAGCGCTTGTCGGGCTTGACGCGCACACG	2350
2351	CACCGCCAGCGCCCGGCTTTCCAGCTTATTCAGCAGCGGTACCACCTGGG	2400
2401	GCGGCTCGATGCTCAGAGCCCGGGCCAGGTCGGCCTGCATCAGGCCGGGG	2450
2451	TTCTGATTGATGATCGCCAGCGCCGAGAATTGCGCGGGGCGCAGATCGTG	2500
2501	GGCCGAGAGGCGGCTGATCAGGTTCTGGAACAGTTTCAGTTGCGCACGGC	2550
2551	GCATGGCGTAGCCGATCAGATCATTCAGCGCCGAATCCATGGGCGCCTGG	2600
2601	GTCTCGGCGGGAGTCGACGCAGCCTCGACCGACTCGGCGAGGGGGGAGGG	2650
2651	CTTGCCCATTCGCGGGGAAGTCCTGAAGATGGAGGTTAACAAGACTATCTA	2700
2701	GTTTGCCGACCTTGGCCGGTGATTGCTACGGCCAATATCGCTCGGCGCCA	2750

Figure 12B

2751	AGACCGACCAGTCCATCACCTGCGAGAAAATTGGTTAAATCAATTAATAG	2800
2801	TTAATTGACATAACTAATTCGCTGCTTTAATTTTCGAGTCATCTTCAAAAC	2850
2851	CCAGAACAAGAGAGCATCGCCATGAGCACATACGAAGGTCGCTGGAAAAC MetSerThrTyrGluGlyArgTrpLysTh	2900
2901	GGTCAAGGTCGAAATCGAAGACGGCATCGCGTTTGTTCATCCTCAATCGCC rValLysValGluIleGluAspGlyIleAlaPheValIleLeuAsnArgP	2950
2951	CGGAAAAACGCAACGCGATGAGCCCGACCCTGAACCGCGAGATGATCGAT roGluLysArgAsnAlaMetSerProThrLeuAsnArgGluMetIleAsp	3000
3001	GTTCTGGAAACCCTCGAGCAGGACCCTGCCGCCGGTGTGCTGGTGCTGAC ValLeuGluThrLeuGluGlnAspProAlaAlaGlyValLeuValLeuTh	3050
3051	CGGTGCGGGCGAAGCCTGGACCGCAGGCATGGACCTCAAGGAATACTTCC rGlyAlaGlyGluAlaTrpThrAlaGlyMetAspLeuLysGluTyrPheA	3100
3101	GCGAAGTGGACGCCGGCCCGGAAATCCTCCAGGAAAAAATCCGCCGCGAA rgGluValAspAlaGlyProGluIleLeuGlnGluLysIleArgArgGlu	3150
3151	GCCTCGCAATGGCAATGGAACTGCTGCGCATGTACGCCAAGCCGACCAT AlaSerGlnTrpGlnTrpLysLeuLeuArgMetTyrAlaLysProThrIl	3200
3201	CGCCATGGTCAATGGCTGGTGCTTCGGCGGCGGTTTCAGCCCGCTGGTGG eAlaMetValAsnGlyTrpCysPheGlyGlyGlyPheSerProLeuValA	3250
3251	CCTGCGACCTGGCGATCTGCGCCGACGAAGCAACCTTCGGTCTCTCGGAA laCysAspLeuAlaIleCysAlaAspGluAlaThrPheGlyLeuSerGlu	3300
3301	ATCAACTGGGGTATCCCGCCGGGCAACCTGGTGAGCAAGGCCATGGCCGA IleAsnTrpGlyIleProProGlyAsnLeuValSerLysAlaMetAlaAs	3350
3351	CACCGTGGGCCACCGCCAGTCGCTCTACTACATCATGACCGGCAAGACCT pThrValGlyHisArgGlnSerLeuTyrTyrIleMetThrGlyLysThrP	3400
3401	TCGGTGGGCAGAAAGCCGCGGAGATGGGCCTGGTCAACGAAAGCGTGCCC heGlyGlyGlnLysAlaAlaGluMetGlyLeuValAsnGluSerValPro	3450
3451	CTGGCGCAACTGCGCGAAGTCACCATCGAGCTGGCGCGTAACCTGCTCGA LeuAlaGlnLeuArgGluValThrIleGluLeuAlaArgAsnLeuLeuGl	3500
3501	AAAAAACCCGGTGGTGCTGCGTGCCGCCAAACACGGTTTCAAACGCTGCC uLysAsnProValValLeuArgAlaAlaLysHisGlyPheLysArgCysA	3550
3551	GCGAACTGACCTGGGAGCAGAACGAGGATTACCTGTACGCCAAGCTCGAT rgGluLeuThrTrpGluGlnAsnGluAspTyrLeuTyrAlaLysLeuAsp	3600
3601	CAGTCGCGTTTGCTGGACACCGAAGGCGGTCGCGAGCAGGGCATGAAGCA GlnSerArgLeuLeuAspThrGluGlyGlyArgGluGlnGlyMetLysGl	3650
3651	ATTCCTCGACGACAAGAGCATCAAGCCTGGCCTGCAAGCGTATAAACGCT nPheLeuAspAspLysSerIleLysProGlyLeuGlnAlaTyrLysArgE	3700
3701	GAAGGACGACGCTGCGGGCGCATTCGCGGAAGGCGAGTGCGCCCTGAAGC nd	3750

Figure 12C

3751	TGCGTTTACATCACTGCTAAGCATTCCGATAAAGACGATAAAGAGGAATC	3800
3801	ACCATGCTGGACGTGCCCCCTGCTGATTGGCGGCCAGTCGTGCCCCGCGCG MetLeuAspValProLeuLeuIleGlyGlyGlnSerCysProAlaAr	3850
3851	CGACGGTCGAACCTTCGAGCGCCGCAACCCGGTGACTGGCGAGTTGGTGT gAspGlyArgThrPheGluArgArgAsnProValThrGlyGluLeuValS	3900
3901	CGCGGGTTGCCGCCGCCACCCTGGAAGATGCCGACGCCGCCGTGGCCGCT erArgValAlaAlaAlaThrLeuGluAspAlaAspAlaAlaValAlaAla	3950
3951	GCCCAGCAAGCGTTTCCCGCGTGCGGCCGCGCTGGCGCCCAATGAACGGCG AlaGlnGlnAlaPheProAlaTrpAlaAlaLeuAlaProAsnGluArgAr	4000
4001	CAGCCGTTTGCTCAAGGCCGCCGAACAATTGCAGGCGCGCAGCGGCGAGT gSerArgLeuLeuLysAlaAlaGluGlnLeuGlnAlaArgSerGlyGluP	4050
4051	TCATCGAGGCGGCGGGCGAGACCGGCGCCATGGCCAACCTGGTACGGGTTC heIleGluAlaAlaGlyGluThrGlyAlaMetAlaAsnTrpTyrGlyPhe	4100
4101	AACGTACGGCTGGCGGCCAACATGCTGCGTGAAGCGGCATCGATGACCAC AsnValArgLeuAlaAlaAsnMetLeuArgGluAlaAlaSerMetThrTh	4150
4151	CCAGGTCAATGGTGAAGTGATTCCCTCGGACGTTCCCGGCAGTTTCGCCA rGlnValAsnGlyGluValIleProSerAspValProGlySerPheAlaM	4200
4201	TGGCCCTGCGCCAGCCCTGTGGCGTGGTGCTGGGCATCGCCCCCTGGAAC etAlaLeuArgGlnProCysGlyValValLeuGlyIleAlaProTrpAsn	4250
4251	GCCCCGGTGATTCTCGCCACCCGGGCGATTGCCATGCCGCTGGCCTGTGG AlaProValIleLeuAlaThrArgAlaIleAlaMetProLeuAlaCysGl	4300
4301	CAACACCGTGGTGCTGAAGGCTTCCGAGCTGAGTCCGGCGGTGCATCGCT yAsnThrValValLeuLysAlaSerGluLeuSerProAlaValHisArgL	4350
4351	TGATCGGCCAGGTGCTGCAGGACGCCGGCCTGGGCGATGGCGTGGTCAAC euIleGlyGlnValLeuGlnAspAlaGlyLeuGlyAspGlyValValAsn	4400
4401	GTCATCAGTAATGCGCCGGCGGATGCGGCACAGATTGTCGAGCGCCTGAT ValIleSerAsnAlaProAlaAspAlaAlaGlnIleValGluArgLeuIl	4450
4451	TGCCAACCCGGCCGTACGCCGGGTCAATTTACCGGTTTCGACCCACGTCG eAlaAsnProAlaValArgArgValAsnPheThrGlySerThrHisValG	4500
4501	GGCGCATTTGTCGGCGAGCTCTCGGCGCGCCACCTCAAACCGGCGTTGCTC lyArgIleValGlyGluLeuSerAlaArgHisLeuLysProAlaLeuLeu	4550
4551	GAGCTGGGCGGCAAGGCACCGTTGCTGGTGCTCGACGATGCCGACCTGGA GluLeuGlyGlyLysAlaProLeuLeuValLeuAspAspAlaAspLeuGl	4600
4601	GGCTGCCGTGCAGGCGGCGGCGTTTGGCGCCTACTTCAACCAGGGACAGA uAlaAlaValGlnAlaAlaAlaPheGlyAlaTyrPheAsnGlnGlyGlnI	4650
4651	TCTGTATGTCCACCGAGCGCCTGATTGTTCGATGCCAAGGTGGCCGACGCC leCysMetSerThrGluArgLeuIleValAspAlaLysValAlaAspAla	4700

Figure 12D

4701	TTTGTCGCCCAGTTGGCGGCCAAGGTCGAGACCCTGCGCGCCGGTGATCC	4750
	PheValAlaGlnLeuAlaAlaLysValGluThrLeuArgAlaGlyAspPr	
4751	TGCCGACCCGGAGTCGGTGCTCGGTTGCTGGTGGACGCCAGCGCTGGCA	4800
	oAlaAspProGluSerValLeuGlySerLeuValAspAlaSerAlaGlyT	
4801	CGCGGATCAAAGCGTTGATCGATGATGCCGTGGCCAAGGGCGCGCCTG	4850
	hrArgIleLysAlaLeuIleAspAspAlaValAlaLysGlyAlaArgLeu	
4851	GTAATCGGCGGGCAACTGGAGGGCAGCATCTTGCAGCCGACCCTGCTCGA	4900
	ValIleGlyGlyGlnLeuGluGlySerIleLeuGlnProThrLeuLeuAs	
4901	CGGTGTCGACGCGAGCATGCGTTTGTACCGCGAAGAGTCCTTCGGCCCGG	4950
	pGlyValAspAlaSerMetArgLeuTyrArgGluGluSerPheGlyProV	
4951	TGGCGGTGGTGCTGCGCGGCGAGGGCGAAGAAGCGCTGTTGCAACTGGCC	5000
	alAlaValValLeuArgGlyGluGlyGluGluAlaLeuLeuGlnLeuAla	
5001	AACGACTCCGAGTTCGGTTTGTGCGGCGGCGATTTTCAGTCGTGACACCGG	5050
	AsnAspSerGluPheGlyLeuSerAlaAlaIlePheSerArgAspThrGl	
5051	CCGTGCCCTGGCCCTGGCCCAGCGGGTCGAATCGGGCATCTGCCACATCA	5100
	yArgAlaLeuAlaLeuAlaGlnArgValGluSerGlyIleCysHisIleA	
5101	ACGGCCCGACCGTGCACGACGAAGCGCAAATGCCTTTTGGCGGGGTCAAG	5150
	snGlyProThrValHisAspGluAlaGlnMetProPheGlyGlyValLys	
5151	TCCAGCGGCTACGGCAGTTTTTGGCGGCAAGGCATCGATTGAGCATTTCAC	5200
	SerSerGlyTyrGlySerPheGlyGlyLysAlaSerIleGluHisPheTh	
5201	TCAGTTGCGCTGGGTCACCCTCCAGAATGGTCCACGGCACTATCCGATCT	5250
	rGlnLeuArgTrpValThrLeuGlnAsnGlyProArgHisTyrProIleE	
5251	GA	5252
	nd	

Figure 12E

Nucleotide sequence of pFI901 (1.8Kb EcoRI/PstI fragment ex pFI973)

```

1  GAATTCGGGA TCTGGGCTGC CAACCAGTTG GAAGAAAAGA TTCTCGAAGT
51  CGGTGTCGAC AACGTCGGCG CCTTCATTGC CGAGCCGATC CAGGGCGCCG
101 GCGGCGTGAT CGTGCCGCCA GAAAGCTACT GGCCGCGCAT CAAGGAAATC
151 CTCGCCAAGT ACGACATCCT GTTCGTCGCC GATGAAGTGA TTTGCGGTTT
201 CGGCCGTACC GGCAGTGGT TCGGCAGCGA TTTCTACGAC CTCAAGCCCG
251 ACATGATGAC CATCGCCAAG GGCCTGACTT CCGGCTACAT CCCGATGGGT
301 GGTCTGATCG TGC GCGATTG GGTGGTCGAA GTGCTGAACG AAGGCGGCGA
351 TTTCAACCAC GGATTCACCT ACTCCGGTCA CCCGGTAGCG GCGGCTGTTG
401 CCCTGGAAAA CATCCGCATC ATGCGCGAAG AGAAGATTAT CGAGCGCGTC
451 CAGGAAGAAA CGGCACCGTA TTTGCAAAAG CGTCTGCGTG AACTCAACGA
501 TCATCCATTG GTGGGTGAAG TTCGCGGGGT AGGGTTGCTG GGCGCTATCG
551 AACTGGTTCA GGACAAAGCC ACGCGCAAAC GTTACGAAGG CAAGGGCGTG
601 GGCATGATCT GCCGGCAGTT CTGCTTCGAC AACGGGCTGA TCATGCGCGC
651 GGTTGGCGAC ACCATGATCA TCGCGCCGCC ACTGGTGATT ACCAAGGCGG
701 AAATCGATGA GCTGGTGAGC AAGGCACGCA AGTGCCTGGA CCTGACCCTG
751 AGTGTGTTGC AGGGCTAAGT GCTAGGCTCT GAGCGGGAGT TGTATGAACT
801 TTCGCTCAGA GCGGTCAGAA AGCTTGGCCT TTCCTTGAAA GACCGCCATG
851 GATGTTGCCA GACTAGCCAC CGTTCCAAAT GCCCGGGTTC GGCGCGGAAC
901 AGGTGGTTCA AAAAAGCAAA AATTGAGC ATTACGCATG AAGGCACTCG
951 GTAAAAAGCT CGCCGGCAAG ACACTCCTTG CCATGTCCCT GATGGGCATC
1001 ATGGCGGGCG CGGTTCAGGC AGATGACAAA GTCTTGACAG TGTACAACTG
1051 GTCCGATTAC ATCGCGCCGG ACACCATCAA GAAGTTTGAA GACGAGTCGG
1101 GCATCAAGGT GGTCTACGAC GTCTTCGACA GTAACGAAAC CCTCGAAGCC
1151 AAGTTGCTGG CCGGCAAGTC CGGTTACGAC ATCGTGGTGC CTTGAACAA
1201 CTTCTGGCC AAGCAGATCA AGGCCGGCGT CTACCAGAAG CTGGACAAGT
1251 CCAAGCTGCC GAACTGGAAG AACCTGAACA CCGATCTGCT CAAGGCCGTT
1301 TCGGTCAGCG ACCCTGGTAA CGAGCACGCC TTCCCGTACA TGTGGGGCTC

```

Figure 13A

1351 GATCGGCATC GGCTTCAACG CCGAGAAGGT CAAGGCCGCG CTGGGTCCGG
1401 ATGCACCGAC CAATTCCTGG GACCTGATCT TCAAACCGGA AAACGCCGCC
1451 AAGCTGAAAT CCTGTGGCAT CAGCGTGCTG GATTCGCCAA CCGAGATGAT
1501 TCCGGTGGCC CTGCACTACC TGGGCTACCC GACCGACAGC CAGGACAAGA
1551 AACAACTGGC CGAGGCCGAG GCACTGTTCC TCAAAGTTCG TCCTTCGATC
1601 GGTTACTTCC ACTCCTCCAA GTACATTTCC GACCTGGCCA ACGGCAACAT
1651 CTGCGTGGCG ATCGGCTACT CGGGTGACAT CTATCAGGCC AAGACTCGCG
1701 CCGCCGAAGC CGGTGACAAG GTCAAGGTCA GCTACAACAT TCCCAAAGAA
1751 GGTGCAGGCA GCTTCTACGA CATGGTCGCC ATCCCTAAAG ATGCCGAAAA
1801 CGTCGAAGGC GCCTACAAGT TCATGACCTT CCTGCAG

Figure 13B

Nucleotide sequence pFI911 (850bp EcoRI/PstI fragment ex pFI973)

```
1  CTGCAGACCT TCTGCCAGGC GCACCGGCTC ACGCAGGGTT TTGACTTCCT
51  GGATCATCAG GCGCTGGTTG CGTTTGACCG ACTGGCCAAT CATCAGGCGA
101 AACGCATTGG AGCCCAGGTC GATAGCGGCG AATAGCGATG CGTCTTCTTT
151 CACGTGAGGA ACTCCTGGCA ACTTCGTCCG CCGAGGGCAA AAAACCGGTT
201 TTGCCGATCC TGCACGGGGT AGATGACATC AGGATGACAT TGGAAATTTT
251 TCTGACAGAC GTTTCGTCAC CAGAACGTCA CAGTCGCGGG GCTAGCATCG
301 GGGCTTCCAA TCGGGTCGGG AGCCTTGAAC ATGCTGTAA CCAACGACAC
351 CCTGATGCAT CGCATCCACC GCGAGTTGCT CGACCACAGT GACGAAGAGC
401 TGGAAGTGA GTTGCTGGAA GACGATCACG ACCTGGCTTC GCTGTTCCGG
451 GATCAACCGG GCGATACCCC GGCCAAGGCC GAGCGCCGTC GTTACTTCAG
501 CGAGTTGTTT CGTTTGACAG GCGAGTTGGT CAAGTTGCAA AGCTGGGTGG
551 TGAAGACCGG GCACAAGGTG GTGATTCTGT TCGAAGGCCG CGATGCCGCT
601 GGCAAAGGGG GCGTGATCAA GCGCATCACC CAGCGTCTTA ATCCACGGGT
651 CTGCCGGGTC GCGGCGCTTC CCGCGCCGAG TGACCGCGAG CGCACCCAGT
701 GGTATTTCCA GCGTTATGTC TCGCACCTGC CCGCCGCCGG CGAGATCGTC
751 CTGTTTCGACC GCAGCTGGTA CAACCGCGCC GGTGTCGAGC AGGTGATGGG
801 CTTTTGCAAC GAGGAACAGT ACGAAGAATT TTTCCGCAGC GTGCCGGAAT
851 TC
```

Figure 14

Nucleotide sequence pFI912 (958bp EcoRI/PstI fragment ex pFI793)

```

1   CTGCAGGGCC TGGGGCATGC CGAGTCGGCG TCGCAGAACG CCTCTGCCTA
51  TGCCTGGGAA CGCAAGCAAA TGCCTGCGCC CGCTCGCCCG GTCGGAGTCG
101 AAGCCGAAGT GGCCGACCCC ATTCATTTTC ATCCGGCCAT GCGCCGGGTG
151 TTGCTGGAAC TGAGGGCCTA TGCCGAGGGC ATGCGTGCGG TCGGTTACTG
201 GGCGGCGCAT TTGTTGGATC AGTCCGAGCA GGCCGAGGAT CTGCCCCACTC
251 GTCAGCGCGC CTTGCAACTG GCGGAGCTGC TGACGCCGGT GATCAAGGCG
301 TTCTTCACCG AGCAGGGTTT TCGCCTGGCC AGCAACGCCT TGCAGGTGTT
351 CGGTGGCTAC GGCTACGTCA GCGAGTTCGC CATCGAACAG ACCCTGCGCG
401 ACAGCCGGAT CGCGATGATT TACGAGGGCA GCAACGAAAT CCAGGCCAAT
451 GACCTGCTGC TGCGCAAAGT GCTGGGGGAT GAAGGTCGCG CCTTTGGCCA
501 ACTGTTGGCG GTCATGCGCG AAGAGGCCGA ACTGGCCTGT AACGACACCC
551 GCTTTGGCGC TGAGCTGGTG CAGCTGTGCG ACAAACTCGA GACAGTGCAA
601 CTTGAGATAG GGGACCTCGC CGTCACGGAG CGCGAATACC CGTATCGAGC
651 CGCTGGCGAT TTCCTGCGCC TGTGTGGCGT GGCGCTGTTG GGGTTTTCTT
701 GGGCGAGAGC GGCACGGGTG TCTCGCCTGT TACCTGACAG CGATCCACTG
751 CGTCCCAACA AACTGGAAAC CGCGCGTTTC TTCTTTGCCT ACCTGCTGCC
801 AGAAGCCGAT CAACGCCTCG CAGCCATTCG GGCGGCGAGA GCGCCGTTGC
851 CGTTTTTGAT CTGAAAAAAC GCCCGCCAGG CCAATGTGG CTCGCTCCCA
901 CAAACAGCGC GAACCACATC GAGCCACCGC CGCCACGCCA GTTGTACAGG
951 CCGAATTC

```

Figure 15

Nucleotide sequence pFI913 (959bp EcoRI/PstI fragment ex pFI793)

```

1   CTGCAGGCTT GCCATATCAG TGGCGACAGC TTCGTCCGCG CTCCAGGCGC
51  AAGGGCCAAC GACCTGCCGA CCGTGCCGAA TAGGCTGTCG GCGTCCGTTA
101 TTCTGGACGC ACCGCAAAAA CTGTTATTTA CCCGGTCTTC TTCCACTGTA
151 GAACCTTTTC ACTATAGCGG CCCTGCGTGT TCTGCGGGAG CTGCTCATGA
201 TTCTGCACGC GATTCCACTT CCAGCCCGTT GCCGCGCCGT GCTGTTGCGG
251 TTTCTGCACG CACGGCTTTT GCATCAGGCT TGCACAGCCA GCCACAAGGG
301 CAGGTAAGCT CTAGCTCGCA CGTCCTGGGC GTCTCCCAGG TCTGCCAACG
351 CGACGCGGAC GCGTCAAACA ACGCCCGGCC CCTAATGAAG CCGGGACACT
401 CAGCCCAGAG GCATTTATGA GTAACAACCT CGACCAGCTC ACCGATTGGT
451 TGAAAGACCA CAAGATCACA GAAGTCGAAT GCATGATTGG CGACTTGACC
501 GGGATCACCC GCGGCAAGAT CTCGCCAACC AACAAGTTCA TTGCCGAAAA
551 AGGCATGCGC CTGCCCCGAGA GTGTGCTGTT GCAGACAGTG ACGGGCGACT
601 ATGTCGAAGA CGACATCTAT TACGAACTGC TCGACCCGGC CGACATCGAC
651 ATGATCTGCC GCCCCGACCA GAACGCGGTG TTCCTCGTGC CATGGGCCAT
701 CGAGCCGACC GCGCAGGTGA TTCACGACAC CTACGACAAG CAGGGCAACC
751 CGATCGAGCT GTCGCCACGC AACGTCCTCA AGAAAGTCCT CAAACTCTAT
801 TCCGACAAGG GCTGGCAGCC GATCGTGGCG CCGGAAATGG AGTTCTACCT
851 GACCAAGCGC AGTGACGACC CGGATTACCC ATTGCAACCG CCGGTTGGCC
901 GTTCCGGACG TCCGGAAATC GGTCGCCAAT CGTTCTCTAT CGAAGCGGCC
951 AACGAATTC

```

Figure 16

Outward reading PCR primers




Figure 17




Figure 18

Nucleotide sequence merged contigs pFI913/PCR product/pFI901(4259bp)

```

1   CTGCAGGCTT GCCATATCAG TGGCGACAGC TTCGTCCGCG CTCCAGGCGC
51  AAGGGCCAAC GACCTGCCGA CGGTGCCGAA TAGGCTGTCTG GCGTCCGTTA
101 TTCTGGACGC ACCGCAAAAA CTGTTATTTA CCCGGTCTTC TTCCACTGTA
151 GAACCTTTTC ACTATAGCGG CCCTGCGTGT TCTGCGGGAG CTGCTCATGA
201 TTCTGCACGC GATTCCACTT CCAGCCCGTT GCCGCGCCGT GCTGTTGCGG
251 TTTCTGCACG CACGGCTTTT GCATCAGGCT TGCACAGCCA GCCACAAGGG
301 CAGGTAAGCT CTAGCTCGCA CGTCCTGGGC GTCTCCCAGG TCTGCCAACG
351 CGACGCGGAC GCGTCAAACA ACGCCCGGCC CCTAATGAAG CCGGGACACT
401 CAGCCCAGAG GCATTTATGA GTAACAACCT CGACCAGCTC ACCGATTGGT
451 TGAAAGACCA CAAGATCACA GAAGTCGAAT GCATGATTGG CGACTTGACC
501 GGGATCACCC GCGGCAAGAT CTCGCCAACC AACAAAGTTCA TTGCCGAAAA
551 AGGCATGCGC CTGCCCCGAGA GTGTGCTGTT GCAGACAGTG ACGGGCGACT
601 ATGTCGAAGA CGACATCTAT TACGAACTGC TCGACCCGGC CGACATCGAC
651 ATGATCTGCC GCCCCGACCA GAACGCGGTG TTCCTCGTGC CATGGGCCAT
701 CGAGCCGACC GCGCAGGTGA TTCACGACAC CTACGACAAG CAGGGCAACC
751 CGATCGAGCT GTCGCCACGC AACGTCCTCA AGAAAGTCCT CAAACTCTAT
801 TCCGACAAGG GCTGGCAGCC GATCGTGGCG CCGGAAATGG AGTTCTACCT
851 GACCAAGCGC AGTGACGACC CGGATTACCC ATTGCAACCG CCGGTTGGCC
901 GTTCCGGACG TCCGGAAATC GGTCCGCAAT CGTTCTCTAT CGAAGCGGCC
951 AACGAATTCG ACCCGCTGTT CGAAGACGTC TACGACTGGT GCGAACTGCA
1001 GGAGCTGGAT CTCGATACGC TGATCCACGA AGACGGCACG GCGCAGATGG
1051 AAATCAACTT CCGTCACGGC GACGCGCTGT CCCTGGCCGA CCAGATCCTG
1101 GTGTTCAAGC GCACCATGCG CGAGGCCGCG CTCAAGCACA ACGTGGCCGC
1151 CACGTTTCATG GCCAAGCCGA TGACCGGCGA GCCTGGCAGC GCCATGCACC
1201 TGCACCAGAG CATCATCGAT ATCGAGACCG GCAAGAACGT CTTCTCCAAT
1251 GAAGACGGGA GCATGAGCCA GTTGTTCTCTC AACCACATCG GCGGCCTGCA
1301 GAAATTCATC CCTGAACTGC TGCCGCTGTT CGCGCCCAAC GTCAACTCGT

```

Figure 19A

```

1351  TCCGCCGCTT CCTGCCGGAC ACTTCGGCGC CGGTGAACGT CGAGTGGGGC
1401  GAAGAAAACC GTACCGTGGG CCTGCGGGTG CCGGATGCCG GCCCTCAAAA
1451  CCGTCGGGTG GAAAACCGCC TGCCGGGTGC CGACGCCAAC CCGTACCTGG
1501  CGATTGCCGC GAGCCTGCTG TGCGGCTACA TCGGCATGGT CGAAGGTATC
1551  AACCCAAGCG CGCCTGTGGT GGGTCGTGGT TACGAGCGGC GCAACCTGCG
1601  TCTGCCGCTG ACCATCGAAG ACGCTCTGGA ACGCATGGAA AACAGCAAGA
1651  CCATCGAGAA ATACCTGGGT CACAACCTCA TCACTGGCTA CGTCGCGGTC
1701  AAGCGGGCCG AGCATGAAAA CTTCAAGCGC GTGATCAGCT CATGGGAACG
1751  GGAATTCCTG TTGTTGCGCG TCTGACACGC CGGGTGCGGC CCTCAAAGC
1801  CGCACTCCAA CCTCACTAGG AGAGCTTTAT GAGCAACAAC CCGCAAACCC
1851  GTGAATGGCA GAACCTGAGC GCCGAACACC ACCTGGCCCC CTTCAGTGAC
1901  TTCAAGCAAT TGAAGGAAAA AGGCCCGCGC GTCATCACCA GCGCCAAGGG
1951  CGTTTACCTG TGGGACAGCG AAGGCAATCA GATCCTCGAC GGCATGGCCG
2001  GCCTGTGGTG CGTGGCCATC GGTACGGCC GCGACGAGTT GGCCGAGGCT
2051  GCCAGCAAGC AGATGCGCGA GTTGCCGTAC TACAACCTGT TTTTCCAGAC
2101  CGCTCACCCG CCCGTCCTCG AGCTGGCCAA GGCAATTTCC GATATCGCGC
2151  CAGCAGGCAT GAACCACGTG TTCTTCACCG GTTCCGGCTC CGAAGGCAAT
2201  GACACCATGC TCGCATGGT TCGCCACTAC TGGGCGATCA AAGGTCAGCC
2251  AAACAAGAAA GTCATTATCA GCCGCAAGAA CGGCTACCAC GGTTGACCG
2301  TGGCCGGCGC CAGCCTGGGC GGCATGACCT ACATGCACGA ACAGGGCGAC
2351  TTGCCGATCC CGGGCATCGT GCACATTCCG CAGCCGTACT GGTTCCGGTGA
2401  AGGCGGCGAC ATGACCCCGG AAGAATTCGG GATCTGGGCT GCCAACCAGT
2451  TGGAAGAAAA GATTCTCGAA GTCGGTGTG ACAAACGTCGG CGCCTTCATT
2501  GCCGAGCCGA TCCAGGGCGC CGGCGGCGTG ATCGTGCCGC CAGAAAGCTA
2551  CTGGCCGCGC ATCAAGGAAA TCCTCGCCAA GTACGACATC CTGTTCGTG
2601  CCGATGAAGT GATTTCGGT TTCGGCCGTA CCGGCGAGTG GTTCGGCAGC
2651  GATTCTACG ACCTCAAGCC CGACATGATG ACCATCGCCA AGGGCCTGAC
2701  TTCCGGCTAC ATCCCGATGG GTGGTCTGAT CGTGCGGAT TCGGTGGTCG
2751  AAGTGCTGAA CGAAGGCGGC GATTTCACC ACGGATTCAC CTACTCCGGT

```

Figure 19B

```

2801  CACCCGGTAG CGGCGGCTGT TGCCCTGGAA AACATCCGCA TCATGCGCGA
2851  AGAGAAGATT ATCGAGCGCG TCCAGGAAGA AACGGCACCG TATTTGCAAA
2901  AGCGTCTGCG TGAACTCAAC GATCATCCAT TGGTGGGTGA AGTTCGCGGG
2951  GTAGGGTTGC TGGGCGCTAT CGAACTGGTT CAGGACAAAG CCACGCGCAA
3001  ACGTTACGAA GGCAAGGGCG TGGGCATGAT CTGCCGGCAG TTCTGCTTCG
3051  ACAACGGGCT GATCATGCGC GCGGTGGCG ACACCATGAT CATCGCGCCG
3101  CCACTGGTGA TTACCAAGGC GGAAATCGAT GAGCTGGTGA GCAAGGCACG
3151  CAAGTGCCTG GACCTGACCC TGAGTGTGTT GCAGGGCTAA GTGCTAGGCT
3201  CTGAGCGGGA GTTGTATGAA CTTTCGCTCA GAGCGGTCAG AAAGCTTGGC
3251  CTTTCCTTGA AAGACCGCCA TGGATGTTGC CAGACTAGCC ACCGTTCCAA
3301  ATGCCCGGGT TCGGCGCGGA ACAGGTGGTT CAAAAAAGCA AAAATTTGGA
3351  GCATTACGCA TGAAGGCACT CGGTAAAAAG CTCGCCGGCA AGACACTCCT
3401  TGCCATGTCC CTGATGGGCA TCATGGCGGG CGCGGTTTCAG GCAGATGACA
3451  AAGTCTTGCA CGTGTACAAC TGGTCCGATT ACATCGCGCC GGACACCATC
3501  AAGAAGTTTG AAGACGAGTC GGGCATCAAG GTGGTCTACG ACGTCTTCGA
3551  CAGTAACGAA ACCCTCGAAG CCAAGTTGCT GGCCGGCAAG TCCGGTTACG
3601  ACATCGTGGT GCCTTCGAAC AACTTCCTGG CCAAGCAGAT CAAGGCCGGC
3651  GTCTACCAGA AGCTGGACAA GTCCAAGCTG CCGAACTGGA AGAACCTGAA
3701  CACCGATCTG CTCAAGGCCG TTTCGGTCAG CGACCCTGGT AACGAGCACG
3751  CCTTCCCGTA CATGTGGGGC TCGATCGGCA TCGGCTTCAA CGCCGAGAAG
3801  GTCAAGGCCG CGCTGGGTCC GGATGCACCG ACCAATTCCT GGGACCTGAT
3851  CTTCAAACCG GAAAACGCCG CCAAGCTGAA ATCCTGTGGC ATCAGCGTGC
3901  TGGATTGCGC AACCGAGATG ATTCCGGTGG CCCTGCACTA CCTGGGCTAC
3951  CCGACCGACA GCCAGGACAA GAAACAAC TGCCGAGGCC AGGCACTGTT
4001  CCTCAAAGTT CGTCCTTCGA TCGGTTACTT CCACTCCTCC AAGTACATTT
4051  CCGACCTGGC CAACGGCAAC ATCTGCGTGG CGATCGGCTA CTCGGGTGAC
4101  ATCTATCAGG CCAAGACTCG CGCCGCCGAA GCCGGTGACA AGGTCAAGGT
4151  CAGCTACAAC ATTCCCAAAG AAGGTGCAGG CAGCTTCTAC GACATGGTCG
4201  CCATCCCTAA AGATGCCGAA AACGTGGAAG GCGCCTACAA GTTCATGACC

```

Figure 19C

4251 TTCCTGCAG

Figure 19D

PRODUCTION OF P-HYDROXYBENZOIC ACID

[0001] The present invention relates principally to the production of vanillin (4-hydroxy-3-methoxybenzaldehyde), particularly to the production of vanillin other than by extraction from the Vanilla pod.

[0002] Vanillin is an important food and drink flavouring agent and a major flavour component of natural vanilla from the Vanilla pod. The use of natural vanilla is limited by its high price. Synthetic vanillin, commonly derived from sulphite liquors produced during the processing of wood pulp for paper manufacture, is frequently used as a low-cost vanilla substitute. Alternative biological processes for the production of natural vanillin and allied flavourings would have considerable industrial value and utility, most particularly if such processes could facilitate the production of vanillin and/or allied flavourings directly in a fermented food or beverage.

[0003] The mechanism of vanillin biosynthesis in Vanilla remains substantially uncharacterised. M. H. Zenk (*Anal. Z. Pflanzenphysiol* 53, 404-414 (1965)) showed that vanillin was derived from trans-ferulate (4-hydroxy-3-methoxy-trans-cinnamate) and proposed a mechanism analogous to the classical β -oxidation of fatty acids, with cleavage of a β -keto thioester to produce acetyl SCoA and vanilloyl SCoA (4-hydroxy-3-methoxybenzoyl SCoA) and subsequent reduction and CoASH release to generate vanillin. C. Funk and P. E. Brodelius (*Plant Physiol.* 94, 95-101; 102-108 (1990); 99, 256-262 (1992)), proposed a different route, in which the 4-hydroxy group of trans-ferulate became successively methylated and demethylated during the pathway of vanillin biosynthesis; however, the detailed enzymology was not elucidated. In potato tubers and in the fungus, *Polyporus hispidus* (C. J. French, C. P. Vance and G. H. N. Towers, *Phytochemistry* 15, 564-566 (1976)), in cell cultures of *Lithospermum erythrorhizon* (K. Yazaki, L. Heide and M. Tabata, *Phytochemistry* 30, 2233-2236 (1991)) and in cell cultures of carrot (J. -P. Schnitzler, J. Madlung, A. Rose and H. U. Seitz, *Planta* 188, 594-600 (1992)), evidence was obtained from in vitro studies that the corresponding analogue of vanillin, 4-hydroxybenzaldehyde, was an intermediate in the formation of 4-hydroxybenzoate from 4-coumarate (4-hydroxy-trans-cinnamate). There was no requirement for ATP or CoASH, thus apparently ruling out a β -oxidation mechanism. Further studies with cell-free extracts of *Lithospermum erythrorhizon*, however, have in contrast recently established the presence of a β -oxidation route for the conversion of 4-coumarate to 4-hydroxybenzoate (R. Löscher and L. Heide, *Plant Physiol.* 106, 271-279 (1994)); in this case, the conversion was dependent on ATP, Mg^{2+} ions and NAD^+ and proceeded via 4-hydroxybenzoyl SCoA, without the intermediate formation of 4-hydroxybenzaldehyde.

[0004] In the Gram-negative bacterium, *Pseudomonas acidovorans*, trans-ferulate was shown to be catabolised to vanillate and acetate, apparently via vanillin (A. Toms and J. M. Wood, *Biochemistry* 9, 337-343 (1970)). Although in cell-free extracts NAD^+ was necessary for the oxidation of vanillin to vanillate and for the further oxidation of vanillate to protocatechuate and formate, no mention was made of any other cofactor requirements. Further studies of ferulate utilisation in *Pseudomonas* 25 species have been reported (V. Andreoni and G. Bestetti, *FEMS Microbiology Ecology* 53,

129-132 (1988); T. Omori, K. Hatakeyama and T. Kodama, *Appl. Microbiol. Biotechnol.* 29, 497-500 (1988); Z. Huang, L. Dostal and J. P. N. Rosazza, *Appl. Env. Microbiol.* 59, 2244-2250 (1993)); however, these have not sought to elucidate further the mechanism of the two-carbon cleavage of ferulate. Zenk et al (1980) *Anal. Biochem.* 101, 182-187 describe a procedure for the enzymatic synthesis and isolation of cinnamoyl-CoA thioesters using a bacterial system. In contrast, the enzymology and genetics of the utilisation of simple benzene derivatives, including benzoic acids and phenols, by *Pseudomonas* have been intensively studied (T. K. Kirk, T. Higuchi and H. -M. Chang (eds.), *"Lignin biodegradation"*, CRC Press, Boca Raton, Fla., USA (1980); D. T. Gibson (ed.), *"Microbial degradation of organic compounds"*, Marcel Dekker, New York (1984); J. L. Ramos, A. Wasserfallen, K. Rose and K. N. Timmis, *Science* 235, 593-596 (1987); C. S. Harwood, N. N. Nichols, M. K. Kim, J. L. Ditty and R. E. Parales, *J. Bacteriol.* 176, 6479-6488 (1994); S. Romerosteiner, R. E. Parales, C. S. Harwood and J. E. Houghton, *J. Bacteriol.* 176, 5771-5779 (1994); J. Inoue, J. P. Shaw, M. Rekik and S. Harayama, *J. Bacteriol.* 177, 1196-1201 (1995)).

[0005] A survey of potential microbial routes to aromatic aldehydes, including routes (i) from trans-cinnamic acids, (ii) from benzoic acids by reduction and (iii) by conversion of aromatic amino acids to phenylpyruvic acids followed by treatment with base, has been presented by J. Casey and R. Dobb (*Enzyme Microb. Technol.* 14, 739-747 (1992)).

[0006] U.S. Pat. No. 5,128,253 describes a method of producing vanillin from ferulic acid by various microorganisms and extracts thereof or enzymes derived therefrom in the presence of a sulphhydryl compound but does not disclose what any of the enzymes involved in the conversion of ferulic acid to vanillin are. U.S. Pat. No. 5,279,950 is a continuation-in-part application of U.S. Pat. No. 5,128,253 which additionally describes that Vanilla calluses can be used in the process.

[0007] WO 94/13614 describes the production of vanillin from ferulic acid by the action of Vanilla root material and makes use of an adsorbent, such as charcoal, to extract vanillin but does not disclose the specific enzymes involved.

[0008] EP 0 453 368 describes that a culture of *Pycnoporus* can convert trans-ferulic acid into vanillin but does not disclose the specific enzymes involved.

[0009] WO 94/02621 describes the production of vanillin from trans-ferulic acid by the action of a lipoxxygenase enzyme. EP 0 405 197 describes the production of vanillin from eugenol/isoeugenol by bacteria from the genera *Serratia*, *Klebsiella* and *Enterobacter* by oxidation.

[0010] Vanillin may also be produced from phenolic stilbenes as is mentioned in Hagedorn & Kaphammer (1994) *Ann. Rev. Microbiol.* 48, 773-800.

[0011] Vanillic acid is also a useful compound as it can be polymerised into oligomers or used as a monomer in the synthesis of polyesters; similarly p-hydroxybenzoic acid is also useful for polymer synthesis.

[0012] A first aspect of the invention provides a method of producing vanillin comprising the steps of

[0013] (1) providing trans-ferulic acid or a salt thereof; and

[0014] (2) providing trans-ferulate:CoASH ligase activity (enzyme activity I), trans-feruloyl SCoA hydratase activity (enzyme activity II), and 4-hydroxy-3-methoxyphenyl- β -hydroxy-propionyl SCoA (HMPHP SCoA) cleavage activity (enzyme activity III).

[0015] The advantages of the present invention over chemical synthesis or extraction from the Vanilla pod include (i) economic advantage over extraction from Vanilla pod and freedom from geographical dependence on Vanilla growing areas; (ii) the ability to produce vanillin by a natural process, involving biological catalysts; (iii) the benefits of generating a natural flavour in situ in a fermented food or beverage, if the genes are expressed in appropriate food-grade hosts—eg lactic acid bacteria or yeasts; and (iv) the possibility of expanding the range of plants in which vanillin and related substances might be produced and from which they might be extracted. These and other examples of the methods of the invention are described in more detail below.

[0016] We have determined the mechanism of chain-shortening of trans-ferulate (trans-ferulic acid) by a strain of *Pseudomonas fluorescens* (named *Ps. fluorescens* biovar. V, strain AN103 and which we have abbreviated at some points to AN103) isolated from soil. Our data indicate clearly that vanillin (4-hydroxy-3-methoxy benzaldehyde) is an intermediate and that the mechanism does not involve β -oxidation. The vanillin pathway of *Ps. fluorescens* biovar. V, strain AN103 is described in FIG. 1. Trans-ferulic acid (or a salt thereof) is interconverted with trans-feruloyl SCoA in the presence of CoASH; trans-feruloyl SCoA is interconverted with 4-hydroxy-3-methoxyphenyl- β -hydroxypropionyl SCoA (HMPHP SCoA); and HMPHP SCoA is interconverted with vanillin.

[0017] For convenience, trans-ferulate:CoASH ligase activity is called enzyme activity I, trans-feruloyl SCoA hydratase activity is called enzyme activity II; and HMPHP SCoA cleavage activity is called enzyme activity III. The interconversions performed by these enzyme activities is shown in FIG. 1.

[0018] The method of producing vanillin provided by the invention therefore includes the steps of exposing trans-ferulic acid or a salt thereof to enzyme activity I and forming a product, exposing the said product of enzyme activity I to enzyme activity II to form a product and exposing the said product of enzyme activity II to enzyme activity III to form a product.

[0019] Trans-ferulic acid or a salt thereof may be provided directly, for example by supplying pre-prepared trans-ferulic acid or a salt thereof, or it may be provided indirectly, for example by supplying a precursor of trans-ferulic acid or a precursor of a salt of trans-ferulic acid and means to convert the said precursor into trans-ferulic acid or a salt thereof. As is described in more detail below, it is convenient if the precursor is an ester of trans-ferulic acid and the means to convert said ester is a suitable esterase.

[0020] By “providing trans-ferulate:CoASH ligase activity (enzyme activity I), trans-feruloyl SCoA hydratase activity (enzyme activity II), and 4-hydroxy-3-methoxyphenyl- β -hydroxy-propionyl SCoA (HMPHP SCoA) cleavage activity (enzyme activity III)” we include the provision of the enzyme activities in any suitable form to effect the said production of vanillin. For example, as is discussed in more

detail below, the method of the invention specifically includes, but is not limited to, the provision of the enzyme activities (a) by intact or permeabilised *Ps. fluorescens* biovar. V, strain AN103 or a mutant thereof, (b) at least one of enzyme activities II or III of which is in a form substantially free of cellular material, (c) by intact or permeabilised cells in culture, particularly microorganisms, which have been genetically modified to contain genes which encode enzyme activities II or III (for example, food grade microorganisms such as lactic acid bacteria and brewing yeast), and (d) by plants which have been genetically modified to contain genes which encode said enzyme activities.

[0021] It is preferred if means for converting vanillin to a non-vanillin product is absent or reduced. Of course, the enzyme activity III is not such a means. Conveniently, these enzyme activities are provided by the soil bacterium *Pseudomonas fluorescens* biovar. V, strain AN103 the said bacterium being that deposited under the Budapest Treaty at the National Collection of Industrial and Marine Bacteria Limited, AURIS Business Centre, 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland under Accession No NCIMB 40783, or a mutant or variant thereof. By “mutant or variant thereof” we include any mutant or variant of the said bacterium provided that the bacterium retains the said enzyme activities whether or not at the same levels. It will be appreciated that the said enzyme activities can be retained even if the genes encoding said enzymes are mutated. For example, mutants which constitutively express (as opposed to conditionally or inducibly express) the said enzyme activities are particularly useful mutants of *Ps. fluorescens* biovar. V, strain AN103, as are variants in which one or more of the enzymes with the said activities exhibit more favourable kinetic characteristics (for example, an increased turnover number or a decreased K_m).

[0022] When *Ps. fluorescens* biovar. V, strain AN103 is growing on trans-ferulate it will derive maximum benefit if vanillin is catabolised further in order to provide more energy. However, in order to maximise the production of vanillin by *Ps. fluorescens* biovar. V, strain AN103 it is preferred that the means for converting vanillin to a non-vanillin product is absent or reduced. We have found that in *Ps. fluorescens* biovar. V, strain AN103 vanillin is converted to vanillic acid or a salt thereof by vanillin:NAD⁺ oxidoreductase. It is preferred if a mutant of *Ps. fluorescens* biovar. V, strain AN103 wherein the vanillin:NAD⁺ oxidoreductase activity is absent or reduced is used in the method. Such a mutant can be made using a gene replacement strategy with a disrupted vanillin:NAD oxidoreductase gene, or a sequence of DNA from which this gene has been deleted. Gene replacement is well known in the art of bacterial genetics. Alternatively, isolation of such a mutant may be achieved by classical chemical mutagenesis, selecting on the basis of inability to grow on vanillin.

[0023] It will be appreciated that there are other means for converting vanillin to a non-vanillin product and it is preferred if these are absent or reduced in the method.

[0024] Although *Ps. fluorescens* biovar. V, strain AN103 or mutants or variants thereof themselves are useful in the method of the invention as whole cells or permeabilised or immobilised cells, it is preferred if the enzyme activities I, II and III are provided by an intact-cell-free system of *Ps. fluorescens* biovar. V, strain AN103 or a mutant or variant

thereof. Suitable systems and extracts may be used by methods well known in the art, for example by French pressure cell or sonication followed by centrifugation. Alternatively, whole cells may be permeabilised using methods well known in the art, for example using detergents such as dimethyl sulphoxide (DMSO).

[0025] Using such an intact-cell-free system allows the necessary substrates and any cofactors to reach readily the relevant enzymes and for the products to be released readily into the reaction medium if this is necessary for further reaction; however as discussed below, at least some of the enzymes of the invention may be involved in substrate (metabolic) channelling.

[0026] We have found that none of the enzyme activities I, II and III from *Ps. fluorescens* biovar. V, strain AN103 is dependent on NAD^+ whereas enzyme activity IV from *Ps. fluorescens* (vanillin: NAD^+ oxido-reductase) requires NAD^+ .

[0027] Thus, a preferred way of reducing means for converting vanillin to a non-vanillin product in an intact-cell-free system of *Ps. fluorescens* biovar. V, strain AN103 (or in a cell-permeabilised system of *Ps. fluorescens* biovar. V, strain AN103) is to omit NAD^+ from the reaction system. Any exogenous NAD^+ is readily and rapidly depleted by the presence of trans-ferulate in the system.

[0028] For the microorganisms of the present invention which can be used in the method of vanillin production, including *Ps. fluorescens* biovar. V, strain AN103, at least three main types of bioreactor may be used for the biotransformation reactions: the batch tank, the packed bed and the continuous-flow stirred tank; their applications and characteristics have been reviewed (M. D. Lilly in "Recent Advances in Biotechnology", eds. F. Vardar-Sukan and S. S. Sukan, Kluwer Academic Publishers, Dordrecht, 1992, pp 47-68 and loc. cit.).

[0029] As is described in more detail below, enzyme activities II and III are available free from other enzyme activities, for example directly or indirectly from *Ps. fluorescens* biovar. V, strain AN103 and from other organisms or cells which have been genetically modified to express genes encoding the said enzyme activities.

[0030] It will be appreciated that other microorganisms will be found which will be useful in the methods of the invention, for example, by screening. Such microorganisms and methods of screening and methods of use form part of the invention. The method of screening for other microorganisms possessing activities I, II and III is essentially that already described in the Materials and Methods section in the Examples for the isolation of AN103. The important aspect is isolation from an environment rich in trans-ferulate or related compounds (eg 4-trans-coumarate, trans-cafeate [3,4-dihydroxy-trans-cinnamate] which, as described below, may also be substrates for enzyme activity I) and selection for growth on trans-ferulate (preferably) as sole carbon source. In practice, preferred sources are those in which plant-derived materials are being degraded; in addition to soil or compost, this would include the outflow or residues from factories or other installations processing such materials—eg sugar-beet factories, cocoa fermentation heaps etc—and the contents of the gastro-intestinal tract, particularly of ruminants and other herbivores. It is possible that

anaerobes might be found possessing these activities and due account can readily be taken of this in the isolation procedure. A priori, isolation of organisms with these activities might also be possible from marine environments.

[0031] Genera in which further microorganisms useful in the invention will be found include *Pseudomonas*, *Arthrobacter*, *Alcaligenes*, *Acinetobacter*, *Flavobacterium*, *Agrobacterium*, *Rhizobium*, *Streptomyces*, *Saccharomyces*, *Penicillium* and *Aspergillus*.

[0032] An alternative or additional approach is to use any one of the *Pseudomonas* genes encoding enzyme activities II or III described herein or redundant sequences designed from the *Pseudomonas* enzyme amino-acid sequences in DNA probes or PCR amplification strategies to find related genes in other organisms. As is made more clear below, enzymes and nucleotide sequences which are functionally equivalent to those of isolated from AN103 but which differ in sequence form part of the invention.

[0033] Our studies indicate that the enzyme which interconverts trans-ferulate and trans-feruloyl SCoA in *Ps. fluorescens* biovar. V, strain AN103 uses Coenzyme A (CoASH), ATP and Mg^{2+} or other functionally equivalent cofactors. Thus, it is preferred that the method further comprises the step of (3) providing any one of the cofactors CoASH, ATP or Mg^{2+} or other functionally equivalent cofactors. ATP is adenosine triphosphate. It is well known that other functionally equivalent cofactors can substitute in some cases for CoASH, ATP or Mg^{2+} . For example Mn^{2+} may be used in place of Mg^{2+} and derivatives or analogues of ATP, preferably with a hydrolysable γ -phosphate, may be used in place of ATP.

[0034] We have also determined that, at least when the enzyme activity I is provided by the *Pseudomonas* AN103 enzyme which interconverts trans-ferulate and trans-feruloyl SCoA and which enzyme uses ATP and Coenzyme ASH, it is convenient to include a system wherein either one, or both, of the cofactors Coenzyme ASH and ATP is recycled. The following ATP generation and CoASH recycling systems are preferred.

[0035] ATP Generation:—

[0036] (i) $\text{trans-Ferulate} + \text{CoASH} + \text{ATP} + \text{H}_2\text{O} \rightarrow \text{Vanillin} + \text{Acetyl SCoA} + \text{AMP} + \text{PPi}$ (overall reaction catalysed by *Ps. fluorescens* biovar. V, strain AN103 extract)

[0037] (ii) $\text{AMP} + \text{ATP} \rightleftharpoons 2 \text{ADP}$ (adenylate kinase)

[0038] (iii) $\text{Acetyl-P} + \text{ADP} \rightleftharpoons \text{Acetate} + \text{ATP}$ (acetate kinase)

[0039] (iv) Sum: $\text{trans-Ferulate} + \text{CoASH} + 2 \text{Acetyl-P} + \text{H}_2\text{O} \rightarrow \text{Vanillin} + \text{Acetyl SCoA} + 2 \text{Acetate} + \text{PPi}$

[0040] CoASH Recycling is Achievable Using Commercially-available Citrate Synthase (EC 4.1.3.7) and Citrate Lyase (EC 4.1.3.6), viz:—

[0041] (v) $\text{Acetyl SCoA} + \text{Oxaloacetate} + \text{H}_2\text{O} \rightleftharpoons \text{Citrate} + \text{CoASH}$ (citrate synthase)

[0042] (vi) $\text{Citrate} \rightleftharpoons \text{Oxaloacetate} + \text{Acetate}$ (citrate lyase)

[0043] Overall Sum, (iv)-(vi):

[0044] (vii) $\text{trans-Ferulate} + 2 \text{Acetyl-P} + 2 \text{H}_2\text{O} \rightarrow \text{Vanillin} + 3 \text{Acetate} + \text{PPi}$

[0045] The acetyl~P used in the overall process, (vii), would not itself be generated by enzymic means; however, none of its atoms would appear in the vanillin product.

[0046] Acetyl phosphate is commercially available or can be synthesised using the method described by Stadtman (1957) *Meth. Enzymol.* 3, 228-231.

[0047] The reagents are commercially available from, for example Sigma Chemical Co, Fancy Road, Poole, Dorset, UK. Citrate lyase is typically from *Enterobacter aerogenes*; citrate synthase is typically from chicken heart, pigeon breast muscle or porcine heart.

[0048] Thus, it is preferred if coenzyme ASH is recycled using the enzymes citrate synthase and citrate lyase; and it is preferred if the ATP is generated using the enzymes adenylate kinase (EC 2.7.4.3) and acetate kinase (EC 2.7.2.1).

[0049] The co-factor recycling system is particularly preferred when using an intact-cell-free system.

[0050] Trans-ferulic acid or a salt thereof is readily available from plant material. Suitably, trans-ferulic acid or a salt thereof is released from the plant material by the action of ferulic acid esterase. Thus, in a particularly preferred embodiment of the invention the trans-ferulic acid or salt thereof is provided by the action of ferulic acid esterase on plant material.

[0051] Trans-ferulic acid and trans-4-coumaric acid can together represent up to 1.5% by weight of the cell walls of temperate grasses (R. D. Hartley and E. C. Jones, *Phytochemistry* 16, 1531-1534 (1977)). Trans-ferulic acid is reported to comprise 0.5% (w/w) of wheat bran (M. C. Ralet, J. -F. Thibault and G. Della Valle, *J. Cereal Sci.* 11, 249-259 (1990)), 3.1% of maize bran (L. Saulnier, C. Marot, E. Chanliaud and J. -F. Thibault, *Carbohydr. Polym.* 26, 279-287 (1995)) and 0.8% of sugar beet pulp (V. Micard, G. M. G. C. Renard and J. -F. Thibault, *Lebensm. -Wiss. u-Technol.* 27, 59-66 (1994)). These materials are amongst the preferred sources of trans-ferulic acid. Since trans-ferulic acid is present esterified with cell-wall polysaccharides, hydrolysis is essential. Alkaline or acid hydrolysis is possible, but enzymic hydrolysis is preferred. Typically, the initial step is the partial enzymic hydrolysis of carbohydrates (arabinans, xylans, rhamnogalacturanans) to which trans-ferulate is linked, followed by the release of trans-ferulate from the oligosaccharide fragments by trans-ferulic acid esterase activity. In practice, both steps may occur simultaneously in the reaction mixture. Descriptions of representative laboratory-scale processes are available in the literature (for example see L. P. Christov and B. A. Prior, *Enzyme Microb. Technol.* 15, 460-475 (1993)); C. B. Faulds and G. Williamson, *Appl. Microbiol. Biotechnol.* 43, 1082-1087 (1995); C. B. Faulds, P. A. Kroon, L. Saulnier, J. -F. Thibault and G. Williamson, *Carbohydrate Polymers* 27, 187-190 (1995)). Phenolic acid-releasing enzymes have been reported from a number of microorganisms, including *Streptomyces olivochromogenes* (C. B. Faulds and G. Williamson, *J. Gen. Microbiol.* 137, 2337-2345 (1991)), *Penicillium pinophilum* (A. Castanares, S. I. McCrae and T. M. Wood, *Enzyme Microb. Technol.* 14, 875-884 (1992)), *Neocallimastix* spp. (W. S. Borneman, R. D. Hartley, W. H. Morrison, D. E. Akin and L. G. Ljungdahl, *Appl. Microbiol. Biotechnol.* 33, 345-351 (1990)), *Schizophyllum commune* (R. C. MacKen-

zie and D. Bilous, *Appl. Envir. Microbiol.* 54, 1170-1173 (1988)) and *Aspergillus* spp. (M. Tenkanen, J. Schuseil, J. Puls and K. Poutanen, *J. Biotechnol.* 18, 69-84 (1991); C. B. Faulds and G. Williamson, *Microbiology* 140, 779-787 (1994)). A trans-ferulic acid esterase (XYLD) has been characterised from *Pseudomonas fluorescens* subsp. *cellulosa*, together with an arabinofuranosidase (XYLC) and an endoxylanase (XYLB; L. M. A. Ferreira, T. M. Wood, G. Williamson, C. B. Faulds, G. P. Hazlewood and H. J. Gilbert, *Biochem. J.* 294, 349-355 (1993)). The genes for all three enzymes have been isolated (G. P. Hazlewood and H. J. Gilbert, in "Xylans and Xylanases", eds. J. Visser, G. Beldman, M. A. Kusters-van Someren and A. G. J. Voragen, Elsevier, Amsterdam, pp 259-273 (1992)). All of these references are incorporated herein by reference.

[0052] Thus, advantageously the trans-ferulic acid or a salt thereof may be provided by the action of trans-ferulic acid esterase on said ester. More particularly, it is advantageous to introduce a gene encoding said esterase into a host cell or organism which is being used in the methods of the invention. Thus, it is convenient to introduce a trans-ferulic acid esterase gene, such as the aforementioned XYLD gene, into a plant which is being used in the methods of the invention.

[0053] Although, as described above, the method may be performed using enzyme activities I, II and III which are provided by *Ps. fluorescens* biovar. V, strain AN103 or mutants or variants thereof themselves, or intact-cell-free extracts thereof, it is preferred if at least one of the enzyme activities II and III is provided by a substantially purified enzyme. Substantially purified enzymes with enzyme activities II and III are described below.

[0054] In a particularly preferred embodiment of the invention the method of the first aspect of the invention further comprises providing a compound, in addition to trans-ferulic acid or a salt thereof, which may be converted by any one of enzyme activities I, II or III into a desirable product. Suitably said compound is converted by any one or more of said enzyme activities into a product which is found in, and preferably contributes to the taste or aroma of, vanilla as extracted from Vanilla pod.

[0055] Vanilla as extracted from Vanilla pod contains vanillin as a major component but also smaller quantities of desirable components such as p-hydroxybenzoic acid, p-hydroxybenzaldehyde and vanillic acid. Typically these components, and vanillin, are present as glucosides in green vanilla pods as well as in the free form. However, upon hydrolysis or fermentation of the green pods or of hydrolysis of the fermented pods, most of the components are present in the free form.

[0056] Thus, it is particularly preferred if said compound is any one of trans-4-coumaric acid or a salt thereof, trans-4-coumaroyl SCoA, trans-caffeic acid or a salt thereof, trans-caffeoyl SCoA, or 3,4-methylenedioxy-trans-cinnamic acid or a salt thereof. By the action of one or more of enzyme activities I, II or III trans-4-coumaric acid or a salt thereof and trans-4-coumaroyl SCoA are converted to p-hydroxybenzaldehyde; trans-caffeic acid or a salt thereof and trans-caffeoyl SCoA are converted to 3,4-dihydroxybenzaldehyde; and 3,4-methylenedioxy-trans-cinnamic acid or a salt thereof is converted to heliotropin.

[0057] It is preferred if the compound is trans-4-coumaric acid or a salt thereof or trans-4-coumaroyl SCoA and that the

desirable product is 4-hydroxybenzaldehyde which is a significant component of natural Vanilla extract.

[0058] The enzyme activities I, II and III from *Ps. fluorescens* biovar V, strain AN103 are able to use trans-cafeate and trans-4-coumarate, (and, as appropriate, the products of their reaction with enzyme activity I) with reasonable efficiency whereas cinnamate and 3,4-methylenedioxy-trans-cinnamate, although may be used as substrates, are poor substrates of the AN103 enzymes.

[0059] Thus, the method of the first aspect of the invention is suited to make vanilla flavourings and aromas which more closely resemble the vanilla from Vanilla pod.

[0060] The method of the first aspect of the invention may, in certain circumstances, also be performed using the host cells and genetically modified cells and organisms as described below in more detail.

[0061] A second aspect of the invention provides a method of producing vanillic acid, or a salt thereof, comprising the steps of

[0062] (1) providing trans-ferulic acid or a salt thereof;

[0063] (2) providing trans-ferulate:CoASH ligase activity, trans-feruloyl SCoA hydratase activity, and 4-hydroxy-3-methoxyphenyl- β -hydroxy-propionyl SCoA (HMPHP SCoA) cleavage activity; and

[0064] (3) providing an activity that interconverts vanillin and vanillic acid.

[0065] For convenience, the activity that interconverts vanillin and vanillic acid is called enzyme activity IV. Conveniently the activity is provided by vanillin:NAD⁺ oxidoreductase (vanillin dehydrogenase). Suitably, this activity is provided by *Ps. fluorescens* biovar. V, strain AN103. Methods of converting vanillin to vanillic acid or a salt thereof are also known in the art, for example Perestelo et al (1989) *App. Environ. Microbiol.* 55, 1660-1662 describes the production of vanillic acid from vanillin by resting cells of *Serratia marcescens* and Pomelto & Crawford (1983) *App. Environ. Microbiol.* 45, 1582-1585 describe whole-cell bioconversion of vanillin to vanillic acid by *Streptomyces viridosporus*.

[0066] The method of producing vanillic acid provided by the invention therefore includes the steps of exposing trans-ferulic acid or a salt thereof to enzyme activity I and forming a product, exposing the said product of enzyme activity I to enzyme activity II to form a product, exposing the said product of enzyme activity II to enzyme activity III to form a product, and exposing the said product of enzyme activity III to enzyme activity IV to form a product.

[0067] It will be appreciated that vanillic acid can be made by the same means as vanillin is made in the method of the first aspect of the invention provided, of course, that enzyme activity IV is supplied.

[0068] A further preferred embodiment of the first aspect of the invention comprises the further step of separating vanillin from the other reaction components.

[0069] Vanillin, and other aromatic aldehydes, are, for example, recoverable by extraction with solvent, including supercritical carbon dioxide, and by organophilic pervaporation, using membranes constructed of hydrophobic poly-

mers (G. Bengston and K. W. Bodekker, in "Bioflavour 95", eds. P. Étievant and P. Schreier, INRA, Paris, pp 393-403 (1995); S. M. Zhang and E. Drioli, *Separ. Sci. Technol.* 8, 1-31 (1994)); pervaporation technology has been applied, for example, to the recovery of flavour compounds of wine (N. Rajagopalan and M. Cheryan, *J. Membrane Sci.* 104, 243-250 (1995)). Solid-phase extraction, followed by desorption with solvent, is also possible, though less preferred.

[0070] However, in some circumstances, particularly where minor reaction products are present which are similar to compounds present in the vanilla isolated from Vanilla pod, vanillin is not isolated.

[0071] A further preferred embodiment of the second aspect of the invention comprises the further step of separating vanillic acid or a salt thereof from the other reaction components.

[0072] Vanillic acid and other carboxylic acids may, for example, be recovered by solid-phase extraction, by solvent extraction under acidic conditions, or by pertraction; for example, L. Boyadzhiev and I. Atanassova (*Process Biochemistry* 29, 237-243 (1994)) describe the recovery of the aromatic amino acid, phenylalanine, by pertraction.

[0073] A third aspect of the invention provides *Pseudomonas fluorescens* biovar. V, strain AN103 as deposited under the Budapest Treaty at the National Collections of Industrial and Marine Bacteria Limited, AURIS Business Centre, 23 St Machar Drive, Aberdeen AB2 1RY, Scotland under Accession No NCIMB 40783, or a mutant or variant thereof. Preferred mutants and variants are the same as those preferred in the first aspect of the invention. A particularly preferred mutant of *Ps. fluorescens* biovar. V, strain AN103 is one which accumulates vanillin when provided with trans-ferulic acid or a salt thereof. Conveniently, this is a mutant of *Ps. fluorescens* biovar. V, strain AN103 wherein vanillin:NAD⁺ oxidoreductase activity is absent or reduced. Suitably, there is a mutation in the gene encoding vanillin:NAD⁺ oxidoreductase such that the enzyme activity is absent or substantially reduced. Such a mutant can be made as described above.

[0074] A fourth aspect of the invention provides a polypeptide which, in the presence of appropriate cofactors if any, is capable of catalysing the interconversion of trans-feruloyl SCoA and 4-hydroxy-3-methoxy-phenyl- β -hydroxypropionyl SCoA (HMPHP SCoA). Such a polypeptide has enzyme activity II. Conveniently, the polypeptide comprises trans-feruloyl SCoA hydratase; more conveniently the polypeptide comprises trans-feruloyl SCoA hydratase from *Ps. fluorescens* biovar. V, strain AN103 or fragments or variants thereof which have at least 1% of the specific activity of the native enzyme (in relation to trans-feruloyl SCoA hydratase activity), preferably at least 10%, more preferably at least 100%.

[0075] The enzyme activity is readily purified as described in the Examples. Modifications to this procedure may be readily made by the person skilled in the art so that a polypeptide with enzyme activity II can be obtained from any suitable source making use of the enzyme activity II assay procedure described in the Examples.

[0076] It is preferred if the polypeptide of the fourth aspect of the invention comprises the amino acid sequence.

MetSerThrTyrGluGlyArgTrpLysThrValLysValGluIleGluAspGlyIleAla (SEQ ID NO:2)
PheValIleLeuAsnArgProGluLysArgAsnAlaMetSerProThrLeuAsnArgGlu
MetIleAspValLeuGluThrLeuGluGlnAspProAlaAlaGlyValLeuValLeuThr
GlyAlaGlyGluAlaTrpThrAlaGlyMetAspLeuLysGluTyrPheArgGluValAsp
AlaGlyProGluIleLeuGlnGluLysIleArgArgGluAlaSerGlnTrpGlnTrpLys
LeuLeuArgMetTyrAlaLysProThrIleAlaMetValAsnGlyTrpCysPheGlyGly
GlyPheSerProLeuValAlaCysAspLeuAlaIleCysAlaAspGluAlaThrPheGly
LeuSerGluIleAsnTrpGlyIleProProGlyAsnLeuValSerLysAlaMetAlaAsp
ThrValGlyHisArgGlnSerLeuTyrTyrIleMetThrGlyLysThrPheGlyGlyGln
LysAlaAlaGluMetGlyLeuValAsnGluSerValProLeuAlaGlnLeuArgGluVal
ThrIleGluLeuAlaArgAsnLeuLeuGluLysAsnProValValLeuArgAlaAlaLys
HisGlyPheLysArgCysArgGluLeuThrTrpGluGlnAsnGluAspTyrLeuTyrAla
LysLeuAspGlnSerArgLeuLeuAspThrGluGlyGlyArgGluGlnGlyMetLysGln
PheLeuAspAspLysSerIleLysProGlyLeuGlnAlaTyrLysArg,

- [0077]

or a fragment or variant thereof.
- [0078]

The amino acid sequence is that given in **FIG. 12** as that encoded by nucleotides 2872 to 3699.
- [0079]

A fifth aspect of the invention provides a polypeptide which, in the presence of appropriate cofactors if any, is capable of catalysing the interconversion of 4-hydroxy-3-methoxyphenyl- β -hydroxy-propionyl SCoA (HMPHP SCoA) and vanillin. Such a polypeptide has enzyme activity III. Conveniently, the polypeptide comprises HMPHP SCoA cleavage enzyme; more conveniently the polypeptide comprises HMPHP SCoA cleavage enzyme from *Ps. fluorescens* biovar. V, strain AN103 or fragments or variants thereof
- which have at least 1% of the specific activity of the native enzyme (in relation to HMPHP SCoA cleavage activity), preferably at least 10%, more preferably at least 100%.
- [0080]

The enzyme activity is readily purified as described in the Examples. Modifications to this procedure may be readily made by the person skilled in the art so that a polypeptide with enzyme activity III can be obtained from any suitable source making use of the enzyme activity III assay procedure described in the Examples.
- [0081]

It is preferred if the polypeptide of the fifth aspect of the invention comprises the amino acid sequence

MetSerThrTyrGluGlyArgTrpLysThrValLysValGluIleGluAspGlyIleAla (SEQ ID NO:2)
PheValIleLeuAsnArgProGluLysArgAsnAlaMetSerProThrLeuAsnArgGlu
MetIleAspValLeuGluThrLeuGluGlnAspProAlaAlaGlyValLeuValLeuThr
GlyAlaGlyGluAlaTrpThrAlaGlyMetAspLeuLysGluTyrPheArgGluValAsp
AlaGlyProGluIleLeuGlnGluLysIleArgArgGluAlaSerGlnTrpGlnTrpLys
LeuLeuArgMetTyrAlaLysProThrIleAlaMetValAsnGlyTrpCysPheGlyGly
GlyPheSerProLeuValAlaCysAspLeuAlaIleCysAlaAspGluAlaThrPheGly
LeuSerGluIleAsnTrpGlyIleProProGlyAsnLeuValSerLysAlaMetAlaAsp
ThrValGlyHisArgGlnSerLeuTyrTyrIleMetThrGlyLysThrPheGlyGlyGln
LysAlaAlaGluMetGlyLeuValAsnGluSerValProLeuAlaGlnLeuArgGluVal
ThrIleGluLeuAlaArgAsnLeuLeuGluLysAsnProValValLeuArgAlaAlaLys
HisGlyPheLysArgCysArgGluLeuThrTrpGluGlnAsnGluAspTyrLeuTyrAla
LysLeuAspGlnSerArgLeuLeuAspThrGluGlyGlyArgGluGlnGlyMetLysGln
PheLeuAspAspLysSerIleLysProGlyLeuGlnAlaTyrLysArg,

[0082] or a fragment or variant thereof.

[0083] The amino acid sequence is that given in **FIG. 12** as that encoded by nucleotides 2872 to 3699.

[0084] A sixth aspect of the invention provides a polypeptide comprising the amino acid sequence

[0089] By “conservative substitutions” is intended combinations such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Such variants may be made using the methods of protein engineering and site-directed mutagenesis as described below and as is well known in the art.

MetLeuAspValProLeuLeulleGlyGlyGlnSerCysProAlaArgAspGlyArgThr
PheGluArgArgAsnProValThrGlyGluLeuValSerArgValAlaAlaAlaThrLeu
GluAspAlaAspAlaAlaValAlaAlaAlaGlnGlnAlaPheProAlaTrpAlaAlaLeu
AlaProAsnGluArgArgSerArgLeuLeuLysAlaAlaGluGThLeuGlnAlaArgSer
GlyGluPheIleGluAlaAlaGlyGluThrGlyAlaNetAlaAsnTrpTyrGlyPheAsn
ValArgLeuAlaAlaAsnMetLeuArgGluAlaAlaSerMetThrThrGlnValAsnGly
GluValIleProSerAspValProGlySerPheAlaMetAlaLeuArgGlnProCysGly
ValValLeuGlyIleAlaProTrpAsnAlaProValIleLeuAlaThrArgAlaIleAla
MetProLeuAlaCysGlyAsnThrValValLeuLysAlaSerGluLeuSerProAlaVal
HisArgLeuIleGlyGlnValLeuGlnAspAlaGlyLeuGlyAspGlyValValAsnVal
IleSerAsnAlaProAlaAspAlaAlaGlnIleValGluArgLeuIleAlaAsnProAla
ValArgArgValAsnPheThrGlySerThrHisValGlyArgIleVaiGlyGluLeuSer
AlaArgHisLeuLysProAlaLeuLeuGluLeuGlyGlyLysAlaProLeuLeuValLeu
AspAspAlaAspLeuGluAlaAlaValGlnAlaAlaAlaPheGlyAlaTyrPheAsnGln
GlyGlnIleCysMetSerThrGluAryLeuIleValAspAlaLysValAlaAspAlaPhe
ValAlaGlnLeuAlaAlaLysValGluThrLeuArgAlaGlyAspProAlaAspProGlu
SerValLeuGlyserLeuvalAspAlaserAlaGlyThrArgIleLysAlaLeuIleAsp
AspAlaValAlaLysGlyAlaArgLeuValIleGlyGlyGlnLeuGluGlySerIleLeu
GlnProThrLeuLeuAspGlyValAspAlaSerMetArgLeuTyrArgGluGluSerPhe
GlyProValAlaValValLeuArgGlyGluGlyGluGluAlaLeuLeuGlnLeuAlaAsn
AspSerGluPheGlyLeuSerAlaAlaIlePheSerArgAspThrGlyArgAlaLeuAla
LeuAlaGlnArgvalGluserGlyIleCysHisIleAsnGlyProThrValHisAspGlu
AlaGlnMetProPheGlyGlyValLysSerSerGlyTyrGlySerPheGlyGlyLysAla
SerIleGluHisPheThrGlnLeuArgTrpValThrLeuGlnAsnGlyProArgHisTyr
ProIle

[0085] (SEQ ID No 4) or a fragment or variant thereof.

[0086] The amino acid sequence is that given in **FIG. 12** as that encoded by nucleotides 3804 to 5249.

[0087] As described in detail in the examples, this polypeptide sequence encodes an enzyme with vanillin:NAD⁺ oxidoreductase activity from *Ps. fluorescens* biovar V, strain AN103.

[0088] By “variants” we include deletions, insertions and substitutions either conservative or non-conservative, where such changes may reduce or enhance the activity, or may not substantially alter the activity. In particular, the seventh aspect of the invention includes the complete polypeptide sequence of *Ps. fluorescens* biovar V, strain AN103 vanillin:NAD⁺ oxidoreductase and this polypeptide itself.

[0090] A preferred embodiment of the invention is a polypeptide as defined in the fourth, fifth or sixth of the invention which is substantially pure.

[0091] By “substantially pure” we mean that the polypeptide is substantially free of other polypeptides, or other macromolecules, with which it is usually found in nature. Suitably, the polypeptide is substantially free of any other polypeptides or macromolecules. It is preferred if the polypeptide has less than 50% by weight of any other polypeptide, preferably less than 10%, more preferably less than 1%, still more preferably less than 0.1% and most preferably less than 0.01%.

[0092] Polypeptides can be purified using methods known in the art. It is preferred if the polypeptide is the product of a recombinant DNA.

[0093] A single polypeptide chain may comprise more than one of the enzyme activities (II) trans-feruloyl SCoA hydratase activity or (III) HMPHP SCoA cleavage activity.

[0094] Our data in the Examples shows that, in the case of *Ps. fluorescens* biovar. V, strain AN103, enzyme activities II and III are found in the same polypeptide chain, the sequence of which is given as the preferred polypeptides of the fifth and sixth aspects of the invention. Thus, when enzyme activities II and III are provided in any aspect of the invention it is most convenient if they are provided in the same polypeptide chain.

[0095] It will be appreciated that, using protein engineering methods or chemical cross-linking it may be possible to produce a single molecule which has enzyme activities II and III. Such a molecule, therefore, forms a further aspect of the invention.

[0096] An seventh aspect of the invention provides a polynucleotide encoding a polypeptide as defined in any one of the fourth, fifth or sixth aspects of the invention.

[0097] By "polynucleotide" we include RNA and DNA. DNA is preferred.

[0098] Thus, this aspect of the invention provides a polynucleotide which encodes any one of a polypeptide which has (II) trans-feruloyl SCoA hydratase activity; (III) HMPHP SCoA cleavage activity; (IV) vanillin:NAD⁺ oxidoreductase activity; or a polypeptide which has more than one of these activities. Preferably the polynucleotide is derived from *Ps. fluorescens* biovar. V, strain AN103. A preferred polynucleotide comprises all or at least a part of the *Ps. fluorescens* DNA contained within the cosmid clone pFI793 as deposited under the Budapest Treaty at the National Collections of Industrial and Marine Bacteria Limited, AURIS Business Centre, 23 St Machar Drive, Aberdeen AB2 1RY, Scotland under Accession No NCIMB 40777, or a fragment or variant thereof.

[0099] The isolation of the cosmid clone pFI 793 is described in Example 5; pFI 793 includes DNA which encodes polypeptides which have enzyme activities II, III and IV. The cosmid clone pFI 793 itself, the genes contained

in the *Ps. fluorescens* DNA thereof, and variants thereof form separate aspects of the invention.

[0100] A variant of a polynucleotide includes any insertion, deletion or substitution of the sequence which encodes a fragment or variant of a polypeptide as defined above.

[0101] For example, site-directed mutagenesis or other techniques can be employed to create single or multiple mutations, such as replacements, insertions, deletions, and transpositions, as described in Botstein and Shortle, *Strategies and Applications of In Vitro Mutagenesis*, *Science*, 229: 193-210 (1985), which is incorporated herein by reference. Since such modified polynucleotides can be obtained by the application of known techniques to the teachings contained herein, such modified polynucleotides are within the scope of the claimed invention.

[0102] Moreover, it will be recognised by those skilled in the art that the polynucleotide sequence (or fragments thereof) of the invention can be used to obtain other DNA sequences that hybridise with it under conditions of high stringency. Such DNA includes any genomic DNA.

[0103] Accordingly, the polynucleotide of the invention includes DNA that shows at least 55 per cent, preferably 60 per cent, and most preferably 70 per cent homology with the polynucleotide sequences identified in the invention, provided that such homologous DNA encodes a protein which is usable in the methods described herein. DNA-DNA, DNA-RNA and RNA-RNA hybridisation may be performed in aqueous solution containing between 0.1×SSC and 6×SSC and at temperatures of between 55° C. and 70° C. It is well known in the art that the higher the temperature or the lower the SSC concentration the more stringent the hybridisation conditions. By high stringency we mean 2×SSC and 65° C. 1×SSC is 0.15M NaCl/0.015M sodium citrate.

[0104] "Variants" of the polynucleotide include polynucleotides in which relatively short stretches (for example 20 to 50 nucleotides) have a high degree of homology (at least 50% and preferably at least 90 or 95%) with equivalent stretches of the polynucleotide of the invention even though the overall homology between the two polynucleotides may be much less. This is because important active or binding sites may be shared even when the general architecture of the protein is different.

[0105] A particularly preferred polynucleotide comprises the nucleotide sequence

```

ATGAGCACATACGAAGGTCGCTGGAACGGTCAAGGTCGAAATCGAAGACGGCATCGCG      (SEQ ID No 1)
TTTGTCATCTCAATCGCCCGGAAAAACGCAACGCGATGAGCCCGACCTGAACCGCGAG
ATGATCGATGTTCTGGAACCCCTCGAGCAGGACCCTGCCGCCGGTGTGCTGGTGCTGACC
GGTGCGGGCGAAGCCTGGACCGCAGGCATGGACCTCAAGGAATACTTCCGCGAAGTGGAC
GCCGGCCCGGAAATCCTCCAGGAAAAAATCCGCCGCGAAGCCTCGCAATGGCAATGGAAA
CTGCTGCGCATGTACGCCAAGCCGACCATCGCCATGGTCAATGGCTGGTGCTTCGGCGGC
GGTTTCAGCCCGCTGGTGGCCTGCGACCTGGCGATCTGCGCCGACGAAGCAACCTTCGGT
CTCTCGGAAATCAACTGGGGTATCCCGCCGGGCAACCTGGTGAGCAAGGCCATGGCCGAC
ACCGTGGGGCCACCGCCAGTCGCTCTACTACATCATGACCGGCAAGACCTTCGGTGGGCAG
AAAGCCCGCGAGATGGGCCTGGTCAACGAAAGCGTGCCCTGGCGCAACTGCGCGAAGTC

```

-continued

ACCATCGAGCTGGCGCGTAACCTGCTCGAAAAAACCCGGTGGTGCTGCGTGCCGCCAAA
CACGGTTTCAAACGCTGCCGCGAACTGACCTGGGAGCAGAACGAGGATTACCTGTACGCC
AAGCTCGATCAGTCGCGTTTGCTGGACACCGAAGGCGGTGCGGAGCAGGGCATGAAGCAATTCC
TCGACGACAAGAGCATCAAGCCTGGCCTGCAAGCGTATAAACGC

- [0106] (as given in **FIG. 12**, nucleotides 2872 to 5249) or a fragment or variant thereof.

[0107] This polynucleotide encodes HMPHP SCoA cleavage enzyme activity and a trans-feruloyl SCoA hydratase activity from *Ps. fluorescens* biovar. V, strain AN103 and encodes the preferred polypeptide of the fifth and sixth aspects of the invention.

[0108] A further particularly preferred polynucleotide comprises the nucleotide sequence
- [0109] (SEQ ID No 3) (as given in **FIG. 12**, nucleotides 3804 to 5249)

[0110] or a fragment or variant thereof. This polynucleotide encodes the polypeptide sequence of the sixth aspect of the invention. It is particularly convenient to isolate the whole gene from cosmid clone pFI 793 as deposited under the Budapest Treaty at NCIMB under Accession No NCIMB 40777.

ATGCTGGACGTGCCCCTGCTGATTGGCGGCCAGTCGTGCCCCGCGCGCGACGGTCGAACC
TTCGAGCGCCGCAACCCGGTGACTGGCGAGITGGTGTCGCGGGTTGCCGCCGCCACCCTG
GAAGATGCCGACGCCGCGGTGGCCGCTGCCCAGCAAGCGTTTCCCGCGTGGGCCGCGCTG
GCGCCCAATGAACGGCGCAGCCCTTTGCTCAAGGCCGCCGAACAATTCCAGGCGCGCAGC
GGCGACTTCATCGAGGGCGGGCGAGACCCGCGCCATGGCCAACCTGGTACGGGTTCAAC
GTACGGCTGGCGGCCAACATGCTGCGTGAAAGCGGCATCGATGACCACCCAGGTCAATGGT
GAAGTGATTCCCTCGGACGTTCCCGGCAGTTTCGCCATGGCCCTGCGCCACCCCTGTGGC
GTGGTGCTGGGCATCGCCCCCTGGAACGCCCCGGTGATTCTCGCCACCCGGQCGATTGCC
ATGCCGCTGGCCTGTGGCAACACCGTGGTGCTGAAGGCTTCCGACCTGAGTCCGGCGGTG
CATCGCTTGATCGCCCAGGTGCTGCAGGACGCCGGCCTGGGCGATGGCGTGGTCAACGTC
ATCAGTAATGCGCCGGCGGATGCGGCACAGATTGTGAGCGCCTGATTGCCAACCCGGCC
GTACGCCGGGTCAATTTACCGGTTTCGACCCACGTCGGGCGCATTGTGCGCGAGCTCTCC
GCGCGCCACCTCAAACCGGCGTTGCTCGAGCTGGGCGGCAAGGCACCGTTGCTCGTGCTC
GACGATGCCGACCTGGAGGCTGCCGTGCAGGCGQCGGCGTTTGGCGCCTACTTCAACCAG
GCACAGATCTGTATGTCCACCGAGCGCCTGATTGTGATGCCAAGGTGGCCGACGCCTTT
GTCGCCCAGTTGGCQGCCAAGGTCGAGACCCTGCGCGCCGGTGATCCTGCCGACCCGGAG
TCGGTGCTCGGTTGCTGGTGACGCCAGCGCTGGCACGCGGATCAAAGCGTTGATCGAT
GATGCCGTGGCCAAGGGCGCGCCTGGTAATCGGCGGGCAACTGGAGGGCAGCATCTTG
CAGCCGACCTGCTCGACGGTGTGACGCGAGCATGCGTTTGTACCCGAAGAGTCCTTC
GGCCCGGTGGCGGTGGTGCTGCGCGCCGAGGGCGAAGAAGCGCTGTTGCAACTGGCCAAC
GACTCCGAGTTCGGTTTGTGCGCGGCGATTTTCAGTCGTGACACCGGCCGTGCCCTGGCC
CTGGCCCAGCGGOTCGAATCGGGCATCTGCCACATCAACGGCCCGACCGTGACGACGAA
GCGCAAATGCCCTTTTGGCGGGGTCAAGTCCAQCGGCTACGGCAGTTTGGCGGCAAGGCA
TCGATTGAGCATTTCACTCAGTTGCGCTGGGTACCCCTCCAGAATGGTCCACGGCACTAT
CCGATC

[0111] The polynucleotides of the invention are all readily isolated from pFI 793 by probing with the given sequences or parts thereof, or by other methods known in the art, and the nucleotide sequences can be confirmed by reference to the deposited cosmid (pFI 793).

[0112] It will be appreciated that fragments and variants of the polynucleotides of the invention can readily be made by the person skilled in the art using standard molecular biological methods such as those described in Sambrook et al "Molecular Cloning, a laboratory manual", (1989), (2nd Edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. The whole gene and variants and fragments thereof are specifically included in this aspect of the invention.

[0113] It is preferred if the polynucleotide, conveniently DNA, is joined to a nucleic acid vector.

[0114] DNA constructs of the invention may be purified from the host cell using well known methods.

[0115] For example, plasmid vector DNA can be prepared on a large scale from cleaved lysates by banding in a CsCl gradient according to the methods of Clewell & Helinski (1970) *Biochemistry* 9, 4428-4440 and Clewell (1972) *J. Bacteriol.* 110, 667-676. Plasmid DNA extracted in this way can be freed from CsCl by dialysis against sterile, pyrogen-free buffer through Visking tubing or by size-exclusion chromatography.

[0116] Alternatively, plasmid DNA may be purified from cleared lysates using ion-exchange chromatography, for example those supplied by Qiagen (Chatsworth, Calif., USA). Hydroxyapatite column chromatography may also be used.

[0117] The DNA is then expressed in a suitable host to produce a polypeptide of the invention. Thus, a DNA encoding a polypeptide of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed in U.S. Pat. Nos. 4,440,859 issued Apr. 3, 1984 to Rutter et al, 4,530,901 issued Jul. 23, 1985 to Weissman, 4,582,800 issued Apr. 15, 1986 to Crowl, 4,677,063 issued Jun. 30, 1987 to Mark et al, 4,678,751 issued Jul. 7, 1987 to Goeddel, 4,704,362 issued Nov. 3, 1987 to Itakura et al, 4,710,463 issued Dec. 1, 1987 to Murray, 4,757,006 issued Jul. 12, 1988 to Toole, Jr. et al, 4,766,075 issued Aug. 23, 1988 to Goeddel et al, and 4,810,648 issued Mar. 7, 1989 to Stalker, all of which are incorporated herein by reference.

[0118] The DNA encoding the polypeptide constituting the compound of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

[0119] Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognised by the

desired host, although such controls are generally available in the expression vector. The vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance. Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell. Host cells that have been transformed by the recombinant DNA of the invention may then be cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which, if desirable, can then be recovered.

[0120] Many expression systems are known, including bacteria (for example *Escherichia coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*), filamentous fungi (for example *Aspergillus*), plant cells and whole plants, animal cells and insect cells.

[0121] The vectors include a prokaryotic replicon, such as the ColE1 ori, for propagation in a prokaryote, even if the vector is to be used for expression in other, non-prokaryotic, cell types. The vectors can also include an appropriate promoter such as a prokaryotic promoter capable of directing the expression (transcription and translation) of the genes in a bacterial host cell, such as *E. coli*, transformed therewith.

[0122] Several promoters are available to direct transcription of bacterial and other heterologous genes in plants. In particular, these include the 35S promoter of cauliflower mosaic virus (CaMV 35S), the ribulose biphosphate carboxylase small subunit promoter and the Agrobacterium T-DNA octopine synthase and manopine synthase promoters. These promoters have been widely used, for example, in conjunction with bacterial genes conferring herbicide resistance (see D. M. Stalker, *ibid.*, pp 82-104). These promoters do not confer any specificity of gene expression at the organ, tissue or organellar levels, or responsiveness of gene expression to environmental influences such as light.

[0123] A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with exemplary bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention.

[0124] Typical prokaryotic vector plasmids are pUC18, pUC19, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, Calif., USA) and pTrec99A and pKK223-3 available from Pharmacia, Piscataway, N.J., USA.

[0125] A typical mammalian cell vector plasmid is pSVL available from Pharmacia, Piscataway, N.J., USA. This vector uses the SV40 late promoter to drive expression of cloned genes, the highest level of expression being found in T antigen-producing cells, such as COS-1 cells.

[0126] An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. This vector

uses the glucocorticoid-inducible promoter of the mouse mammary tumour virus long terminal repeat to drive expression of the cloned gene.

[0127] Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, Calif. 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (YIps) and incorporate the yeast selectable markers HIS3, TRP1, LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere plasmids (YCps)

[0128] A variety of methods have been developed to operably link DNA to vectors via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.

[0129] Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. The DNA segment, generated by endonuclease restriction digestion as described earlier, is treated with bacteriophage T4 DNA polymerase or *E. coli* DNA polymerase I, enzymes that remove protruding, 3'-single-stranded termini with their 3'-5'-exonucleolytic activities, and fill in recessed 3'-ends with their polymerizing activities.

[0130] The combination of these activities therefore generates blunt-ended DNA segments. The blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase. Thus, the products of the reaction are DNA segments carrying polymeric linker sequences at their ends. These DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.

[0131] Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, Conn., USA.

[0132] A desirable way to modify the DNA encoding the polypeptide of the invention is to use the polymerase chain reaction as disclosed by Saiki et al (1988) *Science* 239, 487-491.

[0133] In this method the DNA to be enzymatically amplified is flanked by two specific oligonucleotide primers which themselves become incorporated into the amplified DNA. The said specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.

[0134] The present invention also relates to a host cell transformed with a polynucleotide vector construct of the present invention. The host cell can be either prokaryotic or eukaryotic and it may be comprised in a multicellular organism such as a plant. Bacterial cells are preferred prokaryotic host cells and typically are a strain of *E. coli* such as, for example, the *E. coli* strains DH5 available from Bethesda Research Laboratories Inc., Bethesda, Md., USA, and RR1 available from the American Type Culture Collec-

tion (ATCC) of Rockville, Md., USA (No ATCC 31343). Preferred eukaryotic host cells include yeast and plant cells. Yeast host cells include YPH499, YPH500 and YPH501 which are generally available from Stratagene Cloning Systems, La Jolla, Calif. 92037, USA. Preferred plant host cells and plants include those from *Nicotiana* spp., *Solanum tuberosum* (potato), *Brassica* spp. (eg oil seed rape), *Beta* spp. (eg sugar beet, leaf beet and beetroot), *Capsicum* spp., and *Vanilla* spp.

[0135] Transformation of appropriate cell hosts with a DNA construct of the present invention is accomplished by well known methods that typically depend on the type of vector used. With regard to transformation of prokaryotic host cells, see, for example, Cohen et al (1972) *Proc. Natl. Acad. Sci. USA* 69, 2110 and Sambrook et al (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Transformation of yeast cells is described in Sherman et al (1986) *Methods In Yeast Genetics, A Laboratory Manual*, Cold Spring Harbor, N.Y. The method of Beggs (1978) *Nature* 275, 104-109 is also useful. With regard to plant cells and whole plants three plant transformation approaches are typically used (J. Draper and R. Scott in D. Grierson (ed.), "Plant Genetic Engineering", Blackie, Glasgow and London, 1991, vol. 1, pp 38-81):

[0136] i) *Agrobacterium*-mediated transformation, using the Ti plasmid of *A. tumefaciens* and the Ri plasmid of *A. rhizogenes* (P. Armitage, R. Walden and J. Draper in J. Draper, R. Scott, P. Armitage and R. Walden (eds.), "Plant Genetic Transformation and Expression—A Laboratory Manual", Blackwell Scientific Publications, Oxford, 1988, pp 1-67; R. J. Draper, R. Scott and J. Hamill *ibid.*, pp 69-160);

[0137] ii) DNA-mediated gene transfer, by polyethylene glycol-stimulated DNA uptake into protoplasts, by electroporation, or by microinjection of protoplasts or plant cells (J. Draper, R. Scott, A. Kumar and G. Dury, *ibid.*, pp 161-198);

[0138] iii) transformation using particle bombardment (D. McCabe and P. Christou, *Plant Cell Tiss. Org. Cult.*, 3, 227-236 (1993); P. Christou, *Plant J.*, 3, 275-281 (1992)).

[0139] *Agrobacterium*-mediated transformation is generally ineffective for monocotyledonous plants (eg *Vanilla*), for which approaches ii) and iii) are therefore preferred. In all approaches a suitable selection marker, such as kanamycin- or herbicide-resistance, is preferred or alternatively a screenable marker ("reporter") gene, such as β -glucuronidase or luciferase (see J. Draper and R. Scott in D. Grierson (ed.), "Plant Genetic Engineering", Blackie, Glasgow and London, 1991, vol. 1 pp 38-81).

[0140] Electroporation is also useful for transforming cells and is well known in the art for transforming yeast cell, bacterial cells and plant cells.

[0141] For example, many bacterial species may be transformed by the methods described in Luchansky et al (1988) *Mol. Microbiol.* 2, 637-646 incorporated herein by reference. The greatest number of transformants is consistently recovered following electroporation of the DNA-cell mixture suspended in 2.5×PEB using 6250V per cm at 25 μ FD.

[0142] Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente (1990) *Methods Enzymol.* 194, 182.

[0143] Successfully transformed cells, ie cells that contain a DNA construct of the present invention, can be identified by well known techniques. For example, cells resulting from the introduction of an expression construct of the present invention can be grown to produce the polypeptide of the invention. Cells can be harvested and lysed and their DNA content examined for the presence of the DNA using a method such as that described by Southern (1975) *J. Mol. Biol.* 98, 503 or Berent et al (1985) *Biotech.* 3, 208. Alternatively, the presence of the protein in the supernatant can be detected using antibodies as described below.

[0144] In addition to directly assaying for the presence of recombinant DNA, successful transformation can be confirmed by well known immunological methods when the recombinant DNA is capable of directing the expression of the protein. For example, cells successfully transformed with an expression vector produce proteins displaying appropriate antigenicity. Samples of cells suspected of being transformed are harvested and assayed for the protein using suitable antibodies.

[0145] Thus, in addition to the transformed host cells themselves, the present invention also contemplates a culture of those cells, preferably a monoclonal (clonally homogeneous) culture, or a culture derived from a monoclonal culture, in a nutrient medium; and also, in the case of plant cells, a plant derived from, and containing, such cells.

[0146] It is particularly preferred if the host cell comprises a nucleic acid which encodes any one of, or combination of, a polypeptide which, in the presence of appropriate cofactors if any is capable of catalysing the interconversion of trans-feruloyl SCoA and 4-hydroxy-3-methoxyphenyl- β -hydroxypropionyl SCoA (HMPHP SCoA) or a polypeptide which, in the presence of appropriate cofactors if any, is capable of catalysing the interconversion of 4-hydroxy-3-methoxyphenyl- β -hydroxypropionyl SCoA (HMPHP SCoA) and vanillin.

[0147] It will be appreciated that the host cells of the invention or an extract thereof are particularly suited for use in the methods of the invention. It is particularly preferred if the host cell does not contain means for converting vanillin to a non-vanillin product.

[0148] It is most preferred if the host cell is a plant cell or is comprised in a whole plant or a bacterial cell or a yeast cell. Preferred bacterial hosts include lactic acid bacteria such as *Lactococcus* spp. and *Lactobacillus* spp. Preferred yeast hosts include *Saccharomyces cerevisiae* and its biovars. It is particularly preferred if the host cell is a food-grade host cell (for example a microorganism which is used or can be used in the food or beverage industry). It is also preferred if the plant is an edible plant.

[0149] It will be appreciated that some host cells or host organisms may already contain enzyme activities I, II, III or IV and, in that case, it may be sufficient, in order to use the host cells in the methods of the invention, to introduce into said host cell or host organism one or more polynucleotides which encode enzyme activities II, III or IV which encode those enzyme activities which are deficient in the host cell or host organisms.

[0150] In the case of plants for use in the methods of the invention, it is preferred that the relevant gene expression is directed to target organs, tissues and subcellular organelles where trans-feruloyl SCoA, or other appropriate substrates (eg 4-trans-coumaroyl SCoA or trans-caffeoyl SCoA) for the enzymes encoded by the transferred genes, are most readily available. The stage at which thioesterification with CoASH occurs in plants, in relation to the progressive substitution of the phenyl ring which takes place during the conversion from trans-cinnamate to trans-ferulate, is unclear and may be variable (see R. Whetten and R. Sederoff, *The Plant Cell*, 7, 1001-1013 (1995)). The subcellular localisation or distribution of these intermediates during plant phenylpropanoid metabolism also remains uncertain; it is likely that they are cytosolic, or that some functional organisation of the enzymes which metabolise them occurs. The concept of the metabolic cluster or "metabolon", in which there is a degree of metabolic channelling and free diffusion is restricted, has been proposed and discussed (see R. A. Dixon and N. L. Paiva, *The Plant Cell*, 7, 1085-1097 (1995) and loc cit.).

[0151] Trans-ferulate, 4-trans-coumarate and trans-cafeate are normal metabolic intermediates. Thus, there may be no requirement to manipulate host plants in order to provide trans-feruloyl SCoA. Their concentrations are expected to be influenced in varying degrees by physiological requirements for a wide range of end-products of the phenylpropanoid pathway, including for example lignin, coumarins and flavonoids. There is some evidence that the activity of the first enzyme of the phenylpropanoid pathway, phenylalanine ammonia lyase (PAL: EC 4.3.1.5), can influence the accumulation of end-products of the pathway (N. Bate, J. Orr, W. Ni, A. Meromi, T. Nadler-Hassar, P. W. Doerner, R. A. Dixon, C. J. Lamb and Y. Elkind, *Proc. Natl. Acad. Sci. USA*, 91, 7608-7612 (1994)) so under certain circumstances it is possible to enhance the metabolic effects of the expression of the genes for enzyme activities II and III by increasing the expression of PAL.

[0152] It is well known that gene expression in the phenylpropanoid pathway is responsive to a range of environmental and stress factors, including wounding, chemical elicitors of pathogenic origin, and u/v light. The mechanisms regulating these responses are not very well understood, though several transcription factors have been identified (see R. A. Dixon and N. L. Paiva, *The Plant Cell*, 7, 1085-1097 (1995)). However, particularly when these are more fully characterised, they do or will offer opportunities for predictable and inducible control of gene expression, particular to enhance the provision of substrate.

[0153] Thus, a further aspect of the invention provides a transgenic plant comprising a polynucleotide according to any of the fourth or fifth aspects of the invention. In other words, the transgenic plant is genetically engineered to encode and, preferably, express any one or more of enzyme activities II or III. It is particularly preferred that, following said genetic engineering the plant is able to produce vanillin from trans-feruloyl SCoA. It will be appreciated that, depending on the enzymes present in the host plant, it may be necessary only to provide a gene encoding only a single of said enzyme activities or it may be necessary to provide a gene or genes of any two of said enzyme activities.

[0154] Conveniently, the transgenic plant is genetically engineered to encode and, preferably, express enzyme

activities II and III. It can be readily seen that the transgenic plants of this aspect of the invention may be used in the methods of producing vanillin of the invention, especially when the plant provides the enzyme activity that interconverts trans-ferulic acid or a salt thereof and trans-feruloyl SCoA.

[0155] Preferably the plant is a plant which is readily transformed. Preferably the plant is a plant which is commonly used in agriculture or horticulture and more preferably the plant is an edible plant. Advantageously the plant is a plant in which it is desirable to introduce a vanilla flavour or aroma.

[0156] Preferred plants include those selected from *Nicotiana* spp., *Solanum tuberosum*, *Brassica* spp., *Capsicum* spp., *Beta* spp. and *Vanilla* spp.

[0157] As is described in more detail below the plant may be eaten or may be processed into a foodstuff or beverage. Thus, conveniently the transgenic plant is processed or prepared so that it is not capable of reproduction or cultivation, for example the transgenic plant is harvested from the environment in which it was grown.

[0158] When vanillin (or the desirable products such as p-hydroxybenzaldehyde) is produced in a host cell or organism of the invention, especially if it is produced in a transgenic plant of the invention, the vanillin or desirable product may initially be present in the form of a glycoside, more particularly, a β -D-glycoside, or, in the case of a carboxylic acid, as esters of β -D-glucose (as occurs in *Vanilla* pod). In this case, it is desirable to release the vanillin (and desirable product) into its uncombined form, for example by acid- or base-catalysed hydrolysis or by the use of glycosides such as the β -D-glucosidase (emulsin; S. Hestrin, D. S. Femgold and M. Schramm, *Meth. Enzymol.* **1**, 231-257 (1955); see also D. Chassagne, C. Bayonore, J. Crouzet and K. Baumes in "Bioflavour 95", eds. P. Etievant and P. Schreier, INRA, Paris, pages 217-222 (1995)).

[0159] In relation to the use of a microorganism such as *Ps. fluorescens* biovar V, strain AN103 or of a microorganism which has been genetically modified to contain enzyme activities II and III (or at least those of these activities that it does not normally have), it is preferred that said microorganism is provided with trans-feruloyl SCoA or a means to provide said CoA thioester from trans-ferulic acid or a salt thereof at least in its culture medium.

[0160] Thus, it can be seen from all of the foregoing description that the invention includes biochemical and fermentative processes for producing vanillin and vanillic acid, recombinant or transgenic plants and the use of the said plants in a method of making vanillin or vanillic acid.

[0161] Typically, in a biochemical process the strain of *Pseudomonas* (eg *Ps. fluorescens* biovar. V, strain AN103) provides an enzyme system for the biotransformation of plant derived trans-ferulic acid to vanillin and/or related compounds. Enzyme preparations, whole cells of *Pseudomonas* or a heterologous host organism expressing appropriate *Pseudomonas* genes may be used for this. A

variety of mutants of *Pseudomonas* and various additional enzyme preparations, co-factors or co-factor regenerating systems may be used. The *Pseudomonas* enzymes might be overexpressed in a heterologous host before being extracted and used in a biotransformation.

[0162] Alternatively, but suitably, some form of fermentation process may be used which involves the *Pseudomonas* strain or an appropriate derived mutant or a heterologous host organism in which the genes for biotransformation are expressed. The chosen microorganism is typically grown on a ferulate-rich substrate or a substrate comprising trans-feruloyl SCoA. This could generate a vanillin production process.

[0163] In addition the invention includes recombinant microorganisms (eg lactic acid bacteria) which are modified to contain genes encoding enzyme activities II and III. For example, lactic acid bacteria modified according to the invention may be used to produce vanilla-flavoured yoghurt provided that they are supplied with trans-feruloyl SCoA.

[0164] Advantageously, genes for vanillin production (such as those encoding enzyme activities II and III) are expressed in a variety of plant species such that vanillin accumulates in an appropriate tissue. In this case a new crop plant may be cultivated and vanillin would be extracted. Thus, a sugar beet plant may be made according to the invention in which the beet was rich in vanillin. In addition the development of a novel plant cultivars for direct consumption (eg vanilla-flavoured capsicum), or even for their desirable aroma properties, included in the invention.

[0165] The polypeptides of the invention, or the genes which encode them, may be used either individually or in combination (whether as substantially isolated polypeptides, or in cell-free extracts or as host cells or organisms which encode and, preferably, express said polypeptides) to convert a compound into a desirable product. Certain compounds and desirable products have been described above. However, the invention also includes the production of any other desirable product, such as a flavour or aroma, from substrates related to trans-ferulate and other known substrates of the polypeptides (enzymes) of the invention. Thus, the polypeptides or genes of the invention, either individually or in combination, may be used in processes for converting, for example, synthetic substrates of the said polypeptides (enzymes) into novel flavours and aromas or they may be used to modify the chemical profile of known flavours or aromas.

[0166] Similarly, it will be appreciated that certain desirable products can be made by the further action of enzyme activity IV upon certain compounds, particularly those produced by enzyme activities I, II and III. For example, enzymes activities I, II and III may be used to convert trans4-coumaric acid or trans4-coumaroyl SCoA to p-hydroxybenzaldehyde and enzyme activity IV may then be used to convert p-hydroxybenzaldehyde to p-hydroxybenzoic acid. Thus, the invention includes a method of producing p-hydroxybenzoic acid using at least one of enzyme activities I, II, III and IV and advantageously using all of them.

[0167] A further aspect of the invention provides a food or beverage comprising a host cell comprising a polynucleotide

of the invention, or an extract of said host cell. The host cells comprising one or more polynucleotides of the invention, especially those such host cells which produce vanillin by virtue of the presence of said polynucleotide or polynucleotides, may be used in the production of food or beverages. In particular, as discussed above, lactic acid bacteria which produce vanillin by the methods of the invention may be used in the production of cheese, yogurt and related products including milk drinks. Similarly, yeasts which produce vanillin by the methods of the invention may be used in the production of food and beverages such as bread and beer. Extracts of said host cells may also be used in the food or beverage industry.

[0168] A still further aspect of the invention provides a food or beverage comprising a transgenic plant comprising a polynucleotide of the invention, or a part or extract or said transgenic plant. The transgenic plant comprising one or more polynucleotides of the invention, especially those such transgenic plants which produce vanillin by virtue of the presence of said polynucleotide or polynucleotides, may constitute the food itself or they may be processed to form the food or beverage. For example, a tuber of a transgenic potato of the invention constitutes a food of this aspect of the invention. Alternatively, said transgenic potato may be processed into another foodstuff which is, nevertheless, a food of this aspect of the invention.

[0169] Still further aspects of the invention provide use of *Pseudomonas fluorescens* biovar. V, strain AN103 or a mutant or derivative thereof in a method for producing vanillin, or vanillic acid or salt thereof; use of a polypeptide of the invention in a method for producing vanillin, or vanillic acid or salt thereof; use of a polynucleotide of the invention in a method for producing vanillin, or vanillic acid or salt thereof; and use of a host cell of the invention in a method for producing vanillin or vanillic acid or a salt thereof.

[0170] As is clear from the foregoing the invention also includes a method of producing vanillin or vanillic acid, or other related products, the method comprising providing trans-feruloyl SCoA (or any other suitable CoASH thioester which can be acted upon by enzyme activity II) and providing enzyme activity II, enzyme activity III and, in the case of vanillic acid production or another related product, enzyme activity IV. Trans-feruloyl SCoA is obtainable by the method described in Example 2 or it may be obtained using the methods of Zenk et al (1980) *Anal. Biochem.* 101, 182-187, incorporated herein by reference. Other CoASH thioesters which may be substrates for enzyme II are also described in Zenk et al.

[0171] The preferred method steps and organisms for use in the methods, and the foods and beverages of the earlier aspects of the invention are also preferred in this method of the invention to the extent that they are compatible with this method, and the organisms used in this method.

[0172] As is discussed above, trans-feruloyl SCoA (and related CoASH thioesters such as 4-trans-coumaroyl SCoA and trans-caffeoyl SCoA) are normal metabolic intermediates in plants. Thus, a transgenic plant which comprises a polynucleotide or polynucleotides which encode, and preferably express, enzyme activities II and III in a location in the plant which contains trans-feruloyl SCoA or other suitable CoASH thioester is particularly suited for the purposes

of this aspect of the invention. As is described above, such transgenic plants and products derived therefrom form part of the invention.

[0173] The invention will now be described in more detail with reference to the following Examples and Figures wherein:

[0174] FIG. 1 describes the vanillin pathway in *Pseudomonas fluorescens* biovar. V, strain AN103. HMPHP SCoA is 4-hydroxy-3-methoxy-phenyl- β -hydroxypropionyl SCoA. I is an enzyme that catalyses the interconversion of trans-ferulic acid and trans-feruloyl SCoA; II is an enzyme that catalyses the interconversion of trans-feruloyl SCoA and HMPHP SCoA; III is an enzyme that catalyses the interconversion of HMPHP SCoA and vanillin; and IV is an enzyme that catalyses the interconversion of vanillin and vanillic acid.

[0175] FIG. 2 illustrates the growth of strain AN103 following transfer to MM medium containing 10 mM vanillate (V), 10 mM trans-ferulate (F) or 10 mM trans-ferulate plus 10 mM vanillate (FV). Cultures were previously grown in MM medium containing 10 mM vanillate.

[0176] FIG. 3 indicates the changes in trans-ferulate and vanillate concentrations during growth of strain AN 103 on MM medium containing 10 mM trans-ferulate.

[0177] FIG. 4 shows the production of vanillin (van) and vanillate (VA) by an extract of cells of strain AN103 (165 μ g protein) incubated with trans-ferulate, ATP, CoASH and Mg^{2+} ions, both in the absence of NAD^+ and in its presence (0.5 mM). Cells were grown in the presence of 10 mM trans-ferulate, plus 10 mM vanillate.

[0178] FIG. 5 demonstrates the formation of feruloyl SCoA, vanillin and acetyl SCoA from trans-ferulate supplied to a PD10-treated extract of trans-ferulate-grown cells of strain AN103 (7 μ g protein) in the presence of ATP, CoASH and Mg^{2+} ions.

[0179] FIG. 6 demonstrates the production of vanillin, acetyl SCoA and feruloyl SCoA from HMPHP SCoA supplied to a PD10-treated cell-free extract (7 μ g protein) of trans-ferulate-grown cells of strain AN103.

[0180] FIG. 7 shows the induction over time of trans-ferulate:CoASH ligase activity in response to 10 mM trans-ferulate (F), 10 mM vanillate (V) and 10 mM trans-ferulate plus 10 mM vanillate (FV) present in MM medium. The inocula were grown in MM medium plus 10 mM vanillate; growth conditions, enzyme extraction and assay were as described in Examples 1 and 2.

[0181] FIG. 8 shows SDS-PAGE of A), an extract of cells grown in MM medium with 10 mM trans-ferulate, electrophoresed at successive stages of purification of the HMPHP SCoA cleavage enzyme; successive stages are Crude Extract, Mono Q-purified, Mono-P-purified and Phenyl Superose-purified, and B), extracts of cells grown in MM medium with either 10 mM vanillate or 10 mM trans-ferulate and electrophoresed alongside Mono-P-purified cleavage enzyme; A) silver-stained; B) Coomassie-stained.

[0182] FIG. 9 shows EcoRI/PstI digests of cosmid clones pFI793, pFI794, pFI795 and pFI796 separated on an agarose gel.

[0183] FIG. 10 shows the sequence of the redundant primers designed from 20 N-terminal amino residues of the 31-kDal protein (SEQ ID Nos. 5 and 6).

[0184] FIG. 11 shows a Southern blot of EcoRI/PstI digests of various cosmid clones probed with the PCR product amplified using the N-terminal degenerate oligo-nucleotide primers as shown in FIG. 10.

[0185] FIG. 12 shows the nucleotide sequence of pFI989 (ie the 4370 bp EcoRI/PstI fragment from pFI794), together with the succeeding 882 bp determined from a further subclone, pFI1056 and from pFI794 itself (SEQ ID No 7). The amino acid sequence of the 31 kD protein and that corresponding to the succeeding open reading frame encoding vanillin:NAD⁺ oxidoreductase (vanillin dehydrogenase) (SEQ ID Nos. 2 and 4) are also shown.

[0186] FIG. 13 shows the nucleotide sequence of pFI901 (ie the 1.8 kb EcoRI/PstI fragment from pFI793) (SEQ ID No 8).

[0187] FIG. 14 shows the nucleotide sequence of pFI911 (ie the 850 bp EcoRI/PstI fragment from pFI793) (SEQ ID No 9).

[0188] FIG. 15 shows the nucleotide sequence of pFI912 (ie the 958 bp EcoRI/PstI fragment from pFI793) (SEQ ID No 10).

[0189] FIG. 16 shows the nucleotide sequence of pFI913 (ie the 959 bp EcoRI/PstI fragment from pFI793) (SEQ ID No 11).

[0190] FIG. 17 is a diagrammatic representation of the outward reading primers for pFI901 (P35 and P39), pFI911 (P32 and P36), pFI912 (P33 and P37) and pFI913 (P34 and P38).

[0191] FIG. 18 is a diagrammatic representation showing the formation of the 1.5 kb PCR product, using primers P34 and P39, which spans the region in the cosmid between the inserts of pFI913 and pFI901.

[0192] FIG. 19 shows the nucleotide sequence of the merged contigs pFI913/PCR product/pFI901 (4259 bp) (SEQ ID No 12).

EXAMPLE 1

Isolation and Growth of *Pseudomonas fluorescens*
Biovar. V, Strain AN103

[0193] Experimental

[0194] Growth Media

[0195] Organisms Were Grown on the Following Media:

[0196] Minimal Medium (MM) contained, per 1: KH₂PO₄, 5 g; (NH₄)₂SO₄, 1 g; FeSO₄, 0.5 mg; CaCl₂, 0.5 mg; MnCl₂.5H₂O, 5 mg; (NH₄)₆Mo₂O₇.4H₂O, 1.1 mg; MgSO₄, 5 mg; EDTA, 50 mg; ZnSO₄.7H₂O, 28 mg; CuSO₄.5H₂O, 1.6 mg; CoCl₂.6H₂O, 1.6 mg. The pH was 7.0. Carbon sources were included as indicated.

[0197] Tryptone- and yeast-based medium (LBMod) contained, per 1: tryptone (Bacto; Difco, Detroit, USA), 10 g; yeast extract (Bacto), 5 g; NaCl, 10 g. The pH was adjusted to 7.5. LB Medium was identical with LB Mod, with the addition of glucose (1 g/l).

[0198] Solid media were prepared with the addition of agar (Difco), 15 g/l.

[0199] Isolation of *Pseudomonas fluorescens* biovar. V, Strain AN103

[0200] The organism was isolated from surface soil, on the basis of ability to grow on trans-ferulate as sole carbon source. Initially, a 1 g soil sample was added to 100 ml sterile Minimal Medium (MM), containing trans-ferulic acid (10 mM). After 2 weeks at 25° C., with shaking at 200 rpm, a sample (100 µl) was removed and added to 200 ml of fresh medium containing 10 mM trans-ferulic acid; this was repeated twice. Serial dilution onto solid medium (MM) containing 10 mM trans-ferulate as sole carbon source enabled isolated colonies to be obtained which were replica-plated onto MM plates containing individual substrates as carbon sources. Several strains able to use trans-ferulate as sole carbon source were isolated—one (AN103), which was capable of growing also on vanillin, was selected for further work.

[0201] Growth of Strain AN103

[0202] The organism was grown routinely at 25° C. on MM, with shaking, using vanillic acid (10 mM) or trans-ferulic acid (10 mM) as sole carbon source; 50 ml of medium was used in a 250 ml Erlenmeyer flask. Growth was monitored by measuring absorbance at 550 or 600 nm.

[0203] For long-term storage, bacteria from logarithmic-phase cultures were centrifuged and then resuspended in Minimal Medium (MM) containing 50% glycerol. They were then stored at -70° C. Cultures from these frozen stocks were reinitiated by transfer onto LB or LB-MOD solid medium, followed by inoculation into liquid medium containing 10 mM trans-ferulic acid.

[0204] Results

[0205] The organism was isolated from soil samples rich in decayed vegetation and was shown to be a strain of *Pseudomonas fluorescens* using standard identification techniques. As shown in Table 1, the bacterium would grow not only on trans-ferulate as sole carbon source, but also on several closely-related compounds, including vanillate, protocatechuate and caffeate. Growth on vanillin was observed at low concentrations (<1 mM) but was variable; higher concentrations were growth-inhibitory. If the organism was grown on vanillate, transfer to medium containing trans-ferulate as sole carbon source was followed by a lag in the growth curve; this was not observed if the transfer was to medium containing both vanillate and trans-ferulate (FIG. 2). During a growth cycle on trans-ferulate, a transient increase in vanillate was observed at around the time when trans-ferulate disappearance was maximal (FIG. 3), suggesting that vanillate was a catabolite of trans-ferulate. A small amount of protocatechuate was also observed when the culture medium was examined by TLC (not shown).

TABLE I

Relative growth of <i>Ps. fluorescens</i> biovar. V, strain AN103 on a range of carbon substrates	
Substrates	Relative Growth (%)
Ferulic acid	100
Caffeic acid	79
Sinapic acid	0

TABLE I-continued

Relative growth of <i>Ps. fluorescens</i> biovar. V, strain AN103 on a range of carbon substrates	
Substrates	Relative Growth (%)
Cinnamic acid	0
Vanillin	<100
Vanillic acid	140
Protocatechuic acid	77
Protocatechuic aldehyde	0
Glucose	221
Acetate	47
Methanol	0

Substrates were provided in MM Medium at 10 mM concentration (vanillin, 1 mM) and relative growth after 48 h at 25° C. was monitored by measuring absorbance at 600 nm.

EXAMPLE 2

Trans-ferulate Metabolism in Cell-free Extracts and Mechanism of Cleavage

[0206] Experimental

[0207] Chemicals

[0208] Chemicals and biochemicals were routinely obtained from Sigma Chemical Co. Ltd, Poole, Dorset, UK, Aldrich Chemical Co. Gillingham, Dorset, UK or BDH-Merck, Poole, Dorset, UK. The synthesis of CoASH thioesters is described below.

[0209] Preparation of 4-hydroxy-3-methoxyphenyl- β -hydroxypropionyl SCoA (HMPHP SCoA)

[0210] This compound was prepared starting from a Reformatsky condensation of vanillin with ethyl bromoacetate (see R. L. Shriner, *The Reformatsky Reaction* in "Organic Reactions", R. Adams, W. E. Bachmann, L. F. Fieser, J. R. Johnson and H. R. Snyder, eds., vol. 1, pp 1-37, John Wiley, New York [1942]), followed by purification of the resulting ethyl 4-hydroxy-3-methoxyphenyl- β -hydroxypropionate (ethyl HMPHP) by HPLC, hydrolysis to the free acid, N-succinimidyl group with CoASH and isolation of the CoASH thioester by preparative TLC (see V. Semler, G. Schmidtberg and G. G. Gross, *Z. Naturforsch.* 42c, 1070-1074 [1987]).

[0211] Vanillin (3 g) was mixed with 1.9 ml of ethylbromoacetate and 2 g of dry Zn dust in 60 ml of dry 1,4-dioxane in a round-bottomed flask fitted with drying tubes and a reflux condenser. The reaction mixture was heated gently to boiling using a heating mantle and refluxed gently for ca. 1h. After being allowed to cool, the mixture was acidified with 60 ml of 10% H₂SO₄ and extracted with 4×120 ml of diethyl ether. The combined ether phases were dried with anhydrous Na₂SO₄ and unreacted vanillin was removed by washing with 3×100 ml of sat. K₂S₂O₅. The ether phase was then rotary evaporated under vacuum at ca. 30° C. to remove the ether, leaving a liquid residue (ca. 10 ml). This was then applied to a preparative C-18 reverse-phase HPLC column (Dynamax 60A, 8 μ m, 250 mm×41 mm; Rainin, Woburn, Mass., USA) and eluted at 12 ml min⁻¹ with a gradient of MeOH/H₂O, containing 1 mM trifluoroacetic acid. [Solvent A comprised 40% MeOH/1 mM trifluoroacetic acid; solvent

B comprised 100% MeOH/1 mM trifluoroacetic acid; at time=0 min, solvent was 20% B, rising linearly to 40% B at 28 min and 100% B at 35 min]. Fractions were monitored by absorbance at 280 nm and material eluting between 37 and 45 min was collected. The solvent was removed under vacuum at ca. 35° C. and the remaining material brought to -20° C. overnight. The precipitate which formed was then filtered off rapidly and freeze-dried to give 300mg of white substance. This was identified as 4-hydroxy-3-methoxyphenyl- β -hydroxypropionic acid ethyl ester (ethyl HMPHP) by MS [M⁻]=240 and, on alkaline hydrolysis (1 M KOH; 30 min), gave rise to the free acid.

[0212] To generate the N-succinimidyl ester, 30 mg of ethyl HMPHP was hydrolysed for 40 min at room temperature in 0.5 ml of 1M KOH. Oxalic acid (0.6 ml of 0.5 M) was then added to bring the pH to ca. 3-4. The solution was extracted successively with Et₂O (5×ca. 10 ml); the organic phases were then pooled and evaporated to dryness. N-Hydroxysuccinimide 0.1 mmol; 11.5 mg) was then added in 1.2 ml of dry 1,4-dioxane. This was then followed, gradually, by 0.1 mmol (20.7 mg) of dicyclohexylcarbodiimide in 0.6 ml of dry 1,4-dioxane. The reaction mixture was allowed to stand at room temperature for ca. 4 h and then filtered to remove precipitated DCU, a further 1.8 ml of dry dioxane being added to wash the filter.

[0213] The N-succinimidyl ester was not isolated from the reaction mixture but was converted in situ into the CoASH thioester. Lithium CoASH (40 mg; ca. 0.05 mmol) was dissolved in 2.4 ml of 0.1M NaHCO₃ and the reaction mixture was added; the exchange reaction was performed under N₂, with stirring, for ca. 2 h at room temperature. The pH of the mixture was then adjusted to ca.3-4 by the addition of 70 μ l of 2.8 M HCl and the mixture was stored at -70° C. The CoASH thioester of HMPHP was finally isolated by preparative TLC. Cellulose TLC plates (Avicel; 1000 μ m; Analtech, Newark, Del., USA), to each of which was applied 200 μ l of reaction mixture, were developed in nBuOH/HOAc/H₂O (5/2/3, v/v/v). The CoASH thioester was localised at R_F 0.4-0.5 using a short-wave u/v lamp and recovered from the plate by scraping and elution with 50% MeOH. Identification was confirmed by MS [M⁻=960] and by hydrolysis to the free acid (cf. ethyl HMPHP) which was measured by HPLC and used routinely as the basis for assay. The CoASH thioester showed an absorption maximum at 258 nm, and lacked the absorption maximum at 345 nm characteristic of trans-feruloyl SCoA. This molecule—and the corresponding ethyl ester and free acid—carry an asymmetric centre at the β -carbon; however, no attempt was made here to resolve the optical isomers during or after synthesis.

[0214] Preparation of Vanilloyl SCoA

[0215] Vanilloyl SCoA was produced from vanillic acid via the N-succinimidyl ester, essentially according to the method described by V. Semler, G. Schmidtberg and G. G. Gross (*Z. Naturforsch.* 42c, 1070-1074 [1987]) for the synthesis of piperoyl SCoA.

[0216] To a stirred solution of vanillic acid (5 mmol) and N-hydroxysuccinimide (5 mmol) in 30 ml of dry 1,4-dioxane was added, in small portions, 7.5 mmol of solid dicyclohexylcarbodiimide. The solution was stirred overnight at room temperature, and precipitated DCU was removed by filtration. The filtrate was evaporated under

reduced pressure at 40° C. and the oily residue dissolved in boiling CHCl_3 . The N-succinimidyl vanillate was crystallised from solution by the dropwise addition of petroleum ether (b.p.: 30° C.-40° C.). Approx 750 mg was recovered.

[0217] To generate vanilloyl SCoA from N-succinimidyl vanillate, CoASH (sodium salt; 200 mg) was dissolved in 4 ml of 0.1 M NaHCO_3 . N-Succinimidyl vanillate (120mg in 4 ml of dioxane) was then added gradually over a ca.40 min period at room temperature, sparging with N_2 . A further 4 ml of 0.1M NaHCO_3 was then added, together with a further 8 ml of dioxane. Incubation under N_2 at room temperature, with stirring, was continued for a further 1 h. The pH was then adjusted to ca. 2.8 with 1M HCl and the solution was frozen and stored at -70° C. Isolation of vanilloyl SCoA was by preparative TLC, as described above with n BuOH/HOAc/ H_2O (5/2/3, v/v/v) as solvent. Vanilloyl SCoA (R_F : 0.5-0.6) was identified using a short-wave u/v lamp and recovered by scraping, elution with 40 % MeOH and freeze-drying. Identification was confirmed by MS ($[M^-]=916$) and the thioester liberated vanillic acid on alkaline hydrolysis.

[0218] Preparation of Trans-feruloyl SCoA and other Cinnamoyl SCoA Thioesters

[0219] Trans-feruloyl SCoA was prepared from trans-ferulic acid via the N-succinimidyl ester, as described above for vanilloyl SCoA. Final isolation was achieved similarly by preparative TLC and elution, identification being confirmed by MS and by alkaline hydrolysis to free trans-ferulic acid. Caffeoyl and p-coumaroyl-SCoA thioesters were prepared similarly.

[0220] Preparation of Cell-free Extracts

[0221] Cell-free extracts of logarithmic-phase cultures (6-10 h after inoculation) were prepared by sonication. Cells from ca. 200 ml of medium were pelleted by centrifugation, and resuspended in 5-10 ml of Extraction Buffer (routinely 40 mM KPi; pH 7.2, containing 10 mM dithiothreitol). They were then sonicated (MSE Soniprep 150; Fisons Instruments, Crawley, Sussex, UK) at 4° C. (5×20s; 22 Amplitude microns on full power), and centrifuged (20 000×g; 20 min; 4° C.). Extracts were routinely stored frozen at -70° C. and in some instances buffer-changed using a PD10 column (Pharmacia) before use. The protein contents of extracts were variable—between 0.25 and 1.8 mg/ml.

[0222] Incubation of Cell-free Extracts

[0223] Cell-free extracts were routinely incubated at 30° C. and pH 7.5 in a reaction mixture (1 ml) containing 90 mM Tris HC buffer and 2.5 mM MgCl_2 , together with (as appropriate) 0.5 mM trans-ferulic acid, 0.2 mM CoASH (Li salt) and 2.5 mM ATP. This complete reaction mixture constituted an assay for trans-ferulate: CoASH ligase, where the initial increase in absorbance at 345 nm was monitored against a blank reaction mixture from which CoASH was omitted. Incubations with HMPHP SCoA (generally 0.4 mM) were performed similarly, but with the omission of trans-ferulic acid, CoASH and ATP. Vanillin: NAD^+ oxidoreductase was assayed at 30° C. and, pH 7.0 by monitoring the initial decrease in absorbance at 340 nm against a blank cuvette from which NAD^+ was omitted. Because of the similarity in extinction coefficient at 340 nm for vanillin and for NADH, the sensitivity of the assay was increased by catalysing the regeneration of NADH to NAD^+ by providing lactate dehydrogenase and pyruvate. Reaction mixtures con-

tained, in 1 ml volume, 75 mM KPi buffer, pH 7.0, 0.125 mM vanillin, 1.2 mM Na pyruvate, lactate dehydrogenase (rabbit muscle), 1.1 U and NAD^+ , 0.5 mM.

[0224] HPLC analysis

[0225] Metabolites of trans-ferulic acid, including the CoASH thioesters, were analysed and quantitated by HPLC using a Lichrosorb RP-18 column (20 cm×4.6 mm; Capital HPLC, Broxburn, West Lothian, UK) with a multiphasic gradient; solvent A" was 20 mM NaOAc, adjusted to pH 6.0 and solvent B" was MeOH; the flow rate was 1.2 ml/min; the proportion of solvent B" rose linearly from 0% at 0 min to 10% at 15 min and thence to 50% at 40 min and 70% at 45 min, finally decreasing to 0% at 50 min. Detection was with a Spectra Focus detector (Thermo Separation Products, Stone, Staffs. UK), which permitted u/v spectral analysis of each eluting component. Typical approximate retention times were: CoASH, 3 min; vanillic acid, 7 min; trans-ferulic acid, 19 min; acetyl SCoA, 22 min; HMPHP SCoA, 29 min; vanilloyl SCoA, 31 min; vanillin, 31.5 min; trans-feruloyl SCoA, 34 min.

[0226] Mass Spectrometry

[0227] Mass spectra (+ve and --ve ion) were recorded on a MS 9/50 mass spectrometer (Kratos Instruments, Manchester UK), using xenon fast atom bombardment (FAB) at a potential of 5-7 kV using glycerol as matrix (see G. R. Fenwick, J. Eagles and R. Self, *Biomedical Mass Spectrometry* 10, 382-386 (1983)).

[0228] Protein Assay

[0229] Protein was assayed by the method of M. M. Bradford (*Anal. Biochem.* 72, 248-254 (1976)), using Bio-Rad dye reagent (Bio-Rad Laboratories, Richmond, Calif., USA) and bovine serum albumin as standard.

[0230] Results

[0231] Crude extracts of *Ps. fluorescens* biovar. V, strain AN103, from cells grown on vanillate together with trans-ferulate, were able to produce vanillate when supplied with trans-ferulate, CoASH, ATP, Mg^{2+} ions and NAD^+ . In the absence of NAD^+ , vanillate was not formed and vanillin accumulated in its place (FIG. 4). The quantity of vanillin formed in the absence of NAD^+ was smaller than the amount of vanillate formed in its presence. Essentially no vanillin accumulated in the presence of NAD^+ .

[0232] This utilisation of trans-ferulate by crude extracts was dependent upon CoASH and ATP and partially upon Mg^{2+} ions (Table II) These properties indicate an initial activation of trans-ferulate to trans-feruloyl SCoA by trans-ferulate: CoASH ligase This was further shown by the rapid development of a CoASH-dependent absorbance maximum at 345 nm and particularly by a transient bathochromic shift, causing the appearance of a yellow colour, if the reaction mixture was made alkaline with NaOH (data not shown). In the initial stages of the overall reaction, the linear increase in absorbance at 345 nm enabled the activity of trans-ferulate: CoASH ligase to be assayed directly. During the later stages, however, absorbance at 345 nm would be

contributed by both trans-feruloyl SCoA and vanillin or, in the presence of NAD⁺, NADH, each of which has substantial absorbance at this wavelength.

TABLE II

Cofactor requirements for trans-ferulate utilisation by <i>P. fluorescens</i> biovar. V, strain AN103 cell-free extracts			
Reaction Mixture	Reaction products (nmol)		
	Trans-ferulate (remaining)	Vanillin	Vanillate
Complete	267	n.d.	311
CoASH	550	n.d.	40
NAD ⁺	258	228	23
ATP	513	n.d.	33
Mg ²⁺	425	n.d.	153

n.d. = not detectable
Reaction mixtures (165 µg protein) were incubated for 4 h at 30° C. as described in Experimental, with omissions from the complete reaction mixture as indicated.

[0233] An overall non-oxidative cleavage of trans-feruloyl SCoA is implied in FIG. 5 which shows, in the absence of NAD⁺, an equivalence between the formation of vanillin and that of acetyl SCoA. (The formation of [2-¹³C] acetyl SCoA from trans-ferulate ¹³C-labelled in the α-carbon atom was also confirmed by NMR spectroscopy (not shown).) The cleavage mechanism was investigated further by synthesising chemically the hydrated derivative of trans-feruloyl SCoA, 4-hydroxy-3-methoxy-phenyl-β-hydroxypropionyl SCoA (HMPHP SCoA). This was incubated with cell-free extract and shown to be converted rapidly to acetyl SCoA and vanillin, in equimolar proportions (FIG. 6). A smell of vanillin was obtained when HMPHP SCoA was used as a substrate. This hydrated intermediate was not only metabolised in the forward direction, however, since an almost equivalent back reaction to feruloyl SCoA (putatively trans) was also observed. The rapidity of utilisation of HMPHP SCoA was consistent with the failure to observed its accumulation, using HPLC, during cell-free incubations with trans-ferulate, CoASH, ATP and Mg²⁺ ions. This cleavage of HMPHP SCoA in the absence of NAD⁺ indicated no intervening β-oxidation to the β-keto thioester (4-hydroxy-3-methoxybenzoyl) acetyl SCoA (cf. M. H. Zenk, *Anal. Z Pflanzenphysiol* **53**, 404-414 (1965)). Attempts to prepare this compound for cell-free studies were unsuccessful, but its expected cleavage product, vanilloyl SCoA, was prepared and shown not to be metabolised to vanillin by cell-free extracts in the presence of NADH, even when simultaneous incubations with trans-ferulate in the absence of NAD⁺ actively produced vanillin.

[0234] Besides trans-ferulic acid, caffeic acid and p-coumaric acids were converted to thioesters of CoASH by crude extracts of *Ps. fluorescens* biovar. V, strain AN103 (Table III).

TABLE III

Substrate	Activity (nkat/mg protein)
Ferulate	0.50
Caffeate	0.39
p-Coumarate	0.37

Formation of CoASH thioesters of trans-p-hydroxycinnamic acids by crude extracts of *Ps. fluorescens* AN103. The activity was assayed spectrophotometrically as described for trans-ferulate: CoASH ligase, measuring the initial rate of increase in absorbance at 345 nm in the case of trans-feruloyl SCoA formation, and at the corresponding absorbance maxima for the other SCoA thioesters.

EXAMPLE 3

Mutants in Trans-ferulate Metabolism

[0235] Experimental

[0236] Mutagenesis of *Pseudomonas fluorescens* biovar. V, Strain AN103

[0237] Ethyl methanesulphonate (EMS) was used for mutagenesis. Bacteria were grown for 2 d at 25° C. in minimal medium (MM) with vanillic acid as carbon source; 1 ml of culture was then inoculated into 50 ml of LB-MOD and grown for 16 h at 25° C. The cells were centrifuged and resuspended in 0.1M KH₂PO₄ (1.25 ml) to give a cell density of 4×10⁹ cells/ml (OD₅₈₀ of 1.0=6×10⁷ cells/ml). An aliquot of this cell suspension was serially diluted (10⁻²-10⁻⁸) and plated onto LB-MOD plates (0. ml per plate) to provide control cell counts for assessment of the efficiency of mutagenesis. A cell suspension (1 ml) was incubated with 0.08 ml of EMS in a total of 3 ml of 0.1M KH₂PO₄ at 37° C. for 45 min. The cells were then precipitated by centrifugation at 4° C. and the cell pellet was washed twice with 10 ml of LB-MOD medium, prior to resuspension in 1 ml of this medium. An aliquot was serially diluted (10⁻²-10⁻⁸) and plated onto LB-MOD plates; these were incubated at 25° C. overnight, together with the plates of the unmutagenised cells, to obtain an estimate of kill (70% kill indicates efficient mutagenesis). The remaining mutagenised cells (0.9 ml) were inoculated into LB-MOD medium (50 ml) and incubated overnight at 25° C. The mutagenised cells were then enriched for mutants in trans-ferulate utilisation by treatment with carbenicillin in minimal medium (MM) in the presence of trans-ferulic acid. The cells were harvested by centrifugation at 4° C., washed twice with MM (10 ml) and resuspended in 20 ml of MM. A sample (1 ml) was inoculated into MM (15 ml) and incubated at 25° C. for 1 h; then trans-ferulic acid (10 mM final concentration) and carbenicillin (2 mg/ml final concentration) were added. A control flask was prepared containing trans-ferulic acid, but not carbenicillin. Both flasks were incubated overnight at 25° C. for 16 h, monitoring OD₅₈₀ to estimate growth and confirm the effectiveness of the antibiotic. Penicillinase (10 units) was then added to destroy the carbenicillin, incubating overnight at 25° C. The cells were harvested by centrifugation at 4° C., washed twice in MM (10 ml) and resuspended in 5 ml of MM; 1 ml of these resuspended cells were then inoculated into 50 ml of MM containing 10 mM vanillic acid and incubated at 25° C. for ca. 24 h. These enriched cells were screened by replica-plating for mutants unable to use trans-ferulic acid. The enriched stock was diluted to 10⁻⁶, plated onto LB-MOD (0.1 ml per plate), incubated at 25° C. for 2 d and then replica-plated onto MM containing 10 mM vanillic acid or 10 mM trans-ferulic acid. The plates were incubated at 25° C. for 2-3 d and screened for colonies able to grow on vanillate but unable to grow on trans-ferulate.

[0238] Results

[0239] By mutagenesis of strain AN103 with ethyl methane sulphonate, two classes of mutants unable to utilise trans-ferulate as sole carbon source were isolated; these were van 1, van 2 and van 3 and, secondly, van 10 and van 11. Following growth on vanillate plus trans-ferulate, a representative of the first of these, van 1, showed no activity in cell-free incubations with either trans-ferulate or vanillin and lacked both trans-ferulate: CoASH ligase and the enzyme that converts vanillin to vanillate, vanillin: NAD⁺ oxidoreductase. In contrast, the type representative of the second class, designated van 10, possessed levels of activity of both trans-ferulate: CoASH ligase and vanillin: NAD⁺ oxidoreductase similar to those found in strain AN103, but in the presence of NAD⁺ generated very little vanillate (Table IV). Cell-free extracts of van 10 were examined further for their ability to metabolise HMPHP SCoA. They metabolised this thioester actively, but appeared predominantly to dehydrate it to feruloyl SCoA; vanillin formation was substantially inhibited in comparison to the AN103 extract (Table V). These observations suggested that van 1 was a regulatory mutant, defective in its induction by trans-ferulate, whilst van 10 appeared to be defective in the HMPHP SCoA cleavage activity.

TABLE IV

Trans-ferulate metabolism in cell-free extracts of <i>P. fluorescens</i> biovar. V, strain AN103 and of mutant strains van 1 and van 10.			
Strain	Enzyme activity (nkat mg ⁻¹ protein)		
	Ferulate: CoASH ligase	Vanillin: NAD oxidoreductase	Vanillate formed (nmol mg ⁻¹ protein)
AN103	1.7	1.2	807
van 1	0	~0.05	0
van 10	2.0	1.4	59

Cells were grown for 6 h in MM medium containing 10 mM vanillate together with 10 mM trans-ferulate. Extracts were then prepared as in Example 2 and assayed for trans-ferulate:CoASH ligase and vanillin:NAD⁺ oxidoreductase. Extracts (ca. 0.3 mg of protein) were also incubated for 4 h in the presence of NAD⁺ to determine relative amounts of vanillate formed.

[0240]

TABLE V

Utilisation of HMPHP SCoA by extracts of <i>Ps. fluorescens</i> biovar. V, strains AN103 and van 10			
Strain	ΔA_{345}	Feruloyl SCoA (nmol)	Vanillin (nmol)
AN103	0.75	18.4	23.8
van 10	0.63	29.2	4.5

Extracts (AN103, 14 μ g protein; van 10, 68 μ g protein) were incubated at 30° C. for 7 min in 1 ml vol containing 0.3 mM HMPHP SCoA. The increase in absorbance at 345 nm was measured against a blank reaction mixture containing no extract. Vanillin formation was measured by HPLC; the production of feruloyl SCoA was in this instance calculated from the increase in absorbance at 345 nm, after subtraction of the contribution from vanillin.

EXAMPLE 4

Induction of Trans-ferulate Metabolism in Strain AN103 and Purification of HMPHP SCoA Cleavage Enzyme

[0241] Experimental

[0242] Purification of Trans-feruloyl SCoA Hydratase/aldol Cleavage Enzyme

[0243] Cells (from 21 of culture grown for 72 h on MM with 10 mM trans-ferulic acid as substrate; OD₅₆₅ ca.=0.5) were extracted essentially as described in Example 2 to give 50 ml of crude extract, containing 1.28 mg of protein/ml.

[0244] Extract (16 ml, diluted to 40 ml), was applied at room temperature and 2 ml/min to a Mono Q HR10/10 anion-exchange column (Pharmacia, Piscataway, N.J., USA), preequilibrated with 20 mM Tris buffer (pH 7.5), containing 10 mM dithiothreitol. After elution of unadsorbed protein, protein bound to the column was eluted with a linear gradient of increasing NaCl concentration: from 0 to 0.5M NaCl in 100 ml of buffer.

[0245] Fractions eluting between 0.18 and 0.3 M NaCl and containing activity with HMPHP SCoA, as determined using the microtitre plate assay (see below), were pooled and buffer-changed by dialysis into 25 mM bis-Tris buffer, containing 10 mM dithiothreitol and adjusted to pH 7.1 with iminodiacetic acid. They were then applied at 0.75 ml/min to a Mono P HR 5/20 chromatofocusing column (Pharmacia), preequilibrated with the same buffer. After eluting unadsorbed protein from the column, adsorbed protein was eluted with a gradient of decreasing pH, generated by applying 46 ml of 10% (v/v) Polybuffer 74 (Pharmacia), containing 10 mM dithiothreitol and adjusted to pH 4.0 with iminodiacetic acid. Activity with HMPHP SCoA was eluted between pH 5.5 and 5.1.

[0246] The active fractions were again pooled together, and buffer-changed into 20 mM Tris buffer (pH 7.5), containing 1.7 M (NH₄)₂SO₄ and 10 mM dithiothreitol, using PD10 columns (Pharmacia), before application at 0.5 ml/min to a PhenylSuperose HR 5/5 hydrophobic interaction chromatography column (Pharmacia) preequilibrated with this buffer. Elution of bound protein was achieved with a decreasing gradient of (NH₄)₂SO₄ in buffer, from 1.7 M to zero over 30 ml and then continuing with buffer alone for a further 5 ml. Activity with HMPHP SCoA was eluted in this final 5 ml of buffer.

[0247] At each stage of purification, active fractions were detected by a micro-adaptation of the assay with HMPHP SCoA described above (Example 2); reactions were performed in 100 μ l of reaction mixture for ca. 4 min at room temperature in microtitre wells and absorbance was then measured in an MR 5000 microtitre plate reader (Dynatech, Guernsey, Channel Islands), equipped with a 340 nm filter. The activity of the pooled fractions was measured using HPLC to determine the reaction products of both HMPHP SCoA, (0.4 mM) and trans-feruloyl SCoA (0.28 mM) as substrates. Reaction mixtures containing 10 μ l of enzyme were incubated in 100 μ l volume as described above; the reaction was terminated with 100 μ l of acidified MeOH (pH 3) after 2 min (HMPHP SCoA) or 5 min (trans-feruloyl SCoA) of incubation at 24° C. The proportionality of the

reactions with time and with quantity of enzyme was established in preliminary determinations.

[0248] Samples (10 μ l) of enzyme at each stage of purification were analysed by SDS-PAGE, with Coomassie or silver staining, essentially as described by H. Schagger and G. von Jagow, *Anal. Biochem.* 166, 368-379 (1987). An Atto AE6450 gel apparatus was used (supplied by Genetic Research Instrumentation, Dunmow, Essex, UK).

[0249] Electroelution of protein bands from fixed, stained gels was performed using a Bio-Rad Model 422 electroeluter according to the manufacturer's directions. Eluted protein was then deposited by centrifugation onto a Pro-Spin membrane (Applied Biosystems, Foster City, Calif., USA) used in accordance with the manufacturer's recommendations). N-Terminal sequencing was performed by Alta Bioscience, University of Birmingham, Birmingham, UK.

[0250] Results

[0251] The time-course of induction of trans-ferulate:CoASH ligase in strain AN103 is shown in FIG. 7. Following transfer of vanillate-grown cells to medium containing trans-ferulate, the specific activity; of the ligase in extracts increased approximately linearly over an 8-hour period. An essentially identical time-course was obtained if the cells were transferred instead to medium containing both trans-ferulate and vanillate. Vanillate, a catabolite of trans-ferulate, therefore did not inhibit the induction process.

[0252] Induction of the capacity to grow on a different substrate represents a significant shift in primary metabolism, which in principle might be detectable by electrophoresis of a crude protein extract. Cell-free extracts analysed by SDS-PAGE, with Coomassie staining (see Experimental), did indeed show a distinct difference in protein banding between trans-ferulate-grown cells and vanillate-grown cells (FIG. 8). Extracts from trans-ferulate-grown cells exhibited a new, or very strongly enhanced, band corresponding to a polypeptide of molecular weight ca. 31 kD.

[0253] N-Terminal amino acid sequencing of this polypeptide, following its removal from the gel by electroblotting, gave the following sequence: Ser-Thr-Tyr-Glu-Gly-Arg-Trp-Lys-Thr-Val-Lys-Val-Glu-Ile-Gln-Asp-Gly-Ile-Ala-Phe (SEQ ID No 13).

[0254] Purification of HMPHP SCoA-utilising activity was achieved by Fast Potein Liquid Chromatography (FPLC—Pharmacia). As described above, fractions were screened for activity with HMPHP SCoA using a microtitre plate scanner; active fractions were then pooled together and activity was then measured both with HMPHP SCoA and with trans-feruloyl SCoA, determining the reaction products by HPLC.

[0255] The results of the purification are given in Tables VI and VII. Vanillin and acetyl SCoA were produced in approximately equimolar amounts, throbghout the purification, with either HMPHP SCoA or trans-feruloyl SCoA as substrate. There was an approximate copurification of the activities with trans-feruloyl SCoA and HMPHP SCoA as substrate, including the formation of feruloyl SCoA from HMPHP SCoA (dehydratase reaction; reverse of reaction II): vanillin-forming activity from trans-feruloyl SCoA (reactions II+III) was purified 11.5-fold, vanillin-forming

activity from HMPHP SCoA (reaction III) was purified 11.7-fold and the dehydratase reaction (reverse of reaction II) was purified 9.1-fold. Approximately 20-25% of each of these activities was finally recovered.

TABLE VI

Purification of trans-feruloyl SCoA hydratase/aldol cleavage enzyme.					
Purification stage	Part 1				
	Total activity (nkat)		Total protein (mg)	Specific activity (nkat/mg)	
	trans-feruloyl SCoA	HMPHP SCoA		trans-feruloyl SCoA	HMPHP SCoA
Crude Extract	85.2 (68.2)	59.2 (54.9)	20.5	4.16	2.89
Mono Q Fractions	80.6 (66.2)	45.1 (42.9)	4.37	18.4	10.3
Mono P Fractions	56.9 (51.9)	35.4 (33.4)	1.61	34.1	21.2
Phenyl Superose Fractions	22.1 (19.8)	15.5 (15.1)	0.46	48.0	33.7

Purification stage	Part 2				
	Ratio of activities	Purification (fold)		Recovery (%)	
		trans-feruloyl SCoA	HMPHP SCoA	trans-feruloyl SCoA	HMPHP SCoA
Crude Extract	1.44	1.00	1.00	100	100
Mono Q Fractions	1.79	4.42	3.56	94.6	76.2
Mono P Fractions	1.61	8.20	7.34	66.8	59.8
Phenyl Superose Fractions	1.42	11.5	11.7	25.9	26.2

Purification from cells of *Ps. fluorescens* biovar V, strain AN103, was undertaken as described in Experimental, measuring activity - vanillin as product - with both trans-feruloyl SCoA and HMPHP SCoA as substrates. Values in parentheses show activity measuring acetyl SCoA as product.

[0256]

TABLE VII

HMPHP SCoA dehydratase activity during purification of trans-feruloyl SCoA hydratase/aldol cleavage enzyme				
Purification stage	Total activity (nkat)	Specific activity (nkat/mg)	Purification (fold)	Ratio to HMPHP SCoA Cleavage Activity*
Crude Extract	171	8.34	1.00	2.89
Mono Q Fractions	121	27.7	3.32	2.69
Mono P Fractions	101	60.5	7.25	2.85
Phenyl Superose Fractions	34.9	75.9	9.10	2.25

*see Table VI.
Conditions and other data as Table VI. Dehydratase reaction measured as feruloyl SCoA production.

[0257] SDS-PAGE of the combined active fractions at each stage revealed the enhancement of a 31 kD protein band (**FIG. 8**), indicating purification to apparent homogeneity after chromatography on PhenylSuperose (Pharmacia). This band co-migrated with the band associated with growth of strain AN103 on trans-ferulate and gave the same N-terminal amino-acid sequence: Ser-Thr-Tyr-Glu-Gly-Arg-Trp (SEQ ID No 14).

[0258] Definitive proof of the catalysis of both reactions II and III by this protein was achieved as a result of expression of the gene in *Escherichia coli*. (see Example 5).

[0259] The Mono-P-purified enzyme was able to accept, as alternative substrates to trans-feruloyl SCoA, trans-cafeoyl SCoA and trans-4-coumaroyl SCoA (Table VIII).

TABLE VIII

Substrate	Activity (nkat/mg of protein)
Feruloyl SCoA	0.60
Caffeoyl SCoA	0.36
p-Coumaroyl SCoA	0.72

Utilisation of trans-p-hydroxycinnamoyl SCoA thioesters by trans-feruloyl SCoA hydratase/aldol cleavage enzyme. Activity was determined at 30° C. and with 0.4 mM substrate using enzyme from *Ps. fluorescens* AN103 (2.8 µg of enzyme protein, partially purified by Mono-Q and Mono-P chromatography) as described in Experimental.

EXAMPLE 5

Isolation of the Genes Required for the Conversion of Trans-feruloyl SCoA to Vanillic Acid (Vanillate) in *Pseudomonas fluorescens* Strain AN103

[0260] A strain of *Pseudomonas fluorescens* (biovar. V, AN 103) was isolated from soil at the Institute of Food Research, Norwich Laboratory, which was able to grow on trans-ferulic acid converting it to vanillic acid via vanillin. The proposed biochemical pathway for the conversion of trans-ferulic acid to vanillic acid shown in **FIG. 1** was substantiated in the experiments described above in Experiments 2-4.

[0261] In order to clone the genes required for the conversion of trans-feruloyl SCoA to vanillic acid the strategy of complementing mutant derivatives of *Ps. fluorescens* AN 103 that were unable to grow on trans-ferulate as sole carbon source was used. The isolation and characterization of mutants is described above in Example 3 and mutants van10 and van11 were used for clone isolation. As described in Example 3, these mutants appeared to be defective in a gene involved in the conversion of trans-feruloyl SCoA to vanillin.

[0262] A genomic library of *Ps. fluorescens* AN103 DNA was prepared in the mobilisable cosmid cloning vector pLAFR3 (B. Staskawicz, D. Dahlbeck, N. Keen, and C. Napoli, *J. Bact.* 169, 5789-5794 (1987)). Genomic DNA was isolated from *Ps. fluorescens* AN103 and partially digested with Sau 3A1 at 37° C. for 7-10 min. The DNA was then size-fractionated on a NaCl gradient (1.25-5M). The fraction containing DNA of 20-40 kb was selected and 0.5 µg ligated into the dephosphorylated Bam H1 site of the broad-host-range cosmid cloning vector, pLAFR3. One half of the ligation mix was packaged into bacteriophage lambda particles using a Gigapack II XL kit (Stratagene, La Jolla,

Calif., USA). The packaged cosmids were transfected into *Escherichia coli* strain 803 (W. B. Wood, *J. Mol. Biol.* 16, 118-133 (1966)). Approximately 10,000 primary transfectants were obtained. The lawn of cells obtained was washed from the selection plates and glycerol-containing stocks prepared for storage at -70° C.

[0263] The genomic library of *Ps. fluorescens* AN103 DNA in cosmid pLAFR3 was introduced into the two mutant *Ps. fluorescens* derivative strains van10 and van11 using the helper plasmid, pRK2013 (D. Figurski and D. R. Helinski, *Proc Natl. Acad. Sci. USA* 76, 1648-1652 (1979)). The mutant strains were inoculated into minimal medium MM containing 10 mM vanillic acid and incubated at 25° C. for 2 days. The *Escherichia coli* strain carrying the helper plasmid (*E.coli* 803pRK2013) was inoculated into LB-Mod medium (10 ml) and incubated at 37° C. for 6 h. At the same time, 0.1 ml of the glycerol-containing stock of the AN103 genomic library was similarly inoculated and incubated. The growth of all three cultures was monitored by measuring OD₆₀₀ and appropriate volumes combined in a centrifuge tube to give equal populations of the three organisms. The mixture of cells was centrifuged, resuspended in a minimal volume of the supernatant solution and spread over a sterile gridded cellulose nitrate membrane filter (47 mm diam., Whatman, Maidstone, Kent, UK) on a moist LB-Mod agar plate. The suspension was allowed to air-dry onto the filter for a few minutes and then incubated overnight at 25° C. The bacteria were then washed from the filter using 2 ml of H₂O and aliquots (0.1 ml) were applied to selection plates consisting of MM agar with 10 mM vanillic acid and 5 µg/ml tetracycline. These were incubated at 25° C. for 2 days and the colonies obtained (>1000 per plate) were replica-plated to similar plates containing trans-ferulic acid in place of vanillic acid; these were incubated similarly. Colonies (2-3 per plate) able to grow on the plates containing trans-ferulic acid were selected and inoculated into fresh MM medium containing 10 mM trans-ferulic acid and 5 µg/ml tetracycline. Four such isolates in which the mutation in the *Ps. fluorescens* strains van10 and van11 was complemented by the introduced cosmid were selected for further analysis. These strains were purified and the cosmid DNA was extracted by the mini-preparation method of F. G. Grosveld, H. H. M. Dahl, E. Deboer and R. A. Flavell (*Gene* 13, 227-231 (1981)). The cosmid DNA was transformed into *E. coli* strain 803 and was again isolated as described by D. S. Holmes and M. Quigley (*Anal. Biochem.* 114, 193-197 (1981)). Two of the cosmid clones, pFI 793 and pFI 794, were isolated as complementing *Ps. fluorescens* mutant strain van 10, whereas cosmid clones pFI 795 and pFI 796 complemented *Ps. fluorescens* mutant strain van 11.

[0264] To test whether the plasmid clones pFH 793, pFH 794, pFH 795 and pFI 796 would complement any of the other *Ps. fluorescens* mutants, each plasmid was introduced into *Ps. fluorescens* mutant strains van1, van2, van3, van10 and van11. As described above in Example 3 the mutant strains van1, van2 and van3 appear to be defective in a regulatory function that eliminates at least two different enzyme activities. The *Ps. fluorescens* van mutants were grown on MMO+10 mM vanillic acid agar medium for two days at 25° C. The strain carrying the helper plasmid (803pRK2013) was grown on LB-Mod agar+ kanamycin (25 µg/ml) at 37° C. overnight. The *E.coli* 803 cosmid clones carrying pFH 793, pFI 794, pFH 795 and pFH 796 were grown on LB-Mod agar medium+tetracycline (5 µg/ml) at

37° C. overnight. The bacteria were patch mated (ie a loopful of donor, recipient and helper strain were mixed together on LB-Mod agar and incubated overnight at 25° C). The bacteria were replica plated onto selection medium (MMO+10 mM trans-ferulic acid+tetracycline and MMO+10 mM vanillic acid+tetracycline) and incubated at 25° C. for two days. All four cosmid clones pFP 793, pFI 794, pFI 795 and pFI 796 complemented all of the van mutants (van1, van2, van3, van10 and van11) enabling them to grow on trans-ferulate as sole carbon source.

[0265] The cosmid clone DNAs were analyzed by digestion with restriction endonucleases Hind III and Eco RI to reveal insert DNA. Each of the four clones pFI 793, pFI 794, pFI 795 and pFI 796 carried inserts of between 20 and 30 kb. The four cosmid clones gave distinct restriction patterns, but appeared to share some restriction fragments of the same size. To identify restriction fragments that were common to the cosmid clones cosmid pFI 793 was used as a probe against DNA of all four cosmid DNA preparations that had been double-digested with restriction endonucleases Eco RI and Pst I. Cosmid DNA was isolated using Qiagen midi columns according to the manufacturers instructions and was digested with restriction endonucleases EcoRI and PstI. The resulting fragments were separated by agarose gel electrophoresis and Southern blotted to a Hybond-N filter as described by Sambrook et al (Sambrook, J., Fritsch, E. F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor, N.Y., 1989). Cosmid pFI 793 DNA was linearised, denatured and labelled with digoxigenin prior to probing the Southern blotted DNA according to the instructions supplied by Boehringer (Lewes, Sussex, UK). The pFI 793 probe hybridised to all of the EcoRI/PstI restriction fragments of pFI 795 indicating that these two clones are identical. Excluding the vector band at least six EcoRI/PstI fragments appeared to be common to pFI 793, pFI 794, pFI 795 and pFI 796. These were fragments of 6.6 kb, 2.9 kb, 1.8 kb, 1.4 kb, 1.25 kb and 1.1 kb. The 1.25kb fragment appeared to be a doublet or triplet. The DNA fragment patterns of the four cosmid clones after restriction digestion with EcoRI/PstI are shown in FIG. 9. For clarity the ethidium bromide stained DNA bands have been diagrammatically superimposed on the original agarose gel.

[0266] As described above in Example 4 protein analysis of *Ps. fluorescens* biovar. V, strain AN103 showed that cells grown on trans-ferulate contained much larger amounts of a protein of about 31 kD compared with cells grown on vanillic acid. The twenty N-terminal amino acids of this protein were sequenced. This amino acid sequence was then used to design degenerate oligonucleotide primers that enabled the 60 bp sequence of DNA coding for this N-terminus to be amplified from pFI 793 by PCR (FIG. 10). This sequence was used to probe EcoRI/PstI digests of the cosmid clones. By this technique the fragment containing the region of DNA encoding the 31 kD protein in each of the cosmid clones could be identified (FIG. 11). This proved to be a fragment of 6 kb in cosmids pFI 793 and pFI 795, a fragment of 4.3 kb in cosmid pFI 794 and a fragment of 5.5 kb in cosmid pFI 796.

[0267] The 4.3 Kb EcoRI/PstI fragment of pFI 794 was sub-cloned into the *E. coli* vector pUC19 using strain XLI(Blue) and its nucleotide sequence was determined using an Applied Biosystems DNA Sequencer (Model 373; Perkin Elmer, Warrington, UK); together with the manufac-

turer's Taq DyeDeoxy Terminator Cycle sequencing kit. A primer walking strategy was used with oligonucleotide primers being synthesized on an ABI 392 Synthesizer (Perkin Elmer, Warrington, UK). The DNA sequence of the 4.3 kb fragment is presented in FIG. 12. The open reading frame encoding the same amino-terminus as determined previously starts at position 2872 and is terminated by a stop codon at position 3700. This ORF of 828 bp encodes a protein 276 amino acids long with a molecular size of 31.010 kD in good agreement with the protein gel analysis. The translated amino-acid sequence of this gene is also presented in FIG. 12. In order to confirm the function of this gene it was sub-cloned and expressed in *E. coli*. From the DNA sequence PCR primers were designed to amplify the gene such that it was flanked by restriction endonuclease sites EcoRI and BamHI. The amplified gene retained its native ribosome binding site being initiated at base -29 and ending 6bp downstream of the stop codon. The amplified fragment was cloned into the equivalent sites of the *E. coli* expression vector pSP72 (Promega, Southampton, UK) and transformed into *E. coli* JM109(DE3).

[0268] The *E. coli* 803 clones carrying the hydratase/cleavage enzyme gene, plus a putative promoter, as a PCR product in the vector pRK415 were used in a triparental patch mating experiment essentially as described earlier in relation to complementation by the cosmid clones pFI 793-6. The complemented van 10 strain was demonstrated to have recovered the ability to grow on trans-ferulic acid, confirming directly that the mutation in van 10 resided in the gene encoding the trans-feruloyl SCoA hydratase/cleavage enzyme. The presence of a novel enzyme activity (cf. Example 4) in the *E. coli* clone was demonstrated. *E. coli* cells were grown at 37° C. for 3 h in 50 ml of L medium, containing ampicillin (50 µg/ml) with and without induction by IPTG. Extracts were prepared as described above in Example 2 for *Ps. fluorescens* AN103, but without centrifugation. The crude extract was used for assay. Enzyme activity with both HMPHP SCoA and trans-feruloyl SCoA was determined as described above in Example 4 using HPLC to determine the reaction products. The results presented in Table IX clearly demonstrate that vanillin and acetyl SCoA were produced in equimolar proportions both with trans-feruloyl SCoA and with HMPHP SCoA as substrates. In addition, HMPHP SCoA was also dehydrated to feruloyl SCoA, putatively trans-feruloyl SCoA, demonstrating the reverse of activity II. These results are closely similar to those obtained with the vanillin-forming cleavage enzyme purified from *Pseudomonas fluorescens* AN103, although the ratio of activities with trans-feruloyl SCoA and HMPHP SCoA differs slightly between the two preparations. There was no activity with either trans-feruloyl SCoA or HMPHP SCoA in extracts of an unmanipulated *E. coli* strain, whether induced or not. In the manipulated strain *E. coli* 1039 that expresses the *Pseudomonas* gene the specific activity was slightly lower in the extract made following induction than in that made from uninduced bacteria. Since the assay measures only active enzyme it is conceivable that increased protein expression occurs upon induction but this may result in incorrectly folded and therefore inactive enzyme. It was not possible to detect expression of the 31 kD protein visually on Coomassie-stained, one-dimensional SDS gels because of its co-migration with the strongly expressed β-lactamase encoded by the vector ampicillin resistance marker.

TABLE IX

Expression of trans-feruloyl SCoA hydratase/aldol cleavage enzyme in <i>Escherichia coli</i> .					
<i>E. coli</i> Cell line	Specific activity (nkat/mg of protein)				
	trans-Feruloyl SCoA as substrate		HMPHP SCoA as substrate		
	Vanillin formation	Acetyl SCoA formation	Vanillin formation	Acetyl SCoA formation	Feruloyl SCoA formation
Control	n.d.	n.d.	n.d.	n.d.	n.d.
Control (induced)	n.d.	n.d.	n.d.	n.d.	n.d.
1039	1.53	1.80	1.52	1.80	3.35
1039 (induced)	1.24	1.34	1.27	1.46	3.16

n.d.—not detectable
Enzyme was extracted as described in Example 2 and activity determined as described in Example 4, using trans-feruloyl SCoA (0.28 mM) and HMPHP SCoA (0.4 mM)) as substrates. Reaction mixtures contained ca. 10 µg of protein.

[0269] The DNA downstream of the gene encoding the 31 kD protein was targeted for cloning and sequencing and for analysis of additional open reading frames. A PCR-generated probe was used to identify an overlapping XhoI fragment of 1-5 kb. Sequencing from this fragment and subsequently directly from the parent cosmid clone pFI794 revealed a second open reading frame of 1449 bp beginning at base 3804. The translation of this nucleotide sequence revealed a polypeptide of 483 amino acids. Comparison with sequences in the databases revealed appreciable homology to salicylaldehyde: NAD⁺ oxidoreductase.

[0270] In order to confirm the function of this gene, expression was determined in *E. coli* strain DH5, which contained the vector pUC18 into which the full-length open reading frame had been inserted such that expression was from the lac promoter on the vector. Vanillin: NAD⁺ oxidoreductase activity was confirmed and was absent from a control strain bearing the unmodified pUC 18 vector. Using the enzyme assay described in Example 2, activity with vanillin as substrate was determined as 3.0 nkat/mg of protein; activity with salicylaldehyde was 2.8 nkat/mg.

[0271] Additional sequence analysis of DNA cloned from *Ps. fluorescens* AN103 was undertaken using cosmid clone pFI 793. The 1.8, 0.9 and 0.8 kb EcoRI/PstI fragments were sub-cloned into *E. coli* vector pUCC18 and their nucleotide sequences were determined. Sequencing the 0.9 kb sub-clones revealed that there are two different fragments of the same size. The nucleotide sequences of DNA fragments of 1837 bp, 960 bp, 959 bp and 854 bp in sub-clones pFI 901, pFI 912, pFI 913 and pFI 911 respectively are presented in FIGS. 13 to 16. Outward reading PCR primers were

designed from the ends of each of the four sequences as shown in FIG. 17. Use of these primers in all possible pairwise combination with pFI 793 as template showed that the 1.8 kb fragment of pFI 901 was separated from the 959 bp fragment of pFI 913 by 1.5 kb on the cosmid DNA (FIG. 18). Direct sequence analysis of this 1.5 kb PCR product enabled this together with the 1.8 kb and 959 bp fragments to be merged into one larger fragment of 4.3 kb (FIG. 19).

EXAMPLE 6

Production of Vanillin from Trans-feruloyl SCoA and Enzyme Activities II and III

[0272] Trans-feruloyl SCoA was synthesised as described in Example 2, and was used as a substrate of the trans-feruloyl SCoA hydratase/aldol cleavage enzyme (ie a single polypeptide with enzyme activities II and III) as purified by the method described in Example 4. Vanillin was produced from trans-feruloyl SCoA.

EXAMPLE 7

A Transgenic Tobacco Plant Which Produces Vanillin

[0273] *Nicotiana tabacum* (tobacco) is transformed using a strain of *Agrobacterium tumefaciens* which has been modified so mat it transfers the *Ps. fluorescens* gene encoding enzyme activities II and III (see Example 5) to the tobacco plant. The tobacco plant produces vanillin in those parts of the plant which have trans-feruloyl SCoA present, at least in the form of a vanillin glycoside.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 14

<210> SEQ ID NO 1

<211> LENGTH: 828

<212> TYPE: DNA

<213> ORGANISM: *Pseudomonas fluorescens*

<400> SEQUENCE: 1

-continued

atgagcacat acgaaggtcg ctggaaaacg gtcaagggtcg aaatcgaaga cggcatcgcg 60
tttgtcatcc tcaatcgccc ggaaaaacgc aacgcgatga gcccgaccct gaaccgcgag 120
atgatcgatg ttctggaaac cctcgagcag gaccctgccg ccggtgtgct ggtgctgacc 180
ggtgcgggcg aagcctggac cgcaggcatg gacctcaagg aatacttccg cgaagtggac 240
gccggccccg aaatcctcca ggaaaaaatc cgccgcgaag cctcgcaatg gcaatggaaa 300
ctgctgcgca tgtacgcca gccgaccatc gccatgggtca atggctggtg cttcggcggc 360
ggtttcagcc cgctgggtggc ctgcgacctg gcgatctgcg ccgacgaagc aaccttcggt 420
ctctcgaaa tcaactgggg tatcccgccg ggcaacctgg tgagcaaggc catggccgac 480
accgtgggcc accgccagtc gctctactac atcatgaccg gcaagacctt cgggtgggcag 540
aaagccgccg agatgggcct ggtcaacgaa agcgtgcccc tggcgcaact gcgcgaagtc 600
accatcgagc tggcgcgtaa cctgctcgaa aaaaaccggt tgggtgctgcg tgccgcaaaa 660
cacggtttca aacgtgccc cgaactgacc tgggagcaga acgaggatta cctgtacgcc 720
aagctcgatc agtcgcttt gctggacacc gaaggcggtc gcgagcaggg catgaagcaa 780
ttcctcgacg acaagagcat caagcctggc ctgcaagcgt ataaacgc 828

<210> SEQ ID NO 2
<211> LENGTH: 276
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas fluorescens

<400> SEQUENCE: 2

Met Ser Thr Tyr Glu Gly Arg Trp Lys Thr Val Lys Val Glu Ile Glu
1 5 10 15
Asp Gly Ile Ala Phe Val Ile Leu Asn Arg Pro Glu Lys Arg Asn Ala
20 25 30
Met Ser Pro Thr Leu Asn Arg Glu Met Ile Asp Val Leu Glu Thr Leu
35 40 45
Glu Gln Asp Pro Ala Ala Gly Val Leu Val Leu Thr Gly Ala Gly Glu
50 55 60
Ala Trp Thr Ala Gly Met Asp Leu Lys Glu Tyr Phe Arg Glu Val Asp
65 70 75 80
Ala Gly Pro Glu Ile Leu Gln Glu Lys Ile Arg Arg Glu Ala Ser Gln
85 90 95
Trp Gln Trp Lys Leu Leu Arg Met Tyr Ala Lys Pro Thr Ile Ala Met
100 105 110
Val Asn Gly Trp Cys Phe Gly Gly Gly Phe Ser Pro Leu Val Ala Cys
115 120 125
Asp Leu Ala Ile Cys Ala Asp Glu Ala Thr Phe Gly Leu Ser Glu Ile
130 135 140
Asn Trp Gly Ile Pro Pro Gly Asn Leu Val Ser Lys Ala Met Ala Asp
145 150 155 160
Thr Val Gly His Arg Gln Ser Leu Tyr Tyr Ile Met Thr Gly Lys Thr
165 170 175
Phe Gly Gly Gln Lys Ala Ala Glu Met Gly Leu Val Asn Glu Ser Val
180 185 190
Pro Leu Ala Gln Leu Arg Glu Val Thr Ile Glu Leu Ala Arg Asn Leu
195 200 205

-continued

Leu	Glu	Lys	Asn	Pro	Val	Val	Leu	Arg	Ala	Ala	Lys	His	Gly	Phe	Lys
210						215			220						
Arg	Cys	Arg	Glu	Leu	Thr	Trp	Glu	Gln	Asn	Glu	Asp	Tyr	Leu	Tyr	Ala
225						230			235			240			
Lys	Leu	Asp	Gln	Ser	Arg	Leu	Leu	Asp	Thr	Glu	Gly	Gly	Arg	Glu	Gln
			245						250			255			
Gly	Met	Lys	Gln	Phe	Leu	Asp	Asp	Lys	Ser	Ile	Lys	Pro	Gly	Leu	Gln
			260						265			270			
Ala	Tyr	Lys	Arg												
275															

```
<210> SEQ ID NO 3
<211> LENGTH: 1446
<212> TYPE: DNA
<213> ORGANISM: Pseudomonas fluorescens
<400> SEQUENCE: 3
```

atgctggacg	tgccctgct	gattggcggc	cagtcgtgcc	cgcgcgcga	cggtcgaacc	60
ttcgagcgcc	gcaacccggt	gactggcgag	ttggtgtcgc	gggttgccgc	cgccaccctg	120
gaagatgccg	acgccgccgt	ggccgctgcc	cagcaagcgt	ttcccgctg	ggccgcgctg	180
gcgccaatg	aacggcgag	ccgtttgctc	aaggccgccg	aacaattgca	ggcgcgcagc	240
ggcgagttca	tcgaggcggc	gggcgagacc	ggcgccatgg	ccaactggta	cgggttcaac	300
gtacggctgg	cggccaacat	gctgcgtgaa	gcggcatcga	tgaccaccca	ggtcaatggt	360
gaagtgattc	cctcggacgt	tcccggcagt	ttcgccatgg	ccctgcgcc	gccctgtggc	420
gtggtgctgg	gcatcgcccc	ctggaacgcc	ccggtgattc	tcgccaccgc	ggcgattgcc	480
atgccgctgg	cctgtggcaa	caccgtggtg	ctgaaggctt	ccgagctgag	tccggcggtg	540
catcgcttga	tcggccaggt	gctgcaggac	gccggcctgg	gcgatggcgt	ggtcaacgtc	600
atcagtaatg	cgccggcgga	tgcggcacag	attgtcgagc	gcctgattgc	caacccggcc	660
gtacgccggg	tcaatttcac	cggttcgacc	cacgtcgggc	gcattgtcgg	cgagctctcg	720
gcgcgccacc	tcaaaccggc	gttgctcgag	ctgggcggca	aggcaaccgtt	gctggtgctc	780
gacgatgccg	acctggaggc	tgccgtgcag	gcggcggcgt	ttggcgccca	cttcaaccag	840
ggacagatct	gtatgtccac	cgagcgcctg	attgtcgatg	ccaaggtggc	cgacgccttt	900
gtcgcgccagt	tggcggccaa	ggtcgagacc	ctgcgcgccg	gtgatcctgc	cgacccgag	960
tcggtgctcg	gttcgctggt	ggacgccagc	gctggcacgc	ggatcaaagc	gttgatcgat	1020
gatgccgtgg	ccaagggcgc	gcgcctggta	atcggcgggc	aactggaggg	cagcatcttg	1080
cagccgaccc	tgctcgacgg	tgtcgacgcg	agcatgcgtt	tgtaccgcga	agagtccttc	1140
ggcccggtgg	cggtggtgct	gcgcggcgag	ggcgaagaag	cgctgttgca	actggccaac	1200
gactccgagt	tcggtttgtc	ggcggcgatt	ttcagtcgtg	acaccggccg	tgccctggcc	1260
ctggcccagc	gggtcgaatc	gggcatctgc	cacatcaacg	gccgaccgt	gcacgacgaa	1320
gcgcaaattgc	cttttggcgg	ggtcaagtcc	agcggctacg	gcagttttgg	cggcaaggca	1380
tcgattgagc	atttcactca	gttgcgctgg	gtcaccctcc	agaatggtcc	acggcactat	1440
ccgatac						1446

```
<210> SEQ ID NO 4
<211> LENGTH: 482
```

-continued

<212> TYPE: PRT
<213> ORGANISM: Pseudomonas fluorescens

<400> SEQUENCE: 4

Met Leu Asp Val Pro Leu Leu Ile Gly Gly Gln Ser Cys Pro Ala Arg
1 5 10 15
Asp Gly Arg Thr Phe Glu Arg Arg Asn Pro Val Thr Gly Glu Leu Val
20 25 30
Ser Arg Val Ala Ala Ala Thr Leu Glu Asp Ala Asp Ala Ala Val Ala
35 40 45
Ala Ala Gln Gln Ala Phe Pro Ala Trp Ala Ala Leu Ala Pro Asn Glu
50 55 60
Arg Arg Ser Arg Leu Leu Lys Ala Ala Glu Gln Leu Gln Ala Arg Ser
65 70 75 80
Gly Glu Phe Ile Glu Ala Ala Gly Glu Thr Gly Ala Met Ala Asn Trp
85 90 95
Tyr Gly Phe Asn Val Arg Leu Ala Ala Asn Met Leu Arg Glu Ala Ala
100 105 110
Ser Met Thr Thr Gln Val Asn Gly Glu Val Ile Pro Ser Asp Val Pro
115 120 125
Gly Ser Phe Ala Met Ala Leu Arg Gln Pro Cys Gly Val Val Leu Gly
130 135 140
Ile Ala Pro Trp Asn Ala Pro Val Ile Leu Ala Thr Arg Ala Ile Ala
145 150 155 160
Met Pro Leu Ala Cys Gly Asn Thr Val Val Leu Lys Ala Ser Glu Leu
165 170 175
Ser Pro Ala Val His Arg Leu Ile Gly Gln Val Leu Gln Asp Ala Gly
180 185 190
Leu Gly Asp Gly Val Val Asn Val Ile Ser Asn Ala Pro Ala Asp Ala
195 200 205
Ala Gln Ile Val Glu Arg Leu Ile Ala Asn Pro Ala Val Arg Arg Val
210 215 220
Asn Phe Thr Gly Ser Thr His Val Gly Arg Ile Val Gly Glu Leu Ser
225 230 235 240
Ala Arg His Leu Lys Pro Ala Leu Leu Glu Leu Gly Gly Lys Ala Pro
245 250 255
Leu Leu Val Leu Asp Asp Ala Asp Leu Glu Ala Ala Val Gln Ala Ala
260 265 270
Ala Phe Gly Ala Tyr Phe Asn Gln Gly Gln Ile Cys Met Ser Thr Glu
275 280 285
Arg Leu Ile Val Asp Ala Lys Val Ala Asp Ala Phe Val Ala Gln Leu
290 295 300
Ala Ala Lys Val Glu Thr Leu Arg Ala Gly Asp Pro Ala Asp Pro Glu
305 310 315 320
Ser Val Leu Gly Ser Leu Val Asp Ala Ser Ala Gly Thr Arg Ile Lys
325 330 335
Ala Leu Ile Asp Asp Ala Val Ala Lys Gly Ala Arg Leu Val Ile Gly
340 345 350
Gly Gln Leu Glu Gly Ser Ile Leu Gln Pro Thr Leu Leu Asp Gly Val
355 360 365
Asp Ala Ser Met Arg Leu Tyr Arg Glu Glu Ser Phe Gly Pro Val Ala
370 375 380

-continued

Val Val Leu Arg Gly Glu Gly Glu Glu Ala Leu Leu Gln Leu Ala Asn
385 390 395 400
Asp Ser Glu Phe Gly Leu Ser Ala Ala Ile Phe Ser Arg Asp Thr Gly
405 410 415
Arg Ala Leu Ala Leu Ala Gln Arg Val Glu Ser Gly Ile Cys His Ile
420 425 430
Asn Gly Pro Thr Val His Asp Glu Ala Gln Met Pro Phe Gly Gly Val
435 440 445
Lys Ser Ser Gly Tyr Gly Ser Phe Gly Gly Lys Ala Ser Ile Glu His
450 455 460
Phe Thr Gln Leu Arg Trp Val Thr Leu Gln Asn Gly Pro Arg His Tyr
465 470 475 480
Pro Ile

<210> SEQ ID NO 5
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide

<400> SEQUENCE: 5

tccacgtacg agggccgctg gaagac 26

<210> SEQ ID NO 6
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
oligonucleotide

<400> SEQUENCE: 6

aaacgcgatg ccgtcctgga tctc 24

<210> SEQ ID NO 7
<211> LENGTH: 5252
<212> TYPE: DNA
<213> ORGANISM: Pseudomonas fluorescens

<400> SEQUENCE: 7

gaattctctc gcgctttgcc cagtcctacc cgctggtgca gatcgaggtg cattgcgagt 60
cgtccaagca acttctcttg cgccaggacc togacctgtc catcgtgacc cgcgaaccg 120
gcaacgaaat cggccagctg ttgcgcaagg agcgttttgt ctgggcccag gcccagtgt 180
acaaccctgt cgagcaatca cccttgccgc tggcgatgtt caacagtgtg tgcttctgcc 240
gtctttgggc ctgtaatgcg ctggatgccg ccggacgtga ataccgcatc gcctacaaca 300
gttcgagcct gtcggcgctg atggcagtggt tcagcgccgg gctggcggtg accgctcaat 360
tggaagcct gatccgcag gacatgcgca tcctcggcga ggccgaaggc ctgccccaac 420
tgcccgaggc gagcatcatg ctgctgcgca atctgcataa tccgtcgccg attaccgaat 480
gtctggcgga gcacatcgtc gaaggcttca aactttaag gcgagcatca ccgcgcagag 540
caccagaaaa ccgcagaaca aaccgcgtag tagccgctcc ggcagggcgt gggcaatctt 600
cacgccccaa ctgatactga gcagaccgcc caccgccatg ggcaacgcga tgtgccagtc 660

-continued

gacttgctgg	tgcagggcgt	aggtcgccag	ggttacaccg	gtgctgggta	aagccagtgc	720
caacgacagg	ccctggggcca	ccacctgggt	ggtgccaaac	aagctggtca	ataccggcgt	780
tgcgaccaca	gcgccgcca	ccccgaacaa	gccacccatg	acgccggacg	ccgcgcccag	840
caccccgagc	cagggccacg	aatagcgc	catctgcgagtc	ggtgccgccc	cagtcatgaa	900
catgcgc	atcaggttgtaga	ccgacaaggc	caccagaaac	accacgaacc	cgatgcgc	960
cacctgagcg	tcgatcccca	ccgcccagat	cgaaccgagc	caggcaaagc	agaaccccat	1020
ggaggccaac	ggcagcgcgt	ggcgcaactc	gatgcgatta	cgttggtgat	aacgccataa	1080
cgccagcatc	acgttcggca	ccaccatgac	cagagctgtg	ccctgggcaa	gctgctg	1140
caggccaaat	aacacgcca	gagcgggaat	ggcgatcaag	ccaccgccga	ttccaaacaa	1200
accacctacg	gtccccaagg	ctgcaccgag	cagcaggtac	atcgtcaact	caatcacagg	1260
tcaaattccc	tcacgtcaat	gggtgcatcc	tacgcagtcg	gggctagcgg	ggaaacgcac	1320
agcaacgcac	aatggctatg	ccaaattcgc	acaagcaatc	ctccatgaac	cccacaacgc	1380
tcaccgatca	attgggtcta	ttccttgatg	tcgtggaaac	cggcagtttt	tccgctgcgt	1440
cccgacgcca	tccgctgaca	ccctccgccg	tcgccaggcg	tatcgatagt	ctggaacagg	1500
cgctcgacag	ccaattgttc	gtgcgcacca	ctcatgctgt	gcgtcctacg	ccagcgggat	1560
tggcgtttgc	cgagcgagcc	cgacgcattg	tcggcgagtt	gcgcctggcg	cgggccgagg	1620
tcgcctccct	gagcagcgcg	cctgaaggac	tgattcgggt	cgacgcccc	gcagccttcg	1680
gccgcaggca	cctggcgccg	gtgatctatg	actacgactt	cgccgcctcc	ggcgtgcccg	1740
ggctgcgggg	ccggttgcg	tacctgcgcg	gcgacaacat	cgagttgaaa	gccttcaacg	1800
ccgaagaccg	caaggagcgc	gagttccaga	tggagctggg	ctacgtggtg	caaagcggtc	1860
cgctgaaaaa	cgtcggcctg	gtggcgcgca	aggcaatcta	ccgcaatgac	ttccccactg	1920
gcgcgcgctt	ccgcgatgaa	aaccagacgc	ggtttctggt	gacctatacc	ttgccgatct	1980
ggtgagtgcg	cgtggtgcgg	tggggctgat	ggcccatcgc	cgagcgggct	cgctcctaca	2040
gtggggttgg	tgттаатсac	agaggctgtg	gagcttg	cagccccctgtagg	cgctggcttg	2100
ccagcgaggc	gtaggcactg	ctggcgcaag	gctcaaggcc	ccacaggccc	gctcccaccc	2160
ttcagat	ttctattcctga	taaatcttct	tcagcagccg	cagcagctcg	tcgcgttcct	2220
ggtcgtccag	tgccgaggtg	gcgtcgaggt	cgctttgggc	ggcgatctgg	ttcagttcct	2280
tgagcagggt	ctcgccggtc	ttgctgagga	atatcccgta	cgagcgcttg	tccggcttgc	2340
agcgcacacg	caccgccagc	gcccggcttt	ccagcttatt	cagcagcgg	accacctggg	2400
gcggctcgat	gctcagagcc	cgggccagg	cggcctgc	caggccgggg	ttctgattga	2460
tgatcgccag	cgccgagaat	tgcgcggggc	gcagatcgtg	ggccgagagg	cggctgatca	2520
ggttctggaa	cagtttcagt	tgcgcacggc	gcatggcgta	gccgatcaga	tcattcagcg	2580
ccgaatccat	gggcgcctgg	gtctcgggcg	gagtcgacgc	agcctcgacc	gactcggcga	2640
ggggggaggg	cttggccatt	gcggggaagt	cctgaagatg	gaggttaaca	agactatcta	2700
gtttgcccac	cttggccggt	gattgctacg	gccaatatcg	ctcggcgcca	agaccgacca	2760
gtccatcacc	tgcgagaaaa	ttggttaa	aatтаатag	ttaattgaca	taactaattc	2820
gctgctttaa	tttcgagtca	tcttcaaac	ccagaacaag	agagcatcgc	catgagcaca	2880
tacgaaggtc	gctggaaaac	ggtcaaggtc	gaaatcgaag	acggcatcgc	gtttgtcatc	2940

-continued

ctcaatcgcc	cggaaaaacg	caacgcgatg	agcccgaccc	tgaaccgcga	gatgatcgat	3000
gttctggaaa	ccctcgagca	ggaccctgcc	gccggtgtgc	tggtgctgac	cggtgcgggc	3060
gaagcctgga	ccgcaggcat	ggacctcaag	gaataacttcc	gcgaagtgga	cgccggccccg	3120
gaaatcctcc	aggaaaaaat	ccgccgcgaa	gcctcgcaat	ggcaatggaa	actgctgcgc	3180
atgtacgcca	agccgaccat	cgccatggtc	aatggctggg	gcttcggcgg	cggtttcagc	3240
ccgctggtgg	cctgcgacct	ggcgatctgc	gccgacgaag	caaccttcgg	tctctcgga	3300
atcaactggg	gtatcccgcc	gggcaacctg	gtgagcaagg	ccatggccga	caccgtgggc	3360
caccgccagt	cgctctacta	catcatgacc	ggcaagacct	tcggtgggca	gaaagccgcc	3420
gagatggggc	tgggtcaacga	aagcgtgccc	ctggcgcaac	tgcgcgaagt	caccatcgag	3480
ctggcgcgta	acctgctcga	aaaaaaccgc	gtggtgctgc	gtgccgcaa	acacggtttc	3540
aaacgctgcc	gcgaactgac	ctgggagcag	aacgaggatt	acctgtacgc	caagctcgat	3600
cagtcgcgtt	tgctggacac	cgaaggcggg	cgcgagcagg	gcatgaagca	attcctcgac	3660
gacaagagca	tcaagcctgg	cctgcaagcg	tataaacgct	gaaggacgac	gctgcgggcg	3720
cattgcgcga	aggcgagtgc	gccctgaagc	tgcgtttaca	tcactgctaa	gcattccgat	3780
aaagacgata	aagaggaatc	accatgctgg	acgtgcccct	gctgattggc	ggccagtcgt	3840
gccccgcgcg	cgacggtcga	accttcgagc	gccgcaaccc	ggtgactggc	gagttggtgt	3900
cgcgggttgc	cgccgccacc	ctggaagatg	ccgacgccgc	cgtggccgct	gccagcaag	3960
cgtttcccgc	gtgggccgcg	ctggcgccca	atgaacggcg	cagccgtttg	ctcaaggccg	4020
ccgaacaatt	gcaggcgcgc	agcggcgagt	tcatcgaggc	ggcgggagag	accggcgcca	4080
tggccaactg	gtacgggttc	aacgtacggc	tggcgggcaa	catgctgcgt	gaagcggcat	4140
cgatgaccac	ccaggtcaat	ggtgaagtga	ttccctcgga	cgttcccggc	agtttcgcca	4200
tggccctgcg	ccagccctgt	ggcgtggtgc	tgggcatcgc	cccctggaac	gccccggtga	4260
ttctcgccac	ccgggcgatt	gccatgccgc	tggcctgtgg	caacaccgtg	gtgctgaagg	4320
cttccgagct	gagtccggcg	gtgcacgcgt	tgatcgggca	ggtgctgcag	gacgccggcc	4380
tgggcgatgg	cgtggtcaac	gtcatcagta	atgcgcgggc	ggatgcggca	cagattgtcg	4440
agcgcctgat	tgccaacccg	gccgtacgcc	gggtcaattt	caccggttcg	accacgctcg	4500
ggcgcattgt	cggcgagctc	tcggcgcgcc	acctcaaacc	ggcgttgctc	gagctggggc	4560
gcaaggcacc	gttgctggtg	ctcgacgatg	ccgacctgga	ggctgccgtg	caggcggcgg	4620
cgtttggcgc	ctacttcaac	cagggacaga	tctgtatgtc	caccgagcgc	ctgattgtcg	4680
atgccaaggt	ggccgacgcc	tttgctgccc	agttggcggc	caaggctcag	accctgcgcg	4740
ccggtgatcc	tgccgaccgc	gagtcggtgc	tcggttcgct	ggtggacgcc	agcgtggca	4800
cgcggatcaa	agcgttgatc	gatgatgccg	tggccaaggg	cgcgcgcctg	gtaatcggcg	4860
ggcaactgga	gggcagcatc	ttgcagccga	ccctgctcga	cgggtgtcgac	gcgagcatgc	4920
gtttgtaccg	cgaagagtcc	ttcggccccg	tggcggtggg	gctgcgcggc	gagggcgaag	4980
aagcgtgtt	gcaactggcc	aacgactccg	agttcggttt	gtcggcggcg	attttcagtc	5040
gtgacaccgg	ccgtgccctg	gccctggccc	agcgggtcga	atcgggcatc	tgccacatca	5100
acggcccgac	cgtgcacgac	gaagcgcaaa	tgccTTTTTg	cggggcgaag	tccagcggct	5160
acggcagttt	tggcggcaag	gcatcgattg	agcattttcac	tcagttgcgc	tgggtcaccc	5220

-continued

tccagaatgg tccacggcac tatccgatct ga	5252
<210> SEQ ID NO 8	
<211> LENGTH: 1837	
<212> TYPE: DNA	
<213> ORGANISM: Pseudomonas fluorescens	
<400> SEQUENCE: 8	
gaattcggga tctgggctgc caaccagttg gaagaaaaga ttctcgaagt cgggtgtcgac	60
aacgtcggcg ccttcattgc cgagccgata cagggcgccg gcggcgtgat cgtgccgcca	120
gaaagctact ggccgcgcat caaggaaatc ctcgccaagt acgacatcct gttcgtcgcc	180
gatgaagtga tttgcggttt cggccgtacc ggcgagtggc tcggcagcga tttctacgac	240
ctcaagcccg acatgatgac catcgccaag ggcctgactt ccggctacat cccgatgggt	300
ggtctgatcg tgcgcgattc ggtggtcgaa gtgctgaacg aaggcggcga tttcaaccac	360
ggattcacct actccggtca cccggtagcg gcggctgttg ccctggaaaa catccgcata	420
atgcgcgaag agaagattat cgagcgcgtc caggaagaaa cggcaccgta tttgcaaaaag	480
cgtctgcgtg aactcaacga tcatccattg gtgggtgaag ttcgcggggt agggttgctg	540
ggcgctatcg aactggttca ggacaaagcc acgcgcaaac gttacgaagg caagggcgtg	600
ggcatgatct gccggcagtt ctgcttcgac aacgggctga tcatgcgcgc ggttggcgac	660
accatgatca tcgcgccgcc actggtgatt accaaggcgg aaatcgatga gctggtgagc	720
aaggcacgca agtgcctgga cctgaccctg agtgtgttgc agggctaagt gctaggctct	780
gagcgggagt tgtatgaact ttcgctcaga gcggtcagaa agcttggcct ttccttgaaa	840
gaccgccatg gatgttgcca gactagccac cgttcctaat gcccggttc gccgcggaac	900
aggtggttca aaaaagcaaa aatttgagc attacgcata aaggcactcg gtaaaaagct	960
cgccggcaag acactccttg ccatgtccct gatgggcata atggcgggcg cggttcaggc	1020
agatgacaaa gtcttgacg tgtacaactg gtccgattac atcgcgccgg acaccatcaa	1080
gaagtttgaa gacgagtcgg gcatcaaggt ggtctacgac gtcttcgaca gtaacgaaac	1140
cctcgaagcc aagttgctgg ccggcaagtc cggttacgac atcgtggtgc cttcgaacaa	1200
cttcctggcc aagcagatca aggccggcgt ctaccagaag ctggacaagt ccaagctgcc	1260
gaactggaag aacctgaaca ccgatctgct caaggccgtt tcggtcagcg accctggtaa	1320
cgagcacgcc ttcccgtaca tgtggggctc gatcggcata ggcttcaacg ccgagaaggt	1380
caaggccgcg ctgggtccgg atgcaccgac caattcctgg gacctgatct tcaaaccgga	1440
aaacgccgcc aagctgaaat cctgtggcat cagcgtgctg gattcgccaa ccgagatgat	1500
tccggtggcc ctgcactacc tgggctaccc gaccgacagc caggacaaga aacaactggc	1560
cgaggccgag gcaactgttc tcaaagtctg tccttcgata ggttacttcc actcctccaa	1620
gtacatttcc gacctggcca acggcaacat ctgcgtggcg atcggctact cgggtgacat	1680
ctatcaggcc aagactcgcg ccgccgaagc cggtgacaag gtcaaggtca gctacaacat	1740
tcccaaagaa ggtgcaggca gcttctacga catggctgcc atccctaaag atgccgaaaa	1800
cgtcgaaggc gcctacaagt tcatgacctt cctgcag	1837

<210> SEQ ID NO 9
<211> LENGTH: 852

-continued

<212> TYPE: DNA	
<213> ORGANISM: Pseudomonas fluorescens	
<400> SEQUENCE: 9	
ctgcagacct tctgccaggc gcaccggctc acgcaggggt ttgacttcct ggatcatcag	60
gcgctgggtg cgtttgaccg actggccaat catcaggcga aacgcattgg agcccaggtc	120
gatagcggcg aatagcgatg cgtcttcttt cacgtgagga actcctggca acttcgtccg	180
ccgagggcaa aaaaccggtt ttgccgatcc tgcacggggt agatgacatc aggatgacat	240
tggaaatttt tctgacagac gtttcgtcac cagaacgtca cagtcgcggg gctagcatcg	300
gggcttccaa tcgggtcggg agccttgaac atgctgttaa ccaacgacac cctgatgcat	360
cgcattccacc gcgagttgct cgaccacagt gacgaagagc tggaactgga gttgctggaa	420
gacgatcacg acctggcttc gctgttcgcg gatcaaccgg gcgatacccc ggccaaggcc	480
gagcgccgtc gttacttcag cgagttgttc cgtttgagg gcgagttggt caagttgcaa	540
agctgggttg tgaagaccgg gcacaagggt gtgattctgt tcgaaggccg cgatgccgct	600
ggcaaagggg gcgtgatcaa gcgcattacc cagcgtctta atccacgggt ctgccgggtc	660
gcggcgcttc ccgcgccgag tgaccgcgag cgcacccagt ggtatttcca gcgttatgtc	720
tcgcacctgc ccgccgccgg cgagatcgtc ctggtcgacc gcagctggta caaccgcgcc	780
ggtgtcgagc aggtgatggg cttttgcaac gaggaacagt acgaagaatt tttccgcagc	840
gtgccggaat tc	852
<210> SEQ ID NO 10	
<211> LENGTH: 958	
<212> TYPE: DNA	
<213> ORGANISM: Pseudomonas fluorescens	
<400> SEQUENCE: 10	
ctgcagggcc tggggcatgc cgagtcggcg tcgcagaacg cctctgccta tgcgctggaa	60
cgcaagcaaa tgcgtgcgcc cgctcgcccg gtcggagtcg aagccgaagt ggccgacccc	120
attcattttc atccggccat gcgccgggtg ttgctggaac tgagggccta tgccgagggc	180
atgcgtgcgg tcggttactg ggcggcgcgt ttgttggatc agtccgagca ggccgaggat	240
ctgcccactc gtcagcgcgc cttgcaactg gcggagctgc tgacgccggt gatcaaggcg	300
ttcttcaccg agcagggttt tcgcctggcc agcaacgcct tgcagggtgt cggtggctac	360
ggctacgtca gcgagttcgc catcgaacag accctgcgcg acagccggat cgcgatgatt	420
tacgagggca gcaacgaaat ccaggccaat gacctgctgc tgcgcaaagt gctgggggat	480
gaaggtcgcg cttttggcca actggtggcg gtcattgcgc aagaggccga actggcctgt	540
aacgacaccc gctttggcgc tgagctgggt cagctgtgcg acaaactcga gacagtgcaa	600
cttgagatag gggacctcgc cgtcacggag cgcgaatacc cgtatcgagc cgctggcgat	660
ttcctgcgcc tgtgtggcgt ggcgctgttg gggttttcct gggcgagagc ggcacgggtg	720
tctcgcctgt tacctgacag cgatccactg cgtcccaaca aactggaaac cgcgcgtttc	780
ttctttgcct acctgctgcc agaagccgat caacgcctcg cagccattcg ggcggcgaga	840
gcgccgttgc cgtttttgat ctgaaaaaac gcccgccagg cccaatgtgg ctcgctccca	900
caaacagcgc gaaccacatc gagccaccgc cgccacgcca gttgtacagg ccgaattc	958

-continued

<210> SEQ ID NO 11	
<211> LENGTH: 959	
<212> TYPE: DNA	
<213> ORGANISM: Pseudomonas fluorescens	
<400> SEQUENCE: 11	
ctgcaggctt gccatatcag tggcgacagc ttcgccgcgc ctccaggcgc aagggccaac	60
gacctgccga cggtgccgaa taggctgtcg gcgtccgtta ttctggacgc accgcaaaaa	120
ctgttattta cccggtcttc ttccactgta gaaccttttc actatagcgg ccctgcgtgt	180
tctgcgggag ctgctcatga ttctgcacgc gattccactt ccagcccgtt gccgcgccgt	240
gctgttgccg tttctgcacg cacggctttt gcatcaggct tgcacagcca gccacaagg	300
caggtaagct ctagctcgca cgtcctgggc gtctcccagg tctgccaacg cgacgcggac	360
gcgtcaaaca acgcccggcc cctaataaag ccgggacact cagcccagag gcatttatga	420
gtaacaacct cgaccagctc accgattggg tgaaagacca caagatcaca gaagtcgaat	480
gcatgattgg cgacttgacc gggatcaccg gcggcaagat ctgccaacc aacaagttca	540
ttgccgaaaa aggcattgcg ctgcccgaga gtgtgctgtt gcagacagtg acgggcgact	600
atgtcgaaga cgacatctat tacgaactgc tcgaccgggc cgacatcgac atgatctgcc	660
gccccgacca gaacgcggtg ttccctcgtg catgggccat cgagccgacc gcgcagggtga	720
ttcacgacac ctacgacaag cagggcaacc cgatcgagct gtcgccacgc aacgtcctca	780
agaaagtcct caaactctat tccgacaagg gctggcagcc gatcgtggcg ccggaaatgg	840
agttctacct gaccaagcgc agtgacgacc cggattaccg attgcaaccg ccggttggcc	900
gttccggacg tccggaaatc ggtcgccaat cgttctctat cgaagcggcc aacgaattc	959
<210> SEQ ID NO 12	
<211> LENGTH: 4259	
<212> TYPE: DNA	
<213> ORGANISM: Pseudomonas fluorescens	
<400> SEQUENCE: 12	
ctgcaggctt gccatatcag tggcgacagc ttcgccgcgc ctccaggcgc aagggccaac	60
gacctgccga cggtgccgaa taggctgtcg gcgtccgtta ttctggacgc accgcaaaaa	120
ctgttattta cccggtcttc ttccactgta gaaccttttc actatagcgg ccctgcgtgt	180
tctgcgggag ctgctcatga ttctgcacgc gattccactt ccagcccgtt gccgcgccgt	240
gctgttgccg tttctgcacg cacggctttt gcatcaggct tgcacagcca gccacaagg	300
caggtaagct ctagctcgca cgtcctgggc gtctcccagg tctgccaacg cgacgcggac	360
gcgtcaaaca acgcccggcc cctaataaag ccgggacact cagcccagag gcatttatga	420
gtaacaacct cgaccagctc accgattggg tgaaagacca caagatcaca gaagtcgaat	480
gcatgattgg cgacttgacc gggatcaccg gcggcaagat ctgccaacc aacaagttca	540
ttgccgaaaa aggcattgcg ctgcccgaga gtgtgctgtt gcagacagtg acgggcgact	600
atgtcgaaga cgacatctat tacgaactgc tcgaccgggc cgacatcgac atgatctgcc	660
gccccgacca gaacgcggtg ttccctcgtg catgggccat cgagccgacc gcgcagggtga	720
ttcacgacac ctacgacaag cagggcaacc cgatcgagct gtcgccacgc aacgtcctca	780
agaaagtcct caaactctat tccgacaagg gctggcagcc gatcgtggcg ccggaaatgg	840
agttctacct gaccaagcgc agtgacgacc cggattaccg attgcaaccg ccggttggcc	900

-continued

gttccggacg	tccggaaatc	ggtcgccaat	cgttctctat	cgaagcggcc	aacgaattcg	960
acccgctgtt	cgaagacgtc	tacgactggg	gcgaactgca	ggagctggat	ctcgatacgc	1020
tgatccacga	agacggcacg	gcgcagatgg	aaatcaactt	ccgtcacggc	gacgcgctgt	1080
ccctggccga	ccagatcctg	gtgttcaagc	gcaccatgcg	cgaggccgcg	ctcaagcaca	1140
acgtggccgc	cacgttcatg	gccaagccga	tgaccggcga	gcctggcagc	gccatgcacc	1200
tgcaccagag	catcatcgat	atcgagaccg	gcaagaacgt	cttctccaat	gaagacggga	1260
gcatgagcca	gttgttcctc	aaccacatcg	gcggcctgca	gaaattcatc	cctgaactgc	1320
tgccgctgtt	cgcgcccaac	gtcaactcgt	tccgcgcgtt	cctgccggac	acttcggcgc	1380
cgggtgaacgt	cgagtggggc	gaagaaaacc	gtaccgtggg	cctgcgggtg	ccggatgccg	1440
gccctcaaaa	ccgtcgggtg	gaaaaccgcc	tgccgggtgc	cgacgccaac	ccgtacctgg	1500
cgattgccgc	gagcctgctg	tgccgctaca	tccgcatggg	cgaaggatat	aaccaagcgc	1560
cgctctgtgt	gggtcgtggt	tacgagcggc	gcaacctgcg	tctgccgctg	accatcgaag	1620
acgctctgga	acgcatggaa	aacagcaaga	ccatcgagaa	atacctgggt	cacaacttca	1680
tcactggcta	cgtcgcggtc	aagcgggccg	agcatgaaaa	cttcaagcgc	gtgatcagct	1740
catgggaacg	ggaattcctg	ttgttcgccg	tctgacacgc	cggttgccgc	cctcaaaagc	1800
cgcactccaa	cctcactagg	agagctttat	gagcaacaac	ccgcaaacc	gtgaatggca	1860
gaacctgagc	gccgaacacc	acctggcccc	cttcagtgcg	ttcaagcaat	tgaaggaaaa	1920
aggcccgcgc	gtcatcacca	gcgccaaagg	cgtttacctg	tgggacagcg	aaggcaatca	1980
gatcctcgac	ggcatggccg	gcctgtgggt	cgtggccatc	ggttacggcc	gcgacgagtt	2040
ggccgaggct	gccagcaagc	agatgcgcga	gttgccgtac	tacaacctgt	ttttccagac	2100
cgctcaccgc	cccgtcctcg	agctggccaa	ggcaatttcc	gatatcgcg	cagcaggcat	2160
gaaccacgtg	ttcttcaccg	gttccggctc	cgaaggcaat	gacaccatgc	tgcgcatggt	2220
tcgccactac	tgggcgatca	aaggctcagc	aaacaagaaa	gtcattatca	gccgcaagaa	2280
cggctaccac	ggttcgaccg	tggccggcgc	cagcctgggc	ggcatgacct	acatgcacga	2340
acagggcgac	ttgccgatcc	cgggcacgtg	gcacattccg	cagccgtact	ggttcggtga	2400
aggcggcgac	atgaccccg	aagaattcgg	gatctgggct	gccaaaccag	tggaagaaaa	2460
gattctcgaa	gtcgggtgtc	acaacgtcgg	cgccttcatt	gccgagccga	tccagggcgc	2520
cggcggcggt	atcgtgccgc	cagaaagcta	ctggccgcgc	atcaaggaaa	tcctcgccaa	2580
gtacgacatc	ctgttcgtcg	ccgatgaagt	gatttgcggt	ttcggccgta	ccggcgagtg	2640
gttcggcagc	gatttctacg	acctcaagcc	cgacatgatg	accatcgcca	agggcctgac	2700
ttccggctac	atcccgatgg	gtggtctgat	cgtgcgcgat	tcggtggtcg	aagtgtctgaa	2760
cgaaggcggc	gatttcaacc	acggattcac	ctactccggt	cacccggtag	cggcggctgt	2820
tgccctggaa	aacatccgca	tcatgcgcga	agagaagatt	atcgagcgcg	tccaggaaga	2880
aacggcaccg	tatttgcaaa	agcgtctgcg	tgaactcaac	gatcatccat	tggtgggtga	2940
agttcgcggg	gtagggttgc	tgggcgctat	cgaactgggt	caggacaaa	ccacgcgcaa	3000
acgttacgaa	ggcaagggcg	tgggcatgat	ctgccggcag	ttctgcttcg	acaacgggct	3060
gatcatgcgc	gcggttggcg	acaccatgat	catcgcgcgc	ccactggtga	ttaccaaggc	3120
ggaaatcgat	gagctggtga	gcaaggcacg	caagtgcctg	gacctgacct	tgagtgtgtt	3180

-continued

gcagggctaa gtgctaggct ctgagcggga gttgtatgaa ctttcgctca gagcggtcag 3240
aaagcttggc ctttccttga aagaccgcca tggatgttgc cagactagcc accgttccaa 3300
atgcccgggt tcggcgcgga acaggtgggt caaaaaagca aaaatttgga gcattacgca 3360
tgaaggcact cggtaaaaag ctgcgccgga agacactcct tgccatgtcc ctgatgggca 3420
tcatggcggg cgcggttcag gcagatgaca aagtcttgca cgtgtacaac tgggtccgatt 3480
acatcgcgcc ggacaccatc aagaagtttg aagacgagtc gggcatcaag gtggtctacg 3540
acgtcttcga cagtaacgaa accctcgaag ccaagttgct ggccggcaag tccggttacg 3600
acatcgtggg gccttcgaac aacttcctgg ccaagcagat caaggccggc gtctaccaga 3660
agctggacaa gtccaagctg ccgaactgga agaacctgaa caccgatctg ctcaaggccg 3720
tttcggtcag cgaccctggt aacgagcacg ccttcccgta catgtggggc tcgatcggca 3780
tcggcttcaa cgccgagaag gtcaaggccg cgctgggtcc ggatgcaccg accaattcct 3840
gggacctgat cttcaaaccg gaaaacgccg ccaagctgaa atcctgtggc atcagcgtgc 3900
tggattcgcc aaccgagatg attccggtgg ccctgcacta cctgggctac ccgaccgaca 3960
gccaggacaa gaaacaactg gccgaggccg aggcactgtt cctcaaagtt cgtccttcga 4020
tcggttactt ccactcctcc aagtacattt ccgacctggc caacggcaac atctgcgtgg 4080
cgatcggcta ctcggtgac atctatcagg ccaagactcg cgccgccgaa gccggtgaca 4140
aggtcaaggt cagctacaac attcccaaag aaggtgcagg cagcttctac gacatggtcg 4200
ccatccctaa agatgccgaa aacgtcgaag gcgcctacaa gttcatgacc ttctgcag 4259

<210> SEQ ID NO 13
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas fluorescens

<400> SEQUENCE: 13

Ser Thr Tyr Glu Gly Arg Trp Lys Thr Val Lys Val Glu Ile Gln Asp
1 5 10 15

Gly Ile Ala Phe
20

<210> SEQ ID NO 14
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas fluorescens

<400> SEQUENCE: 14

Ser Thr Tyr Glu Gly Arg Trp
1 5

67. A transgenic plant which, by presence of a transgene, is able to produce p-hydroxybenzoic acid or a β -D-glycoside or β -D-glucose ester thereof.

68. A transgenic plant according to claim 67 which is transgenic for a polynucleotide encoding trans-ferulate:CoASH ligase activity, trans-feruloyl ScoA activity, 4-hydroxy-3-methoxyphenyl- β -hydroxy-propionyl ScoA activity, or vanillin:NAD⁺oxidoreductase activity.

69. A transgenic plant according to claim 68 wherein the vanillin:NAD⁺oxidoreductase activity is afforded by a protein or polypeptide having the amino acid sequence of SEQ ID No: 4.

70. A transgenic plant according to claim 68 wherein the 4-hydroxy-3-methoxyphenyl- β -hydroxy-propionyl ScoA activity is afforded by a protein or polypeptide having the amino acid sequence of SEQ ID No: 2.

71. A transgenic plant according to claim 68 wherein the trans-feruloyl ScoA activity is afforded by a protein or polypeptide having the amino acid sequence of SEQ ID No: 2.

72. A transgenic plant according to claim 68 wherein the plant produces p-hydroxybenzoic acid.

73. A transgenic plant according to claim 68 wherein the plant produces a β -D-glycoside or a β -D-glucose ester of p-hydroxybenzoic acid.

74. A transgenic plant according to claim 68 wherein the polynucleotide encodes 4-hydroxy-3-methoxyphenyl- β -hydroxy-propionyl ScoA activity in a location in the plant which contains 4-trans-coumaroyl SCoA.

75. A transgenic plant according to claim 68 wherein said plant is selected from *Nicotiana* spp., *Solanum tuberosum*, *Brassica* spp., *Beta* spp., *Capsicum* spp. and *Vanilla* spp.

76. A method of producing p-hydroxybenzoic acid or a β -D-glycoside or β -D-glucose ester thereof, the method comprising:

providing a transgenic plant according to claim 67 under conditions effective to convert 4-trans-coumaric acid, salts thereof, or 4-trans-coumaroyl SCoA to p-hydroxybenzoic acid or a β -D-glycoside or β -D-glucose ester thereof.

77. A method according to claim 76 wherein the transgenic plant comprises a heterologous polynucleotide encoding trans-ferulate:CoASH ligase activity, trans-feruloyl ScoA activity, 4-hydroxy-3-methoxyphenyl- β -hydroxy-propionyl ScoA activity, or vanillin:NAD⁺oxidoreductase activity.

78. A method according to claim 77 wherein the vanillin:NAD⁺ oxidoreductase activity is afforded by a protein or polypeptide having the amino acid sequence of SEQ ID No: 4.

79. A method according to claim 77 wherein the 4-hydroxy-3-methoxyphenyl- β -hydroxy-propionyl ScoA activity is afforded by a protein or polypeptide having the amino acid sequence of SEQ ID No: 2.

80. A method according to claim 77 wherein the trans-feruloyl ScoA activity is afforded by a protein or polypeptide having the amino acid sequence of SEQ ID No: 2.

81. A method according to claim 76 wherein p-hydroxybenzoic acid is produced.

82. A method according to claim 76 wherein a β -D-glycoside or β -D-glucose ester of p-hydroxybenzoic acid is produced.

83. A method according to claim 82 further comprising: treating the β -D-glycoside or β -D-glucose ester of p-hydroxybenzoic acid via acid or base-catalysed hydrolysis under conditions effective form p-hydroxybenzoic acid.

84. A method according to claim 82 further comprising: treating the β -D-glycoside or β -D-glucose ester of p-hydroxybenzoic acid with a β -D-glucosidase under conditions effective to form p-hydroxybenzoic acid.

85. A method according to claim 76 wherein the polynucleotide encodes 4-hydroxy-3-methoxyphenyl- β -hydroxy-propionyl ScoA activity in a location in the plant which contains 4-trans-coumaroyl SCoA.

86. A method according to claim 76 wherein the transgenic plant is selected from *Nicotiana* spp., *Solanum tuberosum*, *Brassica* spp., *Beta* spp., *Capsicum* spp. and *Vanilla* spp.

* * * * *